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Abstract
The immune system plays a key role against the development and progression of tumor
cells mainly because of its capability of recognizing and destroying cancerous cells. While
incredible research efforts have been made over the past decades to decipher the complexity
of the tumor-immnue interactions, there is still a lack of a definite and complete picture
of these interactions. This may be attributed to the fact that tumor cells develop intricate
mechanisms to evade detection and control by the immune system and resist treatments.
Although this has been attributed to tumor escape from the immune system, no quantita-
tive studies have been made to precisely characterize key tumor evasion mechanisms from
immune surveillance. There is a growing need for new modeling approaches that take into
account the complexity of immune system response and/or tumor escape mechanisms, and
the recent advances in cancer therapy. This lack has motivated the work in this thesis.
We focused our research on addressing the following three scientific questions: (1) How do
tumors evolve by escaping immune surveillance? (2) How can oncolytic virus infection of
some normal cells in the vicinity of tumor cells enhance oncolytic virotherapy? (3) How
can the use of cell carriers for the delivery of oncolytic virus particles to tumor sites affect
the outcomes of oncolytic virotherapy in the presence of active immune response?
To address these major questions, we have devised three novel mathematical models to
study the behaviour of tumor cells following their interactions with key cytotoxic immune
cells and oncolytic viruses. The results herein this thesis show the development of im-
munoresistant phenotype by tumor cells to effectively evade the immune system. This
thesis supports the natural killer (NK) cell-based immunotherapeutic approaches that are
aimed at enhancing the immune surveillance of tumors. Our work also highlights an inter-
esting possibility of infecting some normal cells in the vicinity of tumor cells to increase
the oncolytic infectious titers within tumor microenvironment. Additionally, our findings
provide pertinent information on how the use of certain cell carriers may enhance oncolytic
virotherapy in the presence of effective immune response within the tumor microenviron-
ment.
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Opsomming
Die immuunstelsel speel ’n sleutelrol om die ontwikkeling en groei van tumor selle teen te
werk, hoofsaaklik as gevolg van die vermoë om kanker selle te herken en te vernietig. Ter-
wyl ongelooflike navorsing oor die afgelope dekades gedoen is om die kompleksiteit van die
tumor-immuun interaksies te ontleed, is daar nog nie ’n definitiewe en volledige beeld van
hierdie interaksies nie. Dit kan toegeskryf word aan die feit dat tumorselle ingewikkelde
meganismes ontwikkel om opsporing en beheer deur die immuunstelsel te ontduik en behan-
delings te weerstaan. Alhoewel dit toegeskryf word aan tumors wat van die immuunstelsel
onsnap, is geen kwantitatiewe studies gedoen om die belangrikste ontduikingsmeganismes
teen immuniteitswaarneming presies te karakteriseer nie. Daar is ’n toenemende behoefte
aan nuwe modelleringsbenaderings wat die kompleksiteit van die immuunstelselrespons en
/ of tumor-ontsnappingsmeganismes in ag neem, asook die onlangse vordering in kankert-
erapie. Hierdie gebrek het die werk in hierdie proefskrif gemotiveer. Ons navorsing is
gefokus daarop om die volgende drie vrae aan te spreek: (1) Hoe verander of ontwikkel
die gewasse deur die immuunstelsel se toesig vry te spring? (2) Hoe kan onkolitiese virus-
infeksie van sommige normale selle in die omtrek van tumor selle onkolitiese viroterapie
verbeter? (3) Watter invloed kan die gebruik van seldraers vir die toediening van onkoli-
tiese virusdeeltjies na die omgewing van die gewas h op die resultaat van onkolitiese virapie
in die teenwoordigheid van aktiewe immuunrespons? Om hierdie hoofvrae aan te spreek,
het ons drie wiskundige modelle opgestel om die gedrag van tumorselle te ondersoek deur
hul interaksies met belangrike sitotoksiese immuunselle en onkolitiese virusse te volg. Die
resultate in hierdie proefskrif toon die ontwikkeling van immunoresistante fenotipe deur
tumorselle om die immuunstelsel doeltreffend te ontduik. Hierdie proefskrif ondersteun die
natuurlike uitwisser (NK) se selgebaseerde immunoterapeutiese benaderings wat daarop
gemik is om die immuunstelsel se opsporing van gewasse te verbeter. Ons werk beklem-
toon ook die interessante moontlikheid om sommige normale selle in die omgewing van
tumorselle te besmet om die onkolitiese infeksie tellings binne die mikro-omgewing van
die tumor te verhoog. Daarbenewens verskaf ons bevindings relevante inligting oor hoe
die gebruik van sekere seldraers onkolitiese viroterapie kan verbeter in die teenwoordigheid
van effektiewe immuunrespons binne die gewas se mikro-omgewing.
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Chapter 1
Introduction and Thesis Overview
In this chapter, we present the motivation and the rationale behind our mathematical
modeling of tumour-immune system interactions and the effects of oncolytic virotherapy
in maintaining tumor control. We also present a short review of immune surveillance of
tumors and the mechanisms that tumors often engage to escape immune response.
1.1 Preview of thesis contributions
This research has three main aims which are:
1. To formulate a novel differential-equation based mathematical model for the immune
surveillance of tumors. The model describes how tumor cells evolve and survive the
brief encounter with the immune system mediated by natural killer (NK) cells and
the activated CD8+ cytotoxic T lymphocytes (CTLs).
2. To develop an original delay differential equation mathematical model describing the
interactions between the oncolytic virus, the tumor cells, the normal cells, and the
antitumoral and antiviral immune responses. We derive the model’s basic reproduc-
tive number within tumor and normal cell populations and use their ratio as a metric
for virus tumor-specificity.
3. To construct a new differential-equation based mathematical model that describes
the use of the mesenchymal stem cell-based and T cell-based therapies for the delivery
of oncolytic viruses to tumor site. We use the model to simulate and compare the
1
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efficacy of delivering oncolytic viruses by either type of therapy. This comparison is
essential for understanding the possible treatment benefits of each therapy.
1.2 Motivation
The motivation for this mathematical modeling of tumor-immune interactions and cancer
therapy stems from the lack of a quantitative framework to precisely predict how certain
types of tumors evolve to elude active immune system and some cancer treatments, partic-
ularly immunotherapy and oncolytic virotherapy. The hypothesis of immune surveillance
(defined as the ability of the immune system to recognize and destroy neoplastic cells before
they develop into clinically detectable tumors) has led to the evolution and development of
immunotherapies. The immunotherapies are currently being utilised in isolation or in com-
bination with conventional chemotherapy. Despite these great advances, tumors however
often display a wide variety of complex mechanisms to evade immune system recognition
and control. Thus, this suggests that there is a clear need for new cancer research which
may be appropriate for eradicating tumors or at least bring them to a controllable state.
Before we describe such modeling attempts in the next chapters, we first give a brief
overview of immune surveillance of tumors.
1.2.1 Immune surveillance
In the early 20th century, Paul Ehrlich, a German scientist, proposed a theory of tumor
immune surveillance [2]. Following his studies about the roles of immune response in con-
trolling infections caused by microorganisms, he investigated if the same observations exist
in cancer [3]. An immune surveillance is an effective host defence against formation and
progression of tumor cells. According to immune surveillance hypothesis, immune effector
cells orchestrate the host body like sentinels in attempt to recognize and eliminate the in-
cipient cancer cells and nascent tumors [2, 4, 5]. An existence and importance of immune
surveillance of tumors in both mice and humans was experimentally and epidemiologically
elucidated by Dunn et al. [2]. The findings of Dunn et al. [2] showed that:
(i) Immune system has capacity to recognise and destroy nascent transformed cells (Elim-
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ination phase (immunosurveillance))
(ii) Some tumor cells may survive immune destruction and become dormant for certain
period of time (Equilibrium phase (i.e., the phase where immuno-editing occurs)
(iii) After some time, selected tumor cell variants from the equilibrium phase can now
grow into clinically detectable tumors.
Importantly, Dunn et al. [2] showed that the host immune system does not only protect
the host organism, but also “sculpts” tumor phenotype. An overwhelming body of re-
search suggests that tumor cells express surface molecules that render them as “non-self”
or “foreign” to the immune system [4–10]. These surface molecules are known as tumor
antigens. Expression of theses antigens can trigger reactions from both the innate and the
adaptive immune system [2, 11, 12]. More recently, an accumulating evidence from geneti-
cally engineered mice suggests that the host immune surveillance, at least to some certain
types of tumors, provides a significant shield against tumor development and progression
[13–15]. In particular, mice with deficiencies in the functionality of activated CD8+ cyto-
toxic T lymphocytes (CTLs), CD4+ T 1h helper T cells, or natural killer (NK) cells showed
an increased incidence of tumorigenesis [15].
Additionally, evidence from clinical epidemiology also confirm and support the existence of
host immune surveillance against human tumors [16]. High infiltration of activated CTLs
and NK cells to patients with colon and ovarian tumors lead to improved prognosis than
those who lacked such immune killer lymphocytes [17–19]. This further shows that host
immune surveillance serves an effective barrier to tumorigenesis and tumor progression.
Additionally, importance of tumor immunosurveillance in humans has been observed in
patients with immunosuppressed transplant organs, where the development and progression
of tumor growth was kept in dormant state by the immune system [20]. The presence of
activated CD8+ cytotoxic T lymphocytes (CTLs) at the tumor site has been shown to
provide an improved prognosis for patients with colorectal tumors [21]. An illustration of
cancer “immunoediting” by Dunn et al. [2] provides additional viable evidence of a key
function of immune surveillance in controlling tumorigenesis (i.e., formation of tumors)
and tumor progression [22–24].
Although immune surveillance of tumor is an essential host first line of defence, accu-
mulating evidence, however, suggests that highly immunogenic tumor cells may employ a
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variety of mechanisms to evade immune destruction and control [2, 13, 23, 25]. Such escape
mechanism are discussed in the next section.
1.2.2 Tumor-immune evasion mechanisms
Evasion of tumor cells from immune system control is currently considered as a second
emerging hallmark of cancer [25]. Emerging evidence indicates that tumors are not passive
targets of host immune lymphocytic cells [26]; instead, they actively display a wide variety
of mechanisms to avoid immune system recognition and control. Such mechanisms are
listed in Table 1.1.





Downregulation of tumor antigens [22, 27, 28]
Downregulation of MHC molecules [22, 29–32]
Expression of Immunosup-
pressive factors
Cytokines (Interleukin 10 (IL-








Apoptosis resistance Downregulation of pro-apoptotic
molecules or up-regulation of anti-
apoptotic molecules (such FLICE-
inhibitory proteins, surface protein
B7-H1)
[29, 36–40]
Counterattack Expression of Fas ligand (FasL) [29, 36, 41–44]
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Expression of TRAIL [tumor necro-
sis factor (TNF)-related apoptosis-
inducing ligand]
[26, 36]
Immune tolerance Lack of costimulatory molecules [29, 36, 45]
Inadequate or inappropriate antigen
(Ag) processing and presentation of
tumor-associated antigens (TAA) by
antigen-presenting cells (APCs)
[26, 29]
Immunesupression by Regulatory T
cells (such as CD4+ CD25+ T cells)
[26, 46, 47]
To date, tumor escape from host immune surveillance presents a major obstacle for im-
munotherapies [44, 47–51]. Molecular and clinical tumor escape mechanisms that enhance
tumorigenesis and tumor progression are now known and have been progressively reviewed
by Whiteside and colleagues [26, 47]. This thesis is concerned with elucidating how some
of these tumor escape hall-marks can be abrogated from a qualitative point of view.
1.3 Thesis outline
The primary contributions to the field of research in this thesis are presented in Chapters
3, 4 and 5. In these chapters, we describe three novel mathematical models that take into
account different aspects of tumor-immune interactions and oncolytic virotherapy. The
structure of this thesis is as follows:
Chapter 2: Background. We present the relevant biological background on tumor
formation and the commonly used cancer treatment procedures. We then give a brief survey
of the relevant mathematical models that directly or indirectly influenced the development
of the novel models in presented in this thesis. At the end of this chapter, we reiterate the
research problem definition and thesis statement.
Chapter 3: Mathematical Model of Tumor-Immune Surveillance. We develop a
novel differential-equation based mathematical model that describes how tumor cells evolve
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and survive the brief encounter with the immune system mediated by natural killer (NK)
cells and the activated CD8+ cytotoxic T lymphocytes (CTLs). We carry out numerical
simulations and discuss the results obtained from the model. Numerical simulations of the
model are comparable with previously published models of tumor-immune interactions.
The model successfully predicts how a low number of key immune cells might lead to
tumor escape. We further illustrates some plausible immunotherapeutic approaches to
endeavor to minimize tumor evasion from immune surveillance.
Chapter 4: Oncolytic Potency and Reduced Virus Tumor-specificity in On-
colytic Virotherapy. A Mathematical Modeling Approach. In this chapter, we
formulate a new delay differential equation mathematical model describing the interactions
between the oncolytic virus, the tumor cells, the normal cells, and the antitumoral and
antiviral immune responses. Therein, we also present a complete and thorough mathemat-
ical analysis of the model and discuss its implications for oncolytic virotherapy. Moreover,
we derive the model’s basic reproduction number, R0, and use it in the model simulation
as a therapeutic index of oncolytic potency and tumor-specificity. This chapter contains
pertinent information on tolerable depletion of normal cells, within tumor vicinity, that
favours significant reduction of tumor burden and/or tumor eradication.
Chapter 5: Mathematical Model of Oncolytic Virus Delivery By Cell Carriers.
In this chapter, we devise a new mathematical model to study the comparative efficacy of
delivering oncolytic viruses by either T cells or mesenchymal stem cells (MSC). The model
consists of a coupled system of ordinary differential equations that elucidate the impact
of delivering oncolytic viral particles by a certain type of a carrier cell to tumor site.
Numerical simulations are carried out to assess the therapeutic benefits of each carrier cell.
The effect of antitumoral and antiviral immune responses within tumor microenvironment
before and after the delivery of oncolytic viruses at tumor site is also investigated.
Chapter 6: Conclusions. We present a conclusion of this thesis, highlight the major
scientific contributions of our work to the field of mathematical oncology, and suggest
plausible future directions.
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Background
In this chapter, we present a succinct review of some of the relevant biology and mathe-
matical modeling approaches that have been used to describe various aspects of the tumor-
immune system dynamics. Observations from the biological experiments and mathematical
modeling of tumor, immune system and oncolytic viruses interactions, motivate the choice
of modeling techniques described in the next chapters of this thesis.
2.1 Biology background
In this section, we review the relevant biological literature pertaining to tumor develop-
ment and progression. We also survey the commonly used cancer treatment treatment
modalities.
2.1.1 Tumor formation
A tumor is a mass of masses of proliferating cells that originated from a single normal
cell that underwent cellular alterations [52, 53] and began to proliferate uncontrollably
[29, 54]. For a given time period, these tumors accumulate more changes that enable them
to progressively acquire attributes that would help them to survive within tissues [55, 56].
Recent evidence indicates that tumor is far more than a mass of proliferating cell, but rather
a complex tissue composed of multiple distinct cell types [25, 57]. These subpopulations
7
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within the tumor, all contribute distinct, but complementary capabilities that support
overall tumor growth in various ways [25]. Hanahan and Weinberg [52] articulated six key
phenotypic differences called “hallmarks” of cancer, which distinguish tumor cells from
normal cells. These are:
1. Activation of tissue invasion and metastasis
2. Evasion of growth suppressors
3. Resistance to cell death
4. induction and sustenance of angiogenesis
5. Sustenance of proliferative signaling
6. Support of replicative immortality
Recently, low level of oxygen, hypoxia, was has been added as a new hallmark of cancer [58].
Hypoxia, usually expressed by advanced solid tumors, results from defective vascularization
of oxygen to a tumor site [59, 60].
An increasing body of research supports inclusion of two additional hallmarks of cancer,
yet not generalized and fully validated, which are involved in the tumorigenesis of some and
perhaps all cancerous cells [25, 61, 62]. Such new hallmarks involve deregulations of cellular
energy metabolism in order to support progressive tumor cell growth and proliferation, and
active tumor cells evasion from immune surveillance [25]. In the next section, we present
a succinct review of current treatment modalities available to cancer patients.
2.2 The immune system
The immune system plays unprecedented role in protecting the body against pathogens
such as bacteria or viruses, and elimination of transformed cells in the body. It has two
major constituents, namely an innate and adaptive immunities. A central difference in
these components lies in their abilities to recognise “non-self” (foreign) cells or transformed
cells, such as a tumor cell. The innate immune cells are capable of recognizing a foreign
cell without being primed (i.e., being trained to recognise) about such foreign cells, while
the adaptive immune cells need to be primed about the existence of the foreign cell or a
transformed cell in the body [4, 5, 7].
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The Natural Killer (NK) cells constitute an important cytotoxic component of the innate
immunity. The NK cells serve as sentinels in the body against pathogens or transformed
cells, and play a crucial role in immunosurveillance of tumors [2, 7, 8, 63]. To identify
abnormal cells or virus infected cells, NK cells use a broad spectrum of “missing self”
signals [10] that help them to distinguish if a target cell should be destroyed or not.
After identifying the target cell to destroy, NK cells may secrete lethal chemicals, such as
perforin which binds to the cell membrane of a target cell, and form lytic pores through
which they send deadly cytokines into the target cell [64, 65]. Serving as a specific part
of the adaptive immunity, the activated CD8+ Cytotoxic T Lymphocytes (CTL) play a
crucial role in controlling the development of tumor cells. The CD8+ CTLs also use similar
cytotoxic pathways to kill the target cells [4, 37]. The CD8+ CTLs are, however, known
to mount a more robust attack against transformed cells than NK cells [4, 64].
As another means of evading the immune system destruction, tumor may usurp the immune
checkpoints expressed on activated T cells [66]. The immune checkpoints are inhibitory
pathways that often reduce the strength and duration of immune responses [67]. The
immune checkpoints inhibitors are drugs that help to block the immune checkpoints by
targeting the blockage of the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or
programmed cell death protein 1 (PD-1) expressed by T cells. The Clinical clinical re-
search is now focusing on combination therapy of immune checkpoint inhibitors with other
therapies, such as oncolytic virotherapy [66, 68]. Even though the immunological activa-
tion induced by the checkpoint inhibitors is non-specific, clinical evidence indicates that
the checkpoint blockade therapy has often resulted in unprecedented enhancement and
durability of the immune responses in some cancer patients [69, 70].
2.3 Cancer treatment modalities
A variety of treatment modalities, such as surgery, chemotherapy and radiotherapy, have
been used to treat different types of cancers over the past decades. Surgery is used where
a tumor can be easily accessed and removed directly. Chemotherapy involves utilization of
chemical drugs that aim at destroying fast replicating cells, which is a typical characteristic
of cancerous cells. Radiotherapy attempts to kill and destroy cancerous cells via a direct
Stellenbosch University  https://scholar.sun.ac.za
Chapter 2. Background 10
application of radiation on the affected area. Despite their individual successes, most of
these therapeutics are often combined to achieve results. However, a commonly reported
limitation of these therapeutics is their relative low efficacy and high toxicity to non-
cancerous, healthy cells. There are other emerging novel therapeutics, like gene therapy,
angiogenetic inhibitors, immunotherapy and oncolytic virotherapy, that are in clinical trials
to treat certain types of cancers. A major aim of all these new treatment modalities is to
minimize unwanted toxicities on normal healthy tissues, while simultaneously maximizing
tumor targeting. In this review, we only provide recent review of therapeutics that are
purported to have better treatment outcomes in clinics.
2.3.1 Chemotherapy
In cancer research, chemotherapy is a treatment modality that involves use of chemical
drugs to combat cancer. Chemotherapeutic agents are usually classified into two broad
categories: “targeted” and “cytotoxic” drugs [71]. Targeted drugs are designed to distract
cancer-specific pathways, for instance, by blocking a kinase oncogene [72]. Cytotoxic drugs
work by directing damaging ribonucleic acid (RNA) or deoxyribonucleic acid (DNA), or
microtubules, and in human body they are believed to preferentially destroy fast prolif-
erating cells [71, 73]. These cytotoxic drugs target rapidly replicating cells, which is a
common attribute of all cancerous cells [74, 75]. Thus, they kill target cells by halting
cell division, facilitating a damage of RNA or DNA. Chemotherapeutic drugs are deliv-
ered via direct injection into a bloodstream (intravenous injection) [76], hepatic arterial
infusion pumps [77], clinical drips (intravenous infusion) [78], or orally as chemotherapy
tablets [79]. These drugs are assumed to circulate through the blood to annihilate rapidly
dividing cells or at least prohibit them from spreading from their primary sites. In this
manner, chemotherapeutic drugs are often considered to be the prime candidates for treat-
ing metastatic tumors. A major outstanding challenge with chemotherapeutic drugs is
that they only target rapidly replicating cells. Thus, they do not distinguish between fast
replicating cancerous and non-cancerous cells. Evidence indicates that there are other
non-cancerous cells, such as bone marrow cells, immune cells and hair follicle cells, that
are know to be fast replicating [73] and such cells, are also destroyed by chemotherapeutic
drugs [71, 73]. Chemotherapeutic agents are usually administered in cycles ranging one to
eight cycles, where one cycle may last between 1− 5 days [80].
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Currently, there are many approved distinct types of chemotherapeutic agents, which are
either administered in isolation or in combinations. It is important to note that chemother-
apeutic drug administration varies from patient to patient. They may be given based on the
type of cancer, its size and stage (i.e., whether is a benign tumor or metastatic tumor). In
clinics, currently there is no unequivocal consent on the optimal chemotherapeutic regimes
[81]. Thus, there is a need for further biological, mathematical and clinical research to
address this issue.
2.3.2 Radiotherapy
Depending on the type of cancer, its resident location, stage and grade, patients may
receive beams of ionising radiation, including X-rays, gamma rays, and heavy ions, that
pierce tumor host tissue and distract the DNA of the cell. This method of cancer treatment
is called Radiotherapy. Damage generated by ionising radiation usually alter the growth
and division patterns of the affected cell. Thus, depending on the extent of damage of DNA
damage, affected cells may undergo either a transient or permanent cell cycle arrest, and/or
cell death [82]. On the other hand, depending on the extent of ionising radiation, healthy
cells can be rapidly regenerated, but tumor cells cannot [83]. However, it is important
to note that if cell is not aligned for apoptosis (i.e., programmed cell death), its survival
depends diametrically on DNA repair [82]. Sometimes, radiotherapy can be administered
prior to clinical surgery in order to reduce tumor burden, thus improving the success of the
surgery. Similar to chemotherapy, a major limitation of radiotherapy is toxicity to healthy
tissue surrounding a tumor [84].
2.3.3 Immunotherapy
Recent evidence indicates a great advancement in field of immunology. Molecular and
cellular understanding of functionality and control of immune system in response to “non-
self” or “foreign” cells in the body has widely opened new promising cancer therapies that
augment the ability of immune response. For instance, recent evidence shows that toll-like
receptor agonists can be used to boost immune responses to combat tumors [85]. Fur-
thermore, major advances in cell-based immunotherapies such as adoptive T cell therapy
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(ACT) [86], NK cell-based immunotherapy [87], and dendritic cell immunotherapy [88]
have been established. Furthermore, an emerging evidence shows that a large numbers of
monoclonal antibodies (mAbs) has recently being developed to treat tumors, and many
of the available antibodies have shown a positive clinical responses. A succinct review of
the current immunotherapies is given by Galluzzi et al. [89]. These immunotherapies are
attractive because they enhance immune surveillance through activation and proliferation
of endogenous cells in cancer patients [87].
2.3.4 Oncolytic virotherapy
Oncolytic virotherapy is a treatment modality that uses viruses that are capable of replicat-
ing in, and killing tumor cells with little or no harm to normal cells [66, 90–95]. Oncolytic
viruses (OVs) either have a natural tumor tropism or are genetically engineered to target
tumor cells [96–100]. Tumor targeting is achieved by deleting and/or inserting specific
genes, potentiating viral replication within tumors while having attenuated replication in
normal cells, in the genome of the oncolytic virus [101, 102]. One of the approaches fos-
tering oncolytic virus to target tumor cells is transductional targeting (sometimes called
oncoselectivity targeting) [91, 103]. If an oncolytic virus shows an increased potency in
replicating within and destroying tumor cells over non-cancerous cells, it is said to be on-
coselective or tumor-specific [104]. There are two approaches for increasing oncoselectivity
for a given virus [104]:
(i) Changing of virus entry tropism. This approach involves changing of the cell type to
which the oncolytic virus often enters most efficiently so that the virus can only bind
and enter into the targeted tumor cell via some specific receptors at its surface.
(ii) Increasing of viral replication. This approach involves increasing of virus replication
in tumor cells or reducing viral replication in healthy non-cancerous cells, or both.
Since neither approach has been employed independently and has shown perfect tumor-
specificity [104], these two approaches are often combined to enhance tumor targeting.
Tumor-specificity, however, remains a complex and challenging multistep process in on-
colytic virotherapy [91, 105, 106].
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Oncolytic viruses (OV) are often injected directly into a tumor (i.e., intratumoral admin-
istration) or they are injected into the blood (i.e., intravenous administration), where the
virons diffuse to tumor sites. Recent research in cancer virology indicates that although
intratumoral virus administration minimizes virus loss and maximizes viral load within
a tumor, intravenous administration offers better treatment protocol [107, 108]. This
is mainly because viruses administered intravenously can reach disseminated metastasis
which cannot otherwise be reached directly. Administering OVs through bloodstream is
currently considered to be a promising treatment option for treating metastatic tumors
[109, 110]. On the other hand, a compelling body of evidence indicates that administra-
tion of OVs systemically has many obstacles [111]. The systemically administered naked
OVs are susceptible to neutralization by circulating anti-bodies, inactivation by comple-
ment proteins and clearance by virus-specific immune cells [66, 109, 112]. In the recent
years, much attention has been paid predominantly on mechanisms of virus interaction
with tumor cells rather than on processes of oncolytic delivery and entry upon arrival at
tumor sites. A new emerging era of oncolytic virotherapy research now focuses on methods
that can effectively protect the OVs from immune response. This includes the use of en-
gineered nanoparticles [113] or carrier cells [114] to effectively deliver OVs to tumor sites.
Many challenges, however, remain to be addressed before these therapies can be routinely
applied in clinical settings. As part of this research, we address some of these systemic
delivery challenges from a qualitative point view. It is interesting to note that some few of
oncolytic viruses, such as T-VEC [115], are now FDA approved, while others are in their
phase II/III of clinical trials [116].
2.3.5 Targeted therapies with tyrosine kinase inhibitors
In the recent years, enormous efforts have been made to tailor treatments to individual
patients or tumor cells. The targeted therapies are aimed at blocking certain molecular
genes or pathways that increase the spread (metastasis) or growth of tumor cells without
harming healthy cells. It is important to note that these therapies target the molecules
which may be present in normal cells, but are abundantly expressed on tumor cells [117].
Of particular interest, are the targeted therapies that uses tyrosine kinase inhibitor domain,
such as ibrutinib, gefitinib and erlotinib. These drugs target the epidermal growth factor
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receptor-(EGFR-) which is often expressed tumors of neck, head or chronic myelogenous
leukemia [118]. These drugs are often taken orally as form of pills, and known to be less
cytotoxic to normal cells than traditional chemotherapy [117, 119]. There exists an ample
clinical evidence that the tyrosine kinase inhibitors are very effective against a number
of cancer types, including the chronic lymphocytic leukemia (CLL) [119, 120] and mantle
cell lymphoma (MCL) [121]. These drugs have been approved by the US Food and Drug
Administration (FDA) for patients with relapsed CLL and MCL.
2.4 Mathematical models of tumor-immune dynamics
In this section, we provide a brief review of appropriate existing mathematical models
that incorporate the dynamics of tumor cell interactions with immune system, normal
cells, and/or oncolytic viruses. Mathematical models reviewed in this chapter provide a
basic understanding of various dynamics of tumor response to treatments, particularly
immunotherapy and oncolytic virotherapy. The non-spatial modeling approaches and as-
sumptions reviewed in this section lay a fundamental understanding for the novel mathe-
matical models contained in Chapters 3− 5.
Currently, a considerable number of mathematical models of tumor-immune interactions
have been developed, using a variety of differential equations based approaches and individual-
based cell techniques. The majority of these models focus on role of immune system against
the growth of a solid tumor prior to tumor escape [122]. In the recent decades, a great
breadth of detailed molecular mechanisms underlying tumor growth and progression en-
abled development of a new generation of mathematical models that are specific and data-
oriented [123, 124]. Despite the overwhelming evidence of molecular mechanisms of tumor
development and progression, a comprehensive knowledge of tumor-immune interactions
is still limited. An understanding of immune system response to tumors is essential for
development of new, and/or refinement of existing therapeautic approaches.
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2.4.1 Models of the tumor and immune cells interactions
In the recent decades, many mathematical models describing the interactions of immune
system with tumors have been developed [125–130]. Most of these model are reviewed
in [123, 124, 131–134]. Of particular interest in this thesis are the models that illustrate
the engagement of immune system in controlling tumor growth and evasion. We present
a review and discussion of some of these models that consider immune surveillance of
tumors. We only present a review of the mathematical models that provided a profound
understanding of the key interactions between tumor cells and immune cells.
Immune surveillance of tumors is considered to be a key host defense mechanism through
which the body attempts to inhibit tumor progression and to retain cellular homeostasis.
A mathematical model describing how tumors expressing Fas ligand (FasL) may induce an
apoptosis on activated lymphocytes via corresponding Fas receptor (Fas) was developed
in [135]. An important immune escape mechanism modeled in this model is the expres-
sion of death ligand, FasL, by tumor cells. Evidence shows that certain types of tumors
constitutively express FasL which might induce apoptosis on activated lymphocytes which
express Fas in response to tumor antigen. The model is constructed to illustrate the fol-
lowing molecular interactions between tumor cells and activated T-cells: (a) Tumors often
exhibit down-regulated levels of Fas receptor compared to activated T-cells; (b) tumor
cells constitutively express the death ligand, FasL, whereas T-cells only express FasL upon
activation. The model predicted that by neutralising the expression of Fas ligand or re-
ceptor on the cell surface, production of soluble forms of Fas and FasL may enable tumors
to evade immune-mediated apoptosis. Through numerical simulations, authors confirmed
that MMP inactivation increases Fas-mediated apoptosis for T-cells than for tumor cells.
Although the model illustrated most important dynamics of the combat between tumor
and T cells, it did not include the possibility of the apoptosis resulting from T-cell-to-T-cell
interactions with up-regulated FasL and Fas receptor expression, and tumor-to-tumor cell
apoptosis. The latter case may be clinically favourable, as it may contribute to tumor de-
struction, whereas the apoptosis resulting from T-cell-to-T-cell interactions may promote
tumor evasion from immune surveillance.
Another interesting mathematical model describing how cancer immune surveillance is
maintained by different immune cells of innate and adaptive immunities was developed
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in [126]. The model focused mainly on different roles played by NK and CD8+ T cells
in battle against tumor development and progression. Using an experimental data from
mouse models, authors investigated parameter estimation and explored model validation.
Sensitivity analysis, a procedure for identifying most important parameters in the model
in regard to tumor treatment, was also performed. From sensitivity analyses, it was found
that the intrinsic tumor cell growth rate and the parameter which indicates how the lysis
rate depends on the CD8+ T cell/tumor ratio, were the most significant parameters in the
model. This model provides a basic understanding about the distinct key roles played by
the natural killer and CD8+ T cells in inhibiting tumor growth and progression. Indeed, the
immune system is undoubtedly known to play an important role against the development
and progression of neoplasm cells [2, 22, 24, 29, 49, 50, 136, 137]. The model, however, did
not illustrate which tumor evasion mechanism do tumor cells evade the immune surveil-
lance. In Chapter 3, we will present and discuss a mathematical modeling framework that
addresses to this aspect of tumor escape from the immune surveillance.
2.4.2 Models of the oncolytic viruses, tumor and immune cells
interactions
One of the promising therapeutic approaches in treating certain cancers involves the use
of virus particles, called oncolytic viruses (OVs). These viruses are capable of infecting
and replicating within tumor cells, and have no or less harm to normal non-cancerous
cells [93, 96–100, 138–140]. The OVs can also be used to boost the antitumor immune
response by expressing pro-inflammatory cytokines and co-stimulatory molecules that are
capable of invoking a targeted immune attack against the infected and uninfected tumor
cells [141, 142]. Over the past decades, several mathematical models that provide insights
into the complex mechanisms inducing the immune response against tumor cells have been
developed. The effects of oncolytic virus infection on tumor and normal cell populations,
prior to adaptive immune response, have been investigated in [143]. The model focused on
elucidating how allowing oncolytic viruses to infect a limited number of normal cells can
be of great benefit to oncolytic virotherapy. In particular, the model showed how apparent
competition mediated by OVs on tumor-normal cell interactions may contribute to tumor
elimination while minimizing the loss of normal cells. Using a combination of analytical and
numerical solutions, it was shown that apparent competition can drive tumor to extinction
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when there is a small number of surviving tumor cells. Additionally, it was elucidated
that the virus burst size and infection rate of tumor cells can have a significant effect in
facilitating tumor clearance within a short time frame. Although this model provides a
fundamental understanding on how the infection of normal cells can enhance oncolytic
virotherapy, it did not fully demonstrate to what extend should normal cells be depleted
to achieve the targeted therapeutic outcome. Most importantly, the model did not show
how to avoid unwanted endemic infections on normal cell population. These two challenges
are fully addressed in the new mathematical model developed in 4.
In another study, the immune response was found to be an indispensable factor that could
influence tumor elimination in oncolytic virotherapy [144]. The effects of the immune
response triggered by sequential virus administration, an adenovirus (Ad) followed by
the oncolytic vesicular stomatitis virus (VSV), were investigated in [144]. The model is
based on the experimental settings in [145]. An ordinary differential equations model was
constructed to describe the dynamics of the tumor-immune interactions in the experiments
in [145]. By considering two biological phenomena, namely multi-stability and multi-
instability, it is illustrated that these phenomena equally influence tumors to change their
states. That is to change from tumor-free state to tumor-present state, or vice-versa. More
importantly, it is indicated that multi-instability can be attributed to an unexpected switch
from the tumor-free state to the tumor-present state. Additionally, it is shown that multi-
stability is driven by immune response, while multi-instability is driven by the presence of
the oncolytic virus.
2.4.3 Models of the delivery of therapeutic agents to tumor sites
Over the past few decades, a considerable number of both experimental and mathematical
models have been developed to address a challenge of low delivery of therapeutic agents to
tumor sites. These includes use of nanoparticles [113, 146, 147] and macrophages [148, 149]
to deliver therapeutic drugs to tumor sites. In this section, we only present a short review
of mathematical models that describe the application of cell-based delivery approaches. In
[148], a simple mathematical model that describes the growth of tumor spheroids in hypoxic
regions was proposed. Since hypoxic regions are known to have low rates of cell prolifera-
tion and poor chemotherapeutic drug permeability, authors proposed the model that uses
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macrophage infiltration capability into early avascular solid tumors. In particular, they in-
vestigated how chemotaxis and chemokine production at tumor sites influence macrophage
trafficking, and also how macrophages can be used as cell carriers of chemotherapeutic
drugs to the hypoxic tumor sites. Through model simulations, a traditional chemother-
apy and a chemotherapy coupled with engineered macrophages (which are used to deliver
therapeutic agents to hypoxic tumor sites) were compared. The model predicted that a
combination of the standard chemotherapy and macrophage-based therapies is more syn-
ergistic, with regard to antitumor efficacy, than the additive impact of each of treatment
protocol. The model also predicted that timing of the combined treatment protocol is an
important factor which determines the outcome of the treatment. Additionally, the model
indicated that the greatest outcome can be achieved when the macrophage-based therapy
is carried out shortly before or simultaneously with conventional chemotherapy.
Another intriguing mathematical model for delivery of therapeutic genes within tumor
microenvironment by engineered macrophages was developed in [149]. This model is an
extension of previous multiphase models developed in [148, 150, 151]. The model is based
on in vitro growth of tumor spheroids. Through numerical simulations, two modes of
drug action in the multicellular tumor spheroids were investigated: either the engineered
macrophages delivered the enzyme which is aimed at activating an externally applied pro-
drug (this was referred as a bystander model) or they delivered cytotoxic drugs directly
to tumor spheroids (this was referred to as a local model). Authors found out that the
bystander model resulted in similar outcomes to conventional chemotherapy due to poor
targeting of hypoxic tumor spheroid regions (i.e., at the center of the spheroid). The local
model, however, indicated high sensitivity of the hypoxic tumor regions. Therefore, the
authors suggested that in order to precisely target tumor hypoxic regions, it is important
to use a chemotherapeutic drug with limited mobility or whose action of mode does not
depend on proliferating cells.
Despite the great therapeutic insights unravelled by the above models, they did not con-
sider the impact of immune response within tumor sites upon successful delivery of ther-
apeutic agents, particularly when the macrophages are used to deliver oncolytic viruses.
Understanding the influence of immune response is vital for designing effective treatment
protocols that are applicable in immunocompetent hosts. This lack of research in this
direction motivates the development of the original research contained in Chapter 5.
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2.5 Summary
In this chapter, in addition to a brief review of commonly used cancer treatment modalities,
we presented a brief literature review of some of the key mathematical models of tumor-
immune interactions, and tumor response to treatments, particularly immunotherapy and
oncolytic virotherapy. This short literature review does indeed indicate that there has
been a substantial advancement in tumor biology and mathematical biology, as well as an
increase in the understanding of complex tumor-immune interactions.
Over the past decades, mathematical modeling of tumor-immune interactions has increased
our understanding of the tumor progression and response to treatments. In some models
discussed above, however, the precise mechanisms by which tumors escape from immune
surveillance have not yet been fully studied. In Chapter 3, we will provide a more closer
relevant look at some of these tumor-immune interactions which might lead to tumor escape
from immune system. In Chapter 4, we will then turn our attention to address some of the
outstanding challenges in oncolytic virotherapy, such as lack of sufficient oncolytic viruses
at tumor site when administering viruses systemically and inappropriate dosing scheme.
Although some of the models discussed above have indicated how cell carriers, such as
engineered macrophages, can be used to deliver therapeutic agents to tumor sites, the effect
of local immune response within tumor microenvironment has not yet been investigated.
The immune system is a major obstacle that can limit the success of oncolytic virotherapy
after the cell carriers have successfully delivered their therapeutic payloads. In Chapter 5,
in addition to determining the efficacy of two carrier cell-based treatments, we investigate
the long-term impact of the immune response within tumor microenvironment.
In the recent decades, many mathematical models describing the interactions of immune
system with tumors have been developed [125–130, 152]. Most of these model are reviewed
in [123, 124, 131–134]. The mathematical models, developed in this thesis are ordinary
differential- and delay-based models. It is worthwhile to note that in the literature, there
exists a wide variety of mathematical methods used to describe various dynamics of effec-
tive therapeutic protocols. The models range from deterministic ODEs models [11, 153],
stochastic process models [154, 155], agent-based models [156, 157], and multiscale models
[158–160]. The agent-based models represent each cell as a separate entity that functions
as an independent agent in accord with some predefined set of cellular rules. The general
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cell behavior is, however, defined by its interactions with other cells and with the host cell
microenvironment. The multiscale models are formulated in lattice-based formulations,
to account for cell-cell interactions and motions. The diffusion of chemicals and small
molecules (virotherpies) among cells are often explicitly described by partial differential
equation (PDE) formulations.
In a nut shell, mathematical and computational models have vastly improved our under-
standing of various biological phenomena and cancer biology. In combination with data,
mathematical models can shed light on the underlying mechanisms during cancer treat-
ment [161]. Moreover, in accord with certain biological assumptions, mathematical models
can provide a valuable information, and generate new predictions about different treatment
aspects, which would otherwise be difficult to make by experimental and clinical studies
only.
2.6 Problem definition and thesis statement
As indicated in the above mathematical background discussion, it is obvious that no at-
tempt has been made to precisely characterize key tumor evasion mechanisms from immune
surveillance, though some models have illustrated a possibility of tumor evasion from im-
mune system. Currently, there is still a limited understanding of how various tumors evolve
to evade immune system detection and control due to complex cellular interactions between
individual tumor cells and immune cells. Thus, there is a growing need for new modeling
approaches that take into account the complexity of immune system response and/or tumor
escape mechanisms, and the recent advances in cancer therapy. As part of this research,
we formulate and develop a quantitative framework that provides a complete picture of
the complex interactions between the growing tumors and immune system, with particular
focus on how individual tumor cells elude immune cells. Additionally, we also provide a
succinct quantitative framework that indicates how tumor burden can be reduced, if not
completely eliminated, with immunotherapy and oncolytic virotherapy. Herein, we report
the development of three novel mathematical models that account for distinct interaction
dynamics between tumor cells, normal cells, immune cells, and oncolytic viruses.
Through mathematical modeling, analysis and simulations, the overall goal of this research
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is to address the following major scientific questions:
1. How do tumors evolve by escaping immune surveillance?
2. How can oncolytic virus infection of some normal cells in the vicinity of tumor cells
enhance oncolytic virotherapy?
3. How can the use of cell carriers for the delivery of oncolytic virus particles to tumor
sites affect the outcomes of oncolytic virotherapy in the presence of active immune
response?
We tackle these three major scientific questions in Chapters 3, 4 and 5 respectively.




We present a novel mathematical model involving various immune cell populations and tu-
mor cell populations to address the following scientific question: How do tumors evolve
by escaping immune surveillance? The model describes how tumor cells evolve and
survive the brief encounter with the immune system mediated by natural killer (NK) cells
and the activated CD8+ cytotoxic T lymphocytes (CTLs). The model is composed of or-
dinary differential equations describing the interactions between these important immune
lymphocytes and various tumor cell populations. Based on up-to-date knowledge of im-
mune evasion and rational considerations, the model is designed to illustrate how tumors
evade both arms of host immunity (i.e. innate and adaptive immunity). The model pre-
dicts that: (a) An influx of an external source of NK cells might play a crucial role in
enhancing NK-cell immune surveillance; (b) The host immune system alone is not fully
effective against progression of tumor cells; (c) The development of immunoresistance by
tumor cells is inevitable in tumor immune surveillance. Our model also supports the im-
portance of infiltrating NK cells in tumor immune surveillance, which can be enhanced by
NK cell-based immunotherapeutic approaches.
22
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3.1 Introduction
Cancer is still one of the major causes of death worldwide. According to the World Health
Organization (WHO), the number of new cancer cases is expected to increase by 70% over
the next two decades [162]. Despite substantial advances in the treatment of certain types
of cancer over the last few years, a definite cure for cancer is still difficult to find. Of par-
ticular importance is the immune system’s ability to destroy cancer cells before they can
cause harm to the body, a function known as immune surveillance. Studies show that the
host immune system can recognize and eliminate cancerous cells [2, 22, 24, 29, 136, 137],
and that immunosurveillance mainly acts as a component of a more general process of
cancer immunoediting through which neoplastic progression may be inhibited [2, 163]. Re-
search also indicates that, despite immune surveillance, tumors do develop in the presence
of a functioning immune system [4, 5, 36, 87]. Additionally, studies suggest that tumor
cells quickly acquire various mechanisms to “escape” immune surveillance and successfully
grow into clinically apparent neoplasms [2, 163–167]. Recent findings also report that tu-
mor escape mechanisms from host immune surveillance present a major impediment for
successful immunotherapy [44, 47–51].
3.1.1 Tumor-immune interactions
The Natural Killer (NK) cells are part of the innate immune-effector cells that provide
a first line of defense in the body against pathogens, and crucially contribute to the im-
munosurveillance of tumors [2, 7, 8]. The NK cells have different cytotoxic properties and
cytokine-production capacities that enable them to eliminate transformed cells (i.e, tumor
cells and viral-infected cells). The NK cells can lyse tumor cells in a variety of distinct
ways by exocytosis of perforin, subsequent binding of perforin to the target tumor cell
membrane and formation of lytic pores or even by cytokine secretion [64, 65]. Some NK
cells can also lyse tumor cells through the expression of the death-inducing ligands Fas lig-
and (FasL) and tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL).
These ligands can induce tumor-cell apoptosis by binding to respective receptors, Fas and
TRAILR on the tumor cell surface [168–172]. Tumor cells could also be killed by TNF-
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α produced by NK cells [87, 173]. Moreover, some natural killer cells, particularly the
natural killer T (NKT) cells [174], secrete various pro-inflammatory cytokines, such as
interferon (IFN)-γ and nitric oxide (NO) which act as danger signals, to inhibit tumor
development and growth [174–176]. Natural killer cells can also lyse tumor cells through
antibody-dependent cellular cytotoxicity (ADCC) which involves binding of antibodies to
the FcγRIIIa receptor (CD16) on the NK cells [177, 178].
As part of the adaptive immunity, the activated CD8+ Cytotoxic T Lymphocytes (CTL)
play a crucial role in controlling the development of tumor cells. Activation of T cells occurs
when the T cell receptors bind to the antigen peptides, on the major histocompatibility
complex (MHC) class molecules, presented to them by the antigen presenting cells, such
dendritic cells or macrophages [179–182]. Upon recognition of antigen peptides on MHC
class I molecules, the activated CTLs can directly kill tumor cells via death cell ligands such
as TRAIL or by secreting cytotoxic granules such as perforin or granzyme [175, 183, 184].
The success of immune surveillance in controlling tumor development and growth may also
depend on the number of cytotoxic T lymphocytes primed to combat the target cancerous
cell. Therefore, another type of T cells called CD4+ T cells become activated and secrete
cytokines, such as interleukin-2 (IL-2), which help in the clonal expansion of the cytotoxic
T lymphocytes [185–187]. The more the cytotoxic T lymphocytes are produced, the better
are the chances of immune surveillance of tumors [185]. Additionally, experimental studies
by Gulubova et al. [188] suggest that a low NK cell number could be attributed to escape
of metastatic cancer cells from the mechanisms of immune surveillance. Thus, the number
of immune cells during the evolution of tumor cells may determine if the host immune
system can effectively control tumor growth [185–188].
In this study, we are interested in the long-time dynamics between tumor cells and the
host immune cells, and only consider the interplay of a tumor cells with natural killer
(NK) cells and cytotoxic T lymphocytes (CTLs). In our modeling framework, we propose
that the tumor cells that survived (through genetic mutations or epigenetic changes) a
brief attack by either NK or CTLs, or both, have higher chances of acquiring resistance to
future attacks by one or both types of immune cells. In fact, a tumor that has survived
a lethal encounter with immune cells, usually develops a variety of defensive mechanisms
to avoid future destruction by immune cells [29, 36, 136]. In turn, after surviving each
encounter with either a NK or CTL, tumor apoptotic resistance to immune system control
Stellenbosch University  https://scholar.sun.ac.za
Chapter 3. Tumour-immune surveillance 25
increases further via secretion of chemicals that diminish effectiveness of immune cells in the
subsequent attacks [136], or by developing mechanisms that down-regulate or inactivate
pro-apoptotic molecules, and up-regulate anti-apoptotic molecules [36, 38]. Tumor cells
that escaped the initial interactions with immune cells are “wild-type” tumor cells because
they are aware of the lethal presence of the immune effectors, and as such, they posses some
defensive mechanism from the immune cell types that attacked them [13, 36, 87, 179, 189].
Therefore, after a finite number of encounters with either NK or CTL, or both, a complete
or maximal resistance to NK-CTL based immunity is acquired [164].
3.1.2 Previous mathematical models
Several mathematical models of tumor-immune system interactions have been developed
by various researchers over the past decades [125–130]. For a comprehensive review of
these models, the reader is referred to excellent review articles in [123, 131–134].
Here, we review some of the key papers in the mathematical modeling of tumor-immune
interactions. We focus specifically on these papers because we have used them in our model
since they mathematically model evasion of tumors from immunosurveillance.
In [126], de Pillis et al. proposed a cancer immunosurveillance model system that consid-
ered different immune responses of innate and adaptive immunities to tumors recognition:
the natural killer (NK) and CD8+ T cells responses. The model tracked the different roles
played by NK and CD8+ T cells on tumor destruction. Based on experimental data, au-
thors developed an innovative functional form to represent the interaction between tumor
cells and the CD8+ T cells. This functional form represents a percentage lysis of CD8+ T
cells to tumor cells. Their model did indeed set the stage for the cancer immunosurveil-
lance modeling. Details of the hypothesis, such as why the functional form did not work
for the natural killer dynamics was kind of lacking. Since in our model we assume that
the tumour cells survive an attack by CD8+ CTLs, we have not used this functional form
in [126]; instead, we follow the dynamics of binding/detachment of CD8+ CTLs to tumor
cells, which lead to tumor escape from immune system, as in [164, 190, 191].
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Webb et al. [135] proposed a mathematical model that represented tumor cell-lymphocyte
interactions and the cell surface expression of Fas and FasL. The model was based upon the
fact that certain types of human cancers produce functional FasL and hence can introduce
an apoptosis on activated lymphocytes in vitro. This model by Webb et al. [135] showed
how tumor cells evade immune surveillance using the FasL/Fas system and their secreted
soluble forms (i.e. the matrix metalloproteinase (MMP) catalyzed soluble degradation
product of the ligand (sFasL)); however it did not show how tumor cells escape from one
or both arms of immune system (i.e. adaptive and innate immunity) and how tumor cells
evolve after evading one or both arms of the host immune system. These shortcomings
from Webb et al. [135] models are of particular interest to our model because tumors
need to circumvent either one or both arms of immunity to maintain progressive growth
[2]. More importantly, our proposed model considers the fact that the innate and adap-
tive immunities perform complementary functions. One of the most common mechanism
by which tumors evade the host immune surveillance is by loss of MHC class I molecule
expression on their cell surfaces. This mechanism only renders T cell responses ineffective.
However, evidence shows that tumor cells that evade the CD8+ T cell-mediated killing by
down-regulation of MHC class I molecules become potential targets for NK cell-mediated
killing [32, 192] via “missing self” signals [10]. If the NK cell is unable to bind to MHC
class I on the target cell, then NK-cell killing signal is triggered [10, 193, 194]. Therefore,
it is important to show how tumor cells evolve and survive from both cytotoxic arms of
immune system.
In [1], de Pillis et al. proposed a mathematical model that tracks the effect of multiple
immune cells, CD8+ T and NK cells, on tumor regression. The model focused on the inter-
action of the CD8+ T and NK cells with various tumor cell lines: NKG2D ligand transduced
and control-transduced (non-ligand) tumor cells. From the simulations, it was shown that
ligand transduced cells can stimulate protective immunity against tumor growth, while
the control-transduced tumor cells can escape immune surveillance. Additionally, it was
shown that the immune system provide better protection against tumors if it is primed
with ligand-transduced cells than with non-ligand tumor cells. These simulations were in
agreement with experimental data by Diefenbach et al. [195] which provided information
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on mouse immune response to the presence of a tumor. This model by de Pillis et al.
[1] provided a baseline framework for our model. In comparison to our proposed model,
ligand transduced tumor cells can be described as those tumor cells which are attacked by
activated CD8+ cytotoxic T lymphocytes (CTLs) (i.e. tumor cells with high expression of
MHC class I molecules in attempt to hide from NK cell-mediated killing [196, 197]) and the
control-transduced tumor cells can be described as those tumor cells which are potential
targets for NK cells (i.e. tumor cells with down-regulated MHC class I molecules on their
cell surfaces in attempt to evade the CD8+ T cell-mediated killing [32, 192]).
Despite major advances in the fight against cancer, the mechanisms by which tumors
escape the immune system’s recognition and control are still not well understood. Our
aim in this work is to gain insight into these dynamics of tumor-immune surveillance via a
mathematical model employing a system of nonlinear ordinary differential equations. To
the best of our knowledge, this is the first attempt to mathematically model how tumor cell
populations escape and acquire resistance to multiple immune cell populations resulting
from their several cell-cell encounters. In this study, we extend recent literature on tumor-
immune surveillance [1, 126, 135] and present a unique study that proposes a predictive




To describe how some immunogenic tumors (i.e. tumors that can be recognized by immune-
effector cells), escape from the host immune surveillance, we first differentiate between the
distinct interaction kinetics between natural killer (NK) cells, and the activated CD8+ cy-
totoxic T lymphocytes (CTLs) with immunogenic tumors. Since both NK cells and CTLs
can employ similar apoptosis mechanisms, we consider Fas/FasL binding between either
type of immune system with the tumor cell. Fas is a 45-kDa type I membrane protein, and
Fas-ligand (FasL) is a 37- to 40-kDa type II membrane protein which are members of the
tumor necrosis factor receptor and ligand families [198, 199].
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A Fas ligand (FasL) is present on cell surface of either an NK cell [168, 169, 172] or an
activated CD8+ CTL [200]. When an immune cell employs a Fas/FasL binding mechanism
to lyse tumor cell, the FasL binds with its cell surface-bound receptor Fas on tumor cell
[201]. This binding results in a complex through which apoptosis signals are sent into the
target tumor cell.
The attachment and detachment between tumor and NK cells via Fas/FasL binding are
depicted in Figure 3.1.
FIG. 3.1. A schematic view of the binding and detachment of a tumor cell to a natural
killer (NK) cell.
The formed complex enables the NK cell or CTL to induce the apoptosis signals to the
bound tumor cell. Binding of Fas on a tumor cell with FasL triggers a cascade of sub-cellular
events that result in apoptosis [202, 203]. Some tumors, however, avoid the apoptosis
through several mechanisms, including down-regulation of death receptors [36, 41, 204] or
expression of anti-apoptotis proteins like B7-H1 [205, 206], Phosphatidylinositol 3′-kinase
(PI3 K) and Akt (protein kinase B) [207] on their cell surface. The evolution of these
mechanisms may ultimately lead to tumor evasion from immune surveillance mediated by
either natural killer cells or activated CD8+ cytotoxic T lymphocyte [2, 196, 208].
A partial schematic interaction dynamics which lead to tumor escape are depicted in Fig-
ure 3.2.
Figure 3.2 indicates the interaction dynamics between a population of natural killer cells,
denoted by N , the population of activated CD8+ cytotoxic T lymphocytes, denoted by L,
and the population of “naive” tumor cells (i.e. tumor cells that have not yet developed any
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FIG. 3.2. A schematic diagram of the interactions between tumor cells, natural killer cells
and the activated CD8+ cytotoxic T lymphocytes. Parameters and variables appearing on
this schematic diagram are summarized in Tables 3.1 & 3.2.
escape mechanism to immune cells), denoted by T 0, and the population of tumor cells that
have escaped immune surveillance once, T 1N and T
1
L, or twice T
1
NL. Note, the superscript
0 appearing in T 0 denotes “naiveness” (i.e. tumor cells that have not yet developed any





denotes “wildness” of tumor cells (i.e. tumor cells that can hide from the specific immune
attack, and develop resistance to that specific immune cell). The subscripts, N,L and NL




NL, respectively denote the type of immune cell that interacted
with the tumor cell.
Accumulating evidence indicates that tumor cells, after surviving an immune attack, they
can either mount a “counter-attack” or develop resistance to immune cells [2, 26, 47]. Our
model does not account for a direct tumor counterattack, as was done in [190, 191]. In our
model, upon surviving their brief encounter with the tumor cells, the immune cells die to
natural cell death, not as a consequence of tumor counterattack. In Matzavinos et al. [190]
a spatio-temporal model of the interactions between tumor cells and tumor-infiltrating cy-
totoxic lymphocytes (TICLs) was proposed. The model included the spatial motility of
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both TICLs and tumor cells via a combination of random motility and chemotactic motion
of the TICLs in response to the presence of chemokines. Authors focused mainly on the
role of the immune system in determining dormant states of the tumor. Similar to our
model, the TICLs are assumed to migrate into the tumor site and interact with the tumor
cells in such a way that TICL-tumor cell complexes are formed. The outcome of these
complexes was two fold: the death of the tumor cells or the inactivation (sometimes even
the death) of the immune lymphocytes. The direct tumor counterattack was attributed
to the death of the immune lymphocytes, TICLs. In Joshi et al [191], a mathematical
model of immunotherapy and cancer vaccination was proposed. The model focused on
the role of antigen presentation and co-stimulatory signaling pathways in cancer immunol-
ogy. The direct tumor counterattack against effector immune cells was ascribed by the
death of effector immune cells as one of the outcomes of the effector-tumor cell complexes.
Counter-intuitively to these models, our model accounts for the development of resistance
to immune cell-mediated killings as a result of one or multiple encounters of tumor cells
with certain immune cells, as was done in [164]. In Al-Tameemi et al [164], a mathematical
model that describes a solid tumor growth in the presence of the immune system response
was presented. The model focused on the spatio-temporal interactions of the immuno-
genic tumor cells and cytotoxic T-lymphocytes (CTLs) in the presence of chemokines and
“chemorepellents”. In [164], as well as in our model, tumor cells and CTLs are assumed
to interact in such a way that CTL-tumor cell complexes are formed. After some time,
the formed CTL-tumor cell complex breaks up. This break-up of complex can lead to a
situation in which both the tumor cell and the CTL are alive, and either the CTL or the
tumor cell survives their brief encounter [164].
In order for the adaptive immunity to mount a specific anti-tumor response, there has to
be a variety of alarming activities from innate immune response that activate the adaptive
immunity [4, 209]. We, however, have not included this step in our model since the focus
is on the interaction dynamics of the activated CD8+ cytotoxic T lymphocytes with tumor
cells.
The kinetic parameters α+N and β
+
L represent respective initial rates of attachment of NK
cells and CTLs to naive tumor cells. Rates of tumor escape following its first brief encounter
with NK or CTL, with no damage on the cells, are denoted by α−N and β
−
L , respectively.
Since the interaction between tumor cells and immune cells may inactivate some immune
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cells, we consider only the immune cells that posses a certain effector fitness (i.e. immune
cytotoxic capacity similar to the one immune cells posses prior to their entanglement with
tumor cells) after their interaction with tumor cells. The quantities, pN and pL, represent
the respective proportions of NK cells and CTLs that are detached, with no damage on the
cells, from complexes formed when tumor cells bound with NK cells and CTLs. Similarly,
the quantities, πN and ζL, denote the respective proportions of NK cells and CTLs that are
detached, with no damage on the cells, from complexes formed when “wild-type” tumors,
T 1N and T
1
L, bound with NK cells and CTLs.
It is known that almost all kinds of tumor cells express Fas [202], and some may express
a Fas ligand, FasL, which might bind with its receptor, Fas, on the activated immune
cell [37]. Through this engagement of Fas receptor with its ligand FasL, tumor cell may
directly lyse the immune cell [29, 36, 135, 207, 210]. Thus, the quantities pT and qT
represent the proportions of tumor cells that escaped (i.e. via tumor “counterattack”) from
the surveillance mediated by NK cells and CTLs, respectively. Therefore, the Fas/FasL
complex constitutes an important role in controlling survival or growth of tumor cells
[202, 211].
Tumor cells interact with NK cell or CTL in such a way that complexes are formed as
shown in Figure 3.1. The complex resulting from binding of natural killer cell or activated
CD8+ cytotoxic T lymphocytes to naive tumor cell is denoted by CN and CL, respectively.
If a tumor has survived a brief encounter with either a NK cell or CTL then such tumor
develops, via mutations or epigenetic changes, a variety of mechanisms that might enable
it to avoid future attacks by the encountered type(s) of immune system [164].
Since we are considering the tumor-immune interactions under immune surveillance, tu-
mor cell that has once survived its encounter with NK cell is still susceptible to further
attacks by CTLs, and vice-versa. Since “wild-type” tumor cells usually develop immune
resistance to a type of immune cell that it has encountered [164], in this study, we assume
that subsequent interactions between that particular “wild-type” tumor with the same
type of immune cell is unlikely. Thus, we are only considering susceptibility of such tumor
cell to other different types of immune cell to illustrate how tumors may ultimately elude
overlapping attacks of distinct immune cells participating in tumor surveillance.
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Tumors do indeed develop complex mechanisms to evade various activities of immune sys-
tem recognition and control [2]. Here, we denote by CNNL and C
L
NL complexes formed from
the interaction of such “wild-type” tumor cells with NK cell and CTLs, respectively. Rate
of binding of NK cells to “wild-type” tumor cell that escaped from CTL surveillance is
denoted by α+L , and the rate of detachment of NK cells from the complex C
N
NL formed with
such tumor cell is denoted by α−L . Similarly, the respective rates of binding and detachment
of CTLs from “wild-type” tumor cell that escaped from NK-cell surveillance are denoted
by β+N and β
−
N .
The parameters and variables described in this section are summarized in Tables 3.1 & 3.2.
3.2.2 Model assumptions
We make the following assumptions for our model based on the discussion above and the
scientific literature on the immune system [1, 30–32, 35, 38, 122, 164, 192, 212, 213]:
(i) All tumors are immunogenic to trigger an immune response, and grow logistically in
the absence of immune response [1].
(ii) If a tumor has escaped from NK-cell surveillance, then the tumor resistance to NK-
mediated killing increases after its brief encounter with NK cell; the same analogy is
also true for the CTL surveillance. This resistance to NK-mediated killing is consid-
ered to occur as a result of up-regulation of MHC class I molecules [38]. Consequently,
up-regulation of these MHC class I molecules renders tumor cells more susceptible
to CTL-mediated killing [30–32, 192, 213]. Thus, phenotypically, the “wild-type”
tumors are different from the naive tumor cells.
(iii) The probability of “wild-type” tumor cell, that escaped NK-mediated killing, being
recognized and also of forming a complex with a NK cell (implicitly embedded in the
parameter α+L ) is small or zero. The same assumption applies to “wild-type” tumor
cell that escaped CTL-mediated killing [164].
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(iv) As part of the innate system, natural killer cells (N) are always present [1, 212] in the
host immune system, but cytotoxic T lymphocytes (L) are only present when tumor
is present [1].
(v) Both NK cells and activated CD8+ CTLs eventually become less effective after the
first encounter with tumor cells [1, 122].
(vi) Both NK and CTLs can lyse tumor cells [1, 35].
3.2.3 Terms used for growth, death and recruitment
We adapt a logistic growth for naive tumor cell, aT 0(1− bT 0), as well as wild-type tumor
cells that have survived the encounter with immune cells, aT ij (1− bT ij ) with j = N,L,NL
and i = 1. The rate of tumor growth is denoted by a, which includes both cell multiplication
(mitosis) and death, and the maximum carrying capacity of the tumor cells is represented
by the parameter b. Since we have assumed that CTLs are only present in the host immune
system only when the tumor is present, the growth term for the activated CD8+ CTLs
consists only of natural cell death. Thus, we have µ2L as the growth term for the activated
CD8+ CTLs. The NK cells are produced from an external source, s, as in [1]. The constant
parameter, s, accounts for the fact that that NK cells, as part of the innate immune, are
always present in the host body, even when no tumor is present. We assume that NK cells
and CTLs die at different constant rates µ1 and µ2, respectively.
The recruitment term, f(C, T ) where C = (CL, C
L
NL) and T = (T
0, T 1N), denotes pro-
liferation function of CTLs due to signals, such as released cytokines, produced in an
autocrine manner by the CTLs in CTL-tumor cell complexes [190, 214]. The function
f reaches some saturation at certain point since the immune system cannot produce






N), where r1 and r2 are constant rates at which CTLs are
recruited due to the formation of the complexes with “naive” and “wild-type” tumor cell
populations, respectively. Note r1 ≥ r2 ≥ 0 because after each brief encounter with immune
cells, the tumor cell develops some resistance towards subsequent interaction or potential
killing of each type of immune system encountered. Model variables are summarized in
Table 3.1.
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TABLE. 3.1. Model Variables
Variables Description
L Activated CD8+ cytotoxic T lymphocytes (CTLs)
N Natural killer (NK) cells
T 0 Naive tumor cells
T 1N Wild-type tumor cells that escaped from NK cells
T 1L Wild-type tumor cells that escaped from activated CD8
+ CTLs
T 1NL Wild-type tumor cells that escaped from both NK cells and
activated CD8+ CTLs
CN Complex formed by NK cell and naive tumor cell
CL Complex formed by CTL and naive tumor cell
CNNL Complex formed by NK cell and wild-type tumor cell that
escaped from activated CD8+ CTLs
CLNL Complex formed by CTL and wild-type tumor cell that
escaped from NK cells
3.2.4 Model equations
Assuming mass action kinetics, the model describing the interactions between various im-
mune cells and tumor cells is given by the following system of nonlinear ordinary differential
equations:
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local kinetics, with N
− β+LLT
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f(C, T ) = r1CL/(g + T
0)︸ ︷︷ ︸
Proliferation of CTLs in response






Proliferation of CTLs in response
to the wild-type tumors
(3.7)














N , πT , πN , ζT , ζL, pN , pT , qL, qT , r1, r2,
s, r1, r2, g, µ1 and µ2, summarized in Table 3.2, are all positive constants. Note, f(C, T )
denotes activation of the CTLs due to signals from binding of the activated CD8+ CTLs
with the tumor cells. Here, pT and qT denotes the proportions of initial tumor cell popula-
tions that escaped the local interactions with NK cells and CTLs, respectively. Similarly,
πT and ζT represent the proportions of the “wild-type” tumor cell populations that escaped
local interactions with NK cells and CTLs, respectively.
The tumor-immune interactions resulting in cell-complexes are governed by the kinetics
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between N & T 0
− α−NCN︸ ︷︷ ︸
Complex detachment







between L & T 0
− β−LCL︸ ︷︷ ︸
Complex detachment


























between N & T 1N
(3.11)
In this model, if either the tumor cell or attacking immune cell does not posses a ligand,




NL(t) are zero because the formation of
complexes requires the ligand to be present. The initial conditions for the model are:
N(0) = N0, L(0) = L0, T











NL = 0. (3.12)
For simplicity, we do not model successive multiple encounters between one immune cell
type and the same tumor cell that survived the first brief encounter. We only consider
the case where the target tumor cells have evaded the NK and/ or CTL surveillance once.
This is to illustrate how tumors acquire resistance to immune surveillance, and ultimately
proliferate without bound or get to equilibrium state of immunoediting as suggested by
Dunn et al. [2]. This model (3.1)− (3.11) can easily be extended to the setup of n tumor
escapes from immune surveillance mediated by NK cells and CTLs. Thus we have omitted
this case in this study. We now present a detailed explanation of each term involved in
each model equation.
In equation 3.1, the first term, s, represents a constant background source rate for nat-
ural killer cells. The second term, −µ1N , represents natural cell death of the NK cell
population. The third term, (−α+NNT 0 + pNα
−
NCN), represents the local interaction dy-
namics between NK cells and naive tumor cells, resulting in binding of NK cells to naive
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tumor cells, −α+NNT 0, and detachment of NK cells from tumor cells, pNα
−
NCN , without
damaging cells. Here, we assume that the NK cells that are detached from NK cell-tumor
complex maintained a high level of effectiveness as before the interaction with tumor cells.
This assumption is usually made when there is no cell damage resulting from detachment





resents the local interaction kinetics between NK cells and the wild-type tumor cells that
survived their brief encounters with the CTLs. The term −α+LNT 1L represent binding of




NL represents detachment of NK cells from
the NK cell-tumor complex. Recently, it has been shown that NK/CTLs can rapidly at-
tack other target cells after their detachment from tumor cells [215]. This later interaction
of NK cells and wild-type tumors may be important and is therefore included in the model.
In equation 3.2, the first term, f(C, T ), denotes recruitment of CTLs in response to the
presence to tumor cells. That is, r1CL/(g + T
0), represents CTL proliferation in response




N) represents the CTL proliferation in response to
wild-type tumor cells that escaped their brief encounter with the natural killer cells. This
functional form is borrowed from the simplified activated CD8+ T-cell recruitment term
from de Pillis et al [216]. Moreover, this CTL recruitment has been used by Matzavinos
et al. [190] and Joshi et al [191]. This functional form is usually employed when one
assumes that the recruitment of CTLs is due to signals, such as released cytokines (sig-
naling molecules that mediate and regulate immune system), produced by immune cells
in tumor-CTL complexes [190, 191]. The second term, −µ2L, represents natural death
of the activated CD8+ CTLs, as in de Pillis et al [1, 131, 212]. Since we have assumed
that activated CD8+ CTLs are only present when the tumor is present, then the acti-
vated CD8+ CTLs do not have an intrinsic growth. This third term, (−β+LLT 0 +qLβ
−
LCL),
represents binding −β+LLT 0, of activated CD8+ CTLs to the naive tumor cells, and detach-
ment, qLβ
−
LCL, of activated CD8
+ CTLs from the naive tumor cells. Similar to NK cell,
activated CD8+ CTLs are susceptible to interactions with the wild-type tumor. Hence,




NL), represents the local interactions of the activated
CD8+ CTLs with the wild-type tumors that escaped from NK cell surveillance. The term





NL represents detachment of the activated CD8
+ CTLs from wild-type tumor cells.
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In equation 3.3, the intrinsic growth dynamics of the naive tumor cells is represented by
logistic growth, aT 0(1 − bT 0). The logistic growth laws are consistent with models fitted
to real tumor growth data [1, 126, 131]. Since naive tumor cells are immunogenic to all
immune cells, the local interactions of the naive tumour cells with NK cells and activated




In equation 3.4, similar to equation (3.3), the first term represents a logistic growth of
the wild-type tumor cells which survived and escape their brief encounters with the NK
cells. The number of escaped tumor cells are represented by the second term, pTα
−
NCN .
However, since tumor cells which evade NK cell surveillance (i.e. tumor cells with up-
regulated expression of major histocompatibility complex (MHC) class I molecules [38])
are susceptible to CTL-mediated killing [30–32, 192, 213], their local interaction with the
activated CD8+ CTLs is represented by the last term, −β+NLT 1N .
In equation 3.5, the equation for wild-type tumor cells discussed is similar to the above
equation. The first term, aT 1L(1− bT 1L), represents logistic growth of the wild-type tumor
cells that survived and escaped their brief encounter with activated CD8+ CTLs. The sec-
ond term, qTβ
−
LCL, represents tumor cells that escaped CTL surveillance (i.e. tumor cells
with down-regulated MHC class I molecules). Down-regulation of MHC class I molecule is
known to be one of the escape mechanisms of tumor cells to evade CTL-mediated killing
[30–32, 192, 213]. However, down-regulation of these MHC class I molecules renders tumor
cells more susceptible to NK cell-mediated killing [32, 192]. Furthermore, evidence shows
that NK cells can recognize tumors that might evade the activated CD8+ CTL-mediated
killing by aberrant human leukocyte antigen (HLA) expression [217].
In equation 3.6, the first term represents logistic growth of the wild-type tumor cells that
are resistant to immune surveillance mediated by both NK cell and activated CD8+ CTLs.
We note that these tumor cells are “multi-immunoresistant” to both cytotoxic immune
cells, and therefore present a major impediment to successful immunotherapy [44, 48–51].
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3.2.5 The reduced model
The intrinsic growth of tumors involves multiple time scales: the proliferation of tumor
cells normally occurs on a time interval of months to years in vivo, while in vitro takes
weeks to months [218]. A complex formed between a NK cell or CTL and tumor cell
occurs on a small time scale (i.e. from several minutes to a few hours [214]). Moreover,
the recruitment of CTLs as well as the influx of NK cells to a tumor site usually occurs
on a much slower time scale (i.e. tens of hours [214]). In order to account for these dif-













. More importantly, we are interested in the interac-
tion between tumor cell populations and the immune system; hence we simplify the model’s
equations (3.1)− (3.11), by using quasi-steady-state approximations for the complexes. By
























LT 1N . (3.14)
By substituting these expressions into the system equations (3.1) − (3.6), we obtain the
following simplified system for the tumor-immune dynamics:
dN
dt
= s− µ1N − (1− pN)α+NNT




















































Followings are the positive initial conditions of the system:
N(0) = N0, L(0) = L0, T






NL(0) = 0, s(0) = s0. (3.21)
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The system of equations (3.15)− (3.20) along with the initial conditions (3.21) constitute
a reduced model of the immune surveillance of tumors that we use to explain how tumor
cells evade immune surveillance in the next section.
3.3 Model simulations and results
In this section, we discuss the numerical simulations of our mathematical model and give
plausible explanations of the proposed model results. The model enables us to simulate
tumor evasion based on various influx of the NK cells and the activated CD8+ CTLs. An
enhanced understanding of how tumors evade immune surveillance may help to identify
which components of host immune-effector forces that need to be augmented to boost
natural protection against tumors [2]. The major goal of this computational study is to
quantitatively elucidate how tumor cells escape from immune surveillance based on the
findings by Dunn et al. [2]:
(i) The immune system has capacity to recognize and destroy nascent transformed cells
(Elimination phase (immunosurveillance)).
(ii) Some tumor cells may survive immune destruction and become dormant (Equilibrium
phase (i.e. the phase where immuno-editing occurs).
(iii) After some time, selected tumor cell variants from the equilibrium phase can now
grow into clinically detectable tumors.
Of particular interest to our model framework is to elucidate how tumor cells most likely
circumvent either one or both arms of host immunity (i.e. innate and adaptive immunity)
in order to maintain progressive growth. A thorough understanding of plausible escape
mechanisms employed by tumor cells is a first necessary step towards the development of
successful strategies for immunotherapy [37, 48, 219].
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3.3.1 Model baseline parameters
To quantitatively analyze our model, we first need to determine the model baseline pa-
rameter values or at least a reasonable physiological range for them. We use data from
the available literature where possible and for other parameters we consider different value
ranges and their impact on the model outputs. A summary of the parameter descriptions
and their numerical values is given in table 3.2. We used most of the baseline parameter
values reported in [1, 164, 190, 191, 212, 214].
We now outline our approach to estimating numerical values for each model parameter.
To date, there is still a lack of quantitative data for Fas/FasL system between tumor cells
and immune system. We determined our model parameter estimates based on a variety
of approaches. First, we sourced all available parameter values from biological literature,
particularly parameter values related to activated CD8+ CTLs. To the best of our knowl-
edge, most of the available estimates of Fas/FasL system is based on the interactions of
activated CD8+ CTLs with tumor cells. However, since the engagement of Fas/FasL sys-
tem in activated CD8+ CTLs is similar to NK cells [220], we held most of the unknown
parameter estimates of binding and detachment of NK cells to tumor cells same as those of
activated CD8+ CTLs with tumor cells. Second, for some parameters, there is no relevant
information available regarding their numerical ranges, we chose parameter values which
confirmed the model’s behavior with biological realism.
Even though the parameter estimates provided in this section are baseline estimates taken
from a variety of sources, model sensitivity to changes in parameter values has been ex-
plored (see Section 3.4). In the following sections, we discuss in detail how numerical values
for each model parameter were estimated.
The natural killer cells
For numerical ranges of source of NK cells, s, we used values within biological ranges stated
in [214]. The death rate of NK cells, µ1 = 4.12 × 10−2cell−1 day−1, is obtained from de
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Pillis et al. [212]. We use same rate of binding of NK cells to tumor, α+N = 1.3×10−7 day−1,
as activated CD8+ CTLs binding rate reported in [164, 191]. The proportion of NK cells
that survived from NK-naive tumor complex and maintained high level of effectiveness,
pN = 0.94, is an ad hoc value and has been chosen to give biologically feasible outcomes.
The value of this proportion is not available in the literature. The formed complexes
between NK cells and tumor cells, may result in inactivation of some the NK cells and
consequently further chances of survival of the tumor cells [164, 190]. Since there is no
information in the literature on the proportion of NK cells that survived from NK-tumor
complex formed with wild-type tumor cell that escaped from CTL and maintained high
level of effectiveness, we chose a value of πN = 0.80 in order to obtain a biologically relevant
outcome from the model. The binding rate of NK cells to tumor cell that escaped from
CTLs, α+L = 1.2 × 10−9day−1 cells−1, is also an ad hoc value that is chosen to give the
biologically reasonable model results. Since the NK cells are capable of lysing tumor cells
via Fas/FasL system [168–172], the chosen value of α+L was motivated from the magnitude
of the values of CTL Fas/FasL binding as considered in [191]. The Fas/FasL system is in the
same family as tumour necrosis factor (TNF) and the extracellular domains of members of
the TNF family are known to be well conserved [135]. That means, the order of magnitude
of the values of Fas/FasL system should not change very much as of those values of TNF
family.
The activated CD8+ cytotoxic T lymphocytes
The rate of activated CD8+ CTLs recruitment due to signals resulting from CTL-naive
tumor interaction, r1 = 0.2988× 108 day−1 cells, is left unchanged from Al-Tameemi et al
[164], Matzavinos et al [190] and Joshi et al [191]. The rate of binding of activated CD8+
CTLs to naive tumor cells, β+L = 1.3×10−7 day−1 cells−1, and rate of detachment of CTLs
from naive tumor cells, β−L = 24 day
−1, are taken from Al-Tameemi et al [164] and Joshi
et al [191]. The constant appearing in recruitment function of the activated CD8+ CTLs,
g, is obtained from Al-Tameemi et al [164], Matzavinos et al [190] and Joshi et al [191].
The recruitment rate of activated CD8+ CTLs recruitment due to the presence of wild-type
tumor cells is given by r2 = 0.2755× 106 day−1 cells. Since there is no data measuring the
relevant recruitment kinetics of activated CD8+ CTLs to wild-type tumor cells, this value
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is chosen to maintain model consistency with biological expectations. Since the activated
CD8+ CTLs binds to tumor cells via the Fas/FasL system, we used same binding and
detachment rates of activated CD8+ CTLs to/from wild-type tumor cells as those of CTL-
naive tumor interactions: β+N = 1.3× 10−7 day−1 cells−1, and β
−
N = 24 day
−1, respectively.
This was motivated by the fact that the Fas/FasL system is in the same family as tumour
necrosis factor (TNF) and the extracellular domains of members of the TNF family are
known to be well conserved [135].
The natural death of the activated CD8+ CTLs, µ2 = 2.0 × 10−2 cell−1 day−1, is taken
from de Pillis et al. [212]. The proportion of activated CD8+ CTLs that survived from
CTL-naive tumor complex and maintained high level of effectiveness, qL = 0.94, as well as
the proportion of activated CD8+ CTLs that survived from CTL-tumor complex formed
with “wild-type” tumor cell that escaped from NK cells and maintained high level of
effectiveness, ζL = 0.85, are ad hoc values that are chosen to obtain the model consistency
with biological expectations.
The naive tumor cells
The tumor growth rate, a = 0.5822 day−1, and the inverse of the tumor carrying capacity,
b = 2.33 × 10−8 cells−1, were left unchanged from the values found by the de Pillis et al.
[1], who derived them by using MATLAB’s least-squares distance to tumor growth data
in mice from Diefenbach et al. [195]. Interestingly, these same values from de Pillis et al.
[1] provide a best fit to our model for naive tumor cell population, equation (3.15), in the
presence of weak immune system. The fitting was done by minimizing the sum of square
errors between observed data points and values of model solutions using the MATLAB
function lsqnonlin, and obtained Figure 3.3. Other parameters, α+N and β
+
L , were discussed
above.
The wild-type tumor cells
Estimation of most the parameters in these tumor cell populations was discussed in the pre-
vious sub-sections, except for the proportion of tumor cells that survived from NK/CTL-
tumor complex and maintained high level of effectiveness: pT = 0.05 from a complex
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between NK cells, N , and naive tumor cells, T 0; qT = 0.05 from the complex formed by
activated CD8+ CTLs, L, and naive tumor cells, T 0; ζT = 0.13 from the complex between
activated CD8+ CTLs, L, and wild-type tumor cells that escaped from NK cell surveil-
lance, T 1N , and πT = 0.18 from the complex formed between NK cells, N , and the wild-type
tumor cells that escaped from NK cell surveillance, T 1L. These parameter values are chosen
to ensure that the model operates within a biologically reasonable regime.
TABLE. 3.2: Tumor-Immune Model Baseline Parame-
ters: Their Definition and Sources
Parameter Definition Value Source
s External influx of NK cells 3.2 × 103 − 3.2 ×
104 day−1 cells
[214]










a The per capita growth rate
of tumor cells
0.5822 day−1 [1]
b The reciprocal carrying ca-
pacity of the tumor cells
2.33×10−8 cells−1 [1]
α+N Rate of binding of NK cells




α−N Rate of detachment of NK
cells from NK-tumor cell
complex
24 day−1 Estimate





β−L Rate of detachment of
CTLs from CTL-tumor
complex
24 day−1 [164, 191]
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α+L Rate of binding of NK cells





α−L Rate of detachment of NK
cells from tumor cell that
escaped from CTL
24 day−1 Estimate
β+N Rate of binding of CTLs





β−N Rate of detachment of
CTLs from tumor cell that
escaped from NK cells
24 day−1 [164]
pN Proportion of NK cells that
survived from NK-naive tu-
mor complex & maintained
high level of effectiveness
0.94 Estimate
pT Proportion of naive tumor
cells that survived from
NK-naive tumor complex
& maintained high level of
effectiveness
0.05 Estimate
qL Proportion of CTLs that
survived from CTL-naive
tumor complex & main-
tained high level of effec-
tiveness
0.94 Estimate
qT Proportion of naive tumor
cells that survived from
CTL-naive tumor complex
& maintained high level of
effectiveness
0.05 Estimate
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πN Proportion of NK cells
that survived from NK-
tumor complex formed
with “wild-type” tumor
cell that escaped from
CTL & maintained high
level of effectiveness
0.80 Estimate
πT Proportion of “wild-type”
tumor cells that escaped
from NK cells
0.18 Estimate




that escaped from NK cells
& maintained high level of
effectiveness
0.85 Estimate
ζT Proportion of “wild-type”
tumor cells that escaped
from CTLs
0.13 Estimate
r1 Rate of CTLs recruitment











g Maximum CTL recruit-
ment by immunogenic tu-
mor cells
2.02× 107 cells [164, 190, 191]
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3.3.2 Simulations and results
The numerical solutions of our model equations (3.15)− (3.20), along with the initial con-
ditions (3.21) are carried out using MATLAB ode23s. This stiff ODE solver, ode23s, was
used in this simulation in order to appropriately handle the differing time scales in the
system. In this simulation, the initial value set for strong immune system consists of 105
NK cells and 102 activated CD8+ lymphocytes as considered by Mamat et al [221]. The
low influx of natural killer (NK) cells, is s = 3.2×103 day−1 cells [214] and the low recruit-
ment of activated CD8+ cytotoxic T lymphocytes (CTLs), is r1 = 0.2988× 108 day−1 cells
[164, 190, 191] and r2 = 0.2755× 108 day−1 cells - estimate.
Comparing with previous studies
Using key model parameters, we started our simulation by comparing our results to a
previously published model by de Pillis et al. [1] who also investigated the interactions of
the NK and CD8+ cells with various tumor cell lines. It is important to emphasize here
that the study in [1] is based on assuming that tumor cells are a homogeneous population,
while in this study tumor cells are considered to be a heterogeneous (i.e. different tumor
cell lines: naive and wild-type tumors) population. This is motivated by the evidence
that tumor cells develop certain immunoresistance to a specific immune cell after surviving
their brief encounters [164]. During tumor cell development, tumor cells mutate in such a
way that they are not all identical [222]. This usually results in heterogeneous tumor cell
sub-populations [222, 223]. Recent evidence shows that tumors cells that survive immune
surveillance usually develop complex mechanisms that enable them to evade the immune
system [25]. By considering different tumor cell populations, our model shows that tumor
escape from immune surveillance may be attributed to evolution and development of these
heterogeneous tumor cell populations. In addition, this model successfully indicates the
advantage of following different tumor populations to reduce tumor escape from immune
surveillance.
Figure 3.3 indicates that naive tumor cells grow logistically in the presence of a weak
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immune response, not only in the absence of the immune response as done in [1]. More
importantly, since NK cells are always present in the body [1, 212], this figure shows
that the fact that tumor cells develop and grow in the presence of functioning immune
surveillance [4].
FIG. 3.3. Plot shows fitting of naive tumor cell population of the model (3.15)− (3.20) to
the real data of tumor growth used by De Pillis et al [1].
Investigating the effects of the weak immune system on tumor evasion
The simulations, as indicated in Figure 3.4 suggest that the model, with the parameter
assumptions and values we used, is capable of reproducing tumor escape from immune
surveillance in a biologically realistic time frame.
It is known that the immune system is capable of recognising and eradicating small tu-
mors, though some tumor cells can slip through the immune system net [4, 36, 224, 225].
Figure 3.4 indicates that tumor cells usually escape immunosurveillance when the immune
system is depleted [1]. Here, by depleted immune system we mean the case when there are
few cytotoxic immune cells at the tumor site. More apparent growth dynamics of each cell
population are given in Figure 3.5(a)− 3.5(b).
The results in Figure 3.5(a) could describe a case where immune system cells are out-
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FIG. 3.4. Plots indicating the growth of the tumor cell populations and immune cells
over time in the instance where there is low influx of natural killer (NK) cells, s = 3.2 ×
103 day−1 cells and low recruitment of activated CD8+ cytotoxic T lymphocytes (CTLs),
r1 = 0.2988 × 10−8 day−1 cells and r2 = 0.2755 × 10−8 day−1 cells. The plot shows that




NL, are capable of evading the immune system.
competed by tumor cells in the search of necessary nutrients required to maintain their
survival. Note that the CTLs are continually declining because we have assumed that
they are only present when the tumor is present, hence they have a negative growth
rate. Thus, we observe in Figure 3.5(b) that all tumor populations are growing when
the immune system is weak (i.e. when there is low influx of natural killer (NK) cells,
s = 3.2× 103 day−1 cells and low recruitment of activated CD8+ cytotoxic T lymphocytes
(CTLs), r1 = 0.2988× 10−8 day−1 cells and r2 = 0.2755× 10−8 day−1 cells).
However, if the immune system is strong (i.e., when there are 105 NK cells and 102 activated
CD8+ lymphocytes), and high influx of NK cells, s = 3.2 × 104 day−1 cells, we obtain
Figure 3.6.
Figure 3.6 demonstrates that the fact that an effective immune surveillance, mediated by
NK cells and activated CD8+ CTLs, is capable of controlling tumor growth [2]. We further
investigate how tumor may evolve if the immune system is weak. Here, a weak immune
system initially consists of 103 NK cells and 10 activated CD8+ cytotoxic T lymphocytes
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(a) Immune cells.
(b) tumor cells.
FIG. 3.5. Plots of individual tumor and immune cell populations when there is low influx of
natural killer (NK) cells and low recruitment of activated CD8+ cytotoxic T lymphocytes
(CTLs). Figure 3.5(a) indicates a natural response of NK cells to the presence of the
tumor, followed by decline to a non-zero level of NK cells. Figure 3.5(b) shows how each
tumor sub-population is growing over time in the case when the immune system is weak.
for the same initial naive tumor cell of 104 cells. More interestingly, by following indi-
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FIG. 3.6. Plots indicating the growth of the tumor cell populations and immune cells over
time in case where there is high influx of natural killer (NK) cells, s = 3.2×104 day−1 cells.
The plot indicates that immune system is capable of eliminating some “wild-type” tumor





vidual plots of each population, we obtain Figure 3.7(a) − 3.7(b). Figure 3.7(a) − 3.7(b)
indicates that even-though the immune system is able to eradicate or reduce some tumor
sub-populations, an evolution of multi-immunoresistant tumors cells, denoted by T 1NL, that
escaped from both arms of immune systems continue increasing. This simulation demon-
strates the fact that tumors do develop in the presence of a functioning immune system
[4, 5, 36, 87].
3.4 Sensitivity analysis
We now explore the sensitivity analysis of the model output to parameter values. We carry
out two standard procedures of evaluating model sensitivity to changes in the parameter
values, namely global sensitivity analysis (GSA) and local sensitivity analysis (LSA).
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(a) Immune cells.
(b) tumor cells.
FIG. 3.7. Plots of individual tumor and immune cell populations when there is high
influx of natural killer (NK) cells and high recruitment rate of activated CD8+ cytotoxic
T lymphocytes (CTLs). Figure 3.7(a) shows a rapid growth of NK cells in response to
the presence of the tumors, followed by saturation because there cannot be an unbounded
supply of NK cells in a realistic biological setting. Figure 3.7(b) shows how each tumor
sub-populations eradicated or reduced over time.
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3.4.1 Global sensitivity analysis (GSA)
We performed a global sensitivity analysis (GSA), where all 22 model parameters are
varied simultaneously, to investigate how variations in all model parameters influence the
model outcome. In particular, we consider one of the most reliable and efficient types of
global sensitivity analysis indexes, namely partial rank correlation coefficient (PRCC) [226].
PRCC measures the relationship (specifically monotonicity) between a model variable of
interest and each model parameter. Results of PRCC help to identify which key input
parameters contribute most to model variability. PRCC takes values between −1 and +1.
The sign of PRCC indicates how the model variable of interest is qualitatively related to
each model parameters. The absolute value of PRCC determines the degree of monotonicity
between the model variable of interest and the specific parameter.
Using the weak immune system baseline conditions, (i.e. 103 NK cells and 10 activated
CD8+ CTLs), we first computed the time to equilibrium (tumor free equilibrium) before
performing the global sensitivity analysis. Here, time to equilibrium is the time immune
system requires to eradicate or at least bring the tumor to a controlled state without any
treatment or boosting. For our model, time to equilibrium is 60 days. After 60 days, most
of the naive tumor growth dynamics have already been established. That means, either the
tumor has been eliminated by the immune system or escaped the immune surveillance. Of
particular interest, are the intermediate time points prior to dynamical equilibrium. These
time points may represent the time periods whose effect in tumor-immune interactions may
be altered through specific immunotherapies to inhibit tumor escape or prolong immune
system control on tumor populations.
We performed PRCC analyses for four different time points in order to investigate which
parameters consistently influence each model cell population in time. The indexes are
evaluated at the following time points 15, 30, 45 and 60 days prior to equilibrium state,
and the model variable chosen for sensitivity analysis is natural killer cells (Equation
(3.15)). For each of the four time points, denoted by 1, 2, 3 and 4, PRCC results are
shown in Figure 3.8. From the PRCCs results presented in Figure 3.8, we conclude that
the parameters for NK source, s, natural death of NK cells, µ1, and the binding rate,
α+L , of NK cells to the “wild-type” tumours, T
1
L, account for most uncertainty for NK cell
population.
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FIG. 3.8. PRCC results showing sensitivity indices of the model parameters with naive
tumor cell population chosen as a baseline PRCC analysis variable.
Figure 3.8 indicates PRCC results which show how parameters s, µ1 and α
+
L are consistently
significant and the most important parameters accountable for most of the variability NK
cells. The PRCC results suggest that the NK cell population over time is mainly affected
by variations in the parameters s, µ1 and α
+
L . PRCC scatter plots of the NK cell population
versus each parameter have been obtained, but we provide only scatter plots of these three
important parameters in Figure 3.9(a)−3.9(c), where the strong correlations are confirmed.
Note that although the scatter plot for the parameter α+L shows weak correlation, parameter
α+L is found to be consistently significant with the PRCC analysis.
In all figures in Figure 3.9(a) − 3.9(c), the axes indicate the residuals of the linear re-
gression between the rank-transformed values of the NK cell population against the rank-
transformed values of each the parameter. Note, Figure 3.9(a) and Figure 3.9(b) are
statistically significant even at 0.001 level, while Figure 3.9(c) is significant at 0.05 level of
significance. The source of NK cells has a strong positive, with PRCC of 0.92697, correla-
tion with NK cell population, while the death rate of NK cells has a strong negative, with
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(a) (b)
(c)
FIG. 3.9. PRCC scatter plots of the most significant parameters s, µ1 and α
+
L (computed
at the last time point, day 60). The title of each plot provides the PRCC value with the
corresponding p-value. The results are significant at the 0.05 level.
PRCC of −0.95583, correlation with NK cell population. The absolute value of the PRCC
value of 0.5 indicates no correlation between the input variable (i.e. parameters in this
case) and the outcome variable (i.e. the NK cell population). Thus, from Figure 3.9(c) we
note that the binding rate of NK cell to tumor cell has a moderate negative correlation,
with the PRCC value of −0.10202 and a small p-values 0.022519 < 0.05, with the NK cell
population. The parameters with large absolute PRCC values, PRCC > |0.5|, with corre-
sponding small p-values < 0.05, are considered to be the most important parameters [227].
These scatter plots illustrate how significant is PRCC analysis in determining monotonic
Stellenbosch University  https://scholar.sun.ac.za
Chapter 3. Tumour-immune surveillance 56
relationships between model variables and parameters using rank-transformation method.
Most interestingly, we performed PRCC analysis with regard to naive tumor cells in order
to investigate which parameters have significant variations in naive tumor population.
This is important because parameters with high influence on naive tumor cell population
may be accountable for tumor escape, leading to a new generation of wild-type tumor,
T 1i , i = N,L,NL. Identification of these parameters can help to design treatment strategies
that specifically target those factors that augment tumor escape from immune surveillance.
The results of the PRCCs are presented in Figure 3.10.
FIG. 3.10. PRCC results showing sensitivity indices of the model parameters with “naive”
tumor cell population chosen as a baseline PRCC analysis variable.
Figure 3.10 shows PRCC results over fourth different points: 15, 30, 45 and 60 days. In this
analysis, different parameters become statistically significant in different time points. For
instance, two parameters, the maximum CTL recruitment by immunogenic tumor cells,
g, and the rate of CTLs recruitment due to CTL-“wild-type” tumor complex, r2, were
statistically significant in the first time point. In the second time point, 30 days, CTLs
recruitment due to CTL-“naive” tumor complex, r1 and the binding rate of CTLs to naive
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tumor cells, β+L , are most influential in determining the tumor escape (|PRCC| > 0.5) and
are statistically significant (p-value < 0.05). In 45 days, only death of NK cells, µ1, and
the proportion of NK cells that survived from NK-tumor complex formed with “wild-type”
tumor cell that escaped from CTL and maintained high level of effectiveness, pN , are most
significant influential parameters. In the last in 60 days, an intrinsic tumor cell growth
rate, a, the binding rate of NK cells to tumor cell that escaped from CTLs, α+L , and re-
cruitment rate of CTLs due to CTL-“wild-type” tumor complex are the only parameters
that account for most variability in the model.
Despite a large number of parameters the model has, we note that it is significantly more
sensitive to variations to few parameters. Interestingly, at later time points, it is highly
sensitive to the intrinsic tumor growth rate a, as was the model by de Pillis et al. [216].
This is very interesting because given some tumor data sets these parameters can be
easily estimated, as was done in de Pillis et al. [1, 126]. One of the most interesting
finding in our analysis results is that the model reveals a higher degree of sensitivity
to key parameters that could be targeted with specific immunotherapies. The NK-cell
based immunotherapy can be used to enhance immune surveillance against developing
tumors [87]. Most interestingly, the fact that tumor-immune interactions can be observed
experimentally [2, 54], our sensitivity analysis indicates that the model parameters, such
as binding rate of NK cells to tumor cells or CTL recruitment, may be desirable targets
for immunotherapy.
3.4.2 Local sensitivity analysis (LSA): Model implications for
immunotherapy
We now provide a brief local sensitivity analysis of our model, equations (3.15)− (3.20), in
order to investigate how specific parameters of interest influence model behavior. Since the
model has many parameters, we only performed sensitivity analysis of parameters that are
associated with model implications for immunotherapy. In particular, we focused on how
specific changes in the source of NK cells, s, affect the number of “wild-type” tumor cells,
T 1L, that are susceptible to NK-cell mediated lysis after surviving their encounter with the
CTLs. To perform sensitivity analysis of our model with respect to the source of NK cells,
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s, we assumed that the NK cell influx parameter can be uniformly increased within the
range of ±10% or ±20% of the initial parameter baseline value.
Figure 3.11 and Figure 3.12 show the effect of varying the source term in the NK cells,
resulting in an increase for NK cell population and reduction of the “wild-type” tumor cells,
particularly T 1L. The NK cell source is varied in a biologically relevant range presented in
Table 3.2 in order to investigate the effect of NK cell influx on tumor regression. From
Figure 3.11, it can be observed when there is low boosting of NK cells, NK cell density
quickly reduces to zero. That means low-level boosting of NK cells, does not increase
NK cell density for longer periods of time. For instance, from Figure 3.11, it can be
seen that 50% boosting of NK cells continue producing elevated NK-cell density for up
to 20 days. Thus, in this simulation, it seems likely that tumor cell evasion from NK-
cell surveillance would occur after 20 days. From Figure 3.12, it can also be observed
FIG. 3.11. The plot showing the effect of varying the source term of NK cells in numerical
solutions. Increasing the source term of NK cells leads increased cell density of NK cells
for certain period of time. Other baseline parameters for these simulations are the same
as in Table 3.2, but we have values of s as indicated on the graph.
that high-level boosting of NK cells results in significant reduction of tumor cells that
are potential targets for NK cell. The presence of a high number of NK cells in tumors
contributes significantly to the host’s anti-tumor immune responses [228]. It is important
to note that Figure 3.12 does not indicate tumor eradication within 40 days, but tumor
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control with different NK-cell boosting levels. This result indicates that the NK cell-based
immunotherapy may be necessary (although perhaps not sufficient) to achieve an increased
tumor regression or a delayed tumor growth.
FIG. 3.12. The evolution of the “wild-type” tumor cells, T 1L, in numerical solutions of
our model, indicating the effect of varying the source term of NK cells. By increasing the
source term of the NK cells does not only decrease the number of tumor cell population but
also reduce time for evolution of these cells. The baseline parameters for these simulation
are given in Table 3.2, with values of the source of NK cells, s, as indicated on the graph.
The above results show that the number of immune cells at the tumor site plays a signif-
icant role in cancer immune surveillance. It is important to emphasize that at each time
step in our simulations, the number of immune cells at the tumor site is characterized by
the intent to interact with tumor cells and/ or carry out tumor lysis. When there are few
immune cells at the tumor site, we assumed that other immune cells, which are not at the
tumors site, are randomly attempting to migrate into immunogenic tumor site. As can
be seen in Figure 3.11 and Figure 3.12, an increment in the source of NK cells, results in
depleted number of tumor cells.
These results also suggest that an infiltration of NK cells can be used as one of the biological
treatment options to boost immune surveillance. Recent evidence indicates that NK-cell
infiltration into tumor tissues has been associated with positive prognosis in patients [87].
Moreover, studies from human cancers demonstrate that when there are few infiltrating
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NK cells into the tumor site, tumor elimination is not feasible [229, 230]. Therefore, as
shown in this study, NK-cell infiltration may be an important immunotherapeutic strategy
to enhance immune surveillance against tumor cells.
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3.5 Discussion
In this chapter, we developed a novel mathematical model for the immune surveillance of
tumors. The model describes how tumor cells evolve and survive the brief encounter with
the immune system mediated by natural killer (NK) cells and the activated CD8+ cytotoxic
T lymphocytes (CTLs). To our knowledge, this is the first mathematical study of the tumor
escape and acquisition of immune resistance to multiple immune cell populations. The key
features of this model are:
(a) The development of immunoresistance by the tumor cells: the model successfully
demonstrates that an evasion of tumor cells from their brief encounters with spe-
cific immune cells may enable tumor cells to acquire an immune-resistant phenotype
through genetic mutations or epigenetic changes. After surviving an immune attack, to
support their growth, tumor cells either mount a “counter-attack” or develop resistance
to immune cells [2, 26, 47].
(b) The inclusion of multiple tumor cell populations: multiple tumor cell populations are
included in this model, so that their respective evasion mechanisms can be quantified
at different stages of tumor growth. To avoid CTL-mediated lysis, tumor cells usually
down-regulate the major histocompatibility complex (MHC) class I molecules [30–32,
192, 213]. However, this down-regulation of MHC class I molecules renders tumor cells
more susceptible to NK cell-mediated killing [32, 192]. Thus, the model qualitatively
illustrates these dynamics of tumor hiding from immune cells.
The model predicts that the low NK cell number could be attributed to escape of cancer
cells from the mechanisms of immune surveillance as shown in Figures 3.4 and 3.5(b).
It also predicts that the development of immunoresistance by tumor cells is inevitable in
tumor immune surveillance as shown in Figures 3.6 and 3.7(b). In addition to an impor-
tant strategy of promoting tumor regression by focusing on increasing CD8+ T cell activity
[126] (i.e. to augment the negative CTL growth), our model supports boosting of NK cells.
Most interestingly, an immune-boosting of NK cells may offer a better strategy for devising
novel and more effective immunotherapies aimed at eliminating nascent tumor escape and
reducing acquired immune resistance. Evidence from experimental studies indicates that
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insufficient NK cell recruitment leads to tumor progression [231]. Additionally, the model
indicates that the host immunity can only effectively control tumor growth of certain cell
populations if the immune system is strong, as can be seen in Figure 3.6, otherwise tumor
growth progression would be uncontrollable. Recent progress in NK cell immunobiology
indicates that tumor cells can be eradicated only when immune responses are adequate [87].
The major results from this model are highlighted as follows:
An influx of the external source of NK cells might play a crucial role in en-
hancing NK-cell immune surveillance. The numerical simulations indicate that an
infiltration of the external source of NK cells might play a crucial role when there are insuf-
ficient NK cells in the body as seen in Figure 3.11 and Figure 3.12. Increasing the source
term of NK cells leads to an increased number of NK cells and consequently a decrease
in the number of tumor cell populations. This could be used as an adoptive cellular im-
munotherapy (ACI), a treatment in which the anti-tumor leukocytes, like activated CD8+
cytotoxic T lymphocytes (CTLs) or activated NK cells, are activated and cultured in large
numbers in a laboratory and transferred into tumor bearing host. Advances in anti-tumor
treatments such as cytokine-based immunotherapy [232] and adoptive cellular therapy [86]
indicated that NK-cell based immunotherapies provide a better prognosis against tumors
[87].
Immune system alone is not fully effective against progression of tumor cells.
The model’s simulations show that the immune system alone is not fully effective against
progression of tumor cells. For example, Figure 3.6 elucidates the dynamics of tumor-
immune interactions with a strong immune system, but the multi-immunoresistant tumor
cell population continues to grow. It is also worthwhile to note that the NK cell population
needs to be high enough, in the range of 1.0× 104 − 3.2× 104 day−1 cells, for an effective
anti-tumor response as shown in Figure 3.12. Recent evidence indicates that the presence of
a high number of NK cells at the tumor site contributes significantly to the host’s immune
surveillance [228].
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It has been suggested that low NK cell numbers in tumors increases chances of tumor
escape from immune surveillance [8, 87, 188, 228, 229, 233]. This has been shown by our
model as depicted in Figure 3.4 and Figure 3.5(a) − 3.5(b). In this scenario, all tumor
cell populations grow uncontrollably within a short period of time. This demonstrates
that the number of immune cells necessary for inhibition of tumor growth is of paramount
importance [8]. The NK cells, as part of innate immunity, are the first immune effectors to
attack developing tumor cells before the strong specific immunity comes into play [2, 193].
Evidence from clinical studies indicates that improved survival rate of patients with gastric
carcinoma was significantly enhanced in patients with a high rate of NK infiltration than
in those with a low level of NK infiltration [234]. Hence, the low number of NK cells at
the tumor site, may give tumor cells a chance to evade immune surveillance.
More importantly, studies show that high levels of NK cells, particularly tumor infiltrat-
ing NK cells (TINKs), have demonstrated a favorable tumor regression in patients with
colorectal carcinoma [235] and in squamous cell lung cancer [236]. This suggests that in-
creasing NK-cell influx into tumor tissues could represent a positive prognostic outcome,
as implicitly shown by the model’s simulations in Figure 3.12.
Multi-immunoresistance. Finally, we note that while some tumor cell populations are
decreased, naive tumor cells, T 0, and wild-type tumors that escaped from activated CD8+
CTLs, T 1L, in Figure 3.7(b), the multi-immunoresistant tumor population, T
1
NL, is not
altered significantly. Development of the multi-immunoresistant tumor cell population is
a major problem in cancer immune surveillance [47, 51].
Recent evidence shows that even-though a NK cell immunity complements a CD8+ cyto-
toxic T lymphocytes (CTLs) immunity, poor prognosis has been observed from patients
with HLA-I-defective melanoma cells [237]. This indicates that tumors are capable of de-
ploying complex mechanisms to evade NK cell immunosurveillance as well. Experimental
studies of Gulubova et al. [188] indicate that low NK cell numbers at the tumor site
could be attributed to escape of metastatic cancer cells from the mechanisms of immune
surveillance. This is confirmed by our simulation as indicated in Figure 3.4.
More importantly, the model simulations, depicted in Figure 3.11 and Figure 3.12, sup-
port the importance of infiltrating NK cells in tumor immune surveillance, which can be
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enhanced by NK cell-based immunotherapeutic approaches like infiltration of autologous
(patients’ own) NK cells [87, 238].
An important drawback of the proposed model is that the multi-immunoresistant tumor
population persists growing regardless of the presence of a high NK cell influx or a high
recruitment of activated CD8+ cytotoxic T lymphocytes (CTLs) to the tumor site. This
problem can be avoided by combining immunotherapy, as indicated by external source of
NK cells in our model, with other therapies like chemotherapy and/ or oncolotic virotherapy
[239, 240].
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Oncolytic Potency and Reduced
Virus Tumor-Specificity in Oncolytic
Virotherapy. A Mathematical
Modeling Approach
In the present chapter, we address by means of mathematical modeling the following main
question: How can oncolytic virus infection of some normal cells in the vicin-
ity of tumor cells enhance oncolytic virotherapy? To this end, we formulate a
mathematical model describing the interactions between the oncolytic virus, the tumor
cells, the normal cells, and the antitumoral and antiviral immune responses. The model
consists of a system of delay differential equations with one (discrete) delay. We derive
the model’s basic reproductive number within tumor and normal cell populations and use
their ratio as a metric for virus tumor-specificity. Numerical simulations are performed for
different values of the basic reproduction numbers and their ratios to investigate potential
trade-offs between tumor reduction and normal cells losses. A fundamental feature unrav-
elled by the model simulations is its great sensitivity to parameters that account for most
variation in the early or late stages of oncolytic virotherapy. From a clinical point of view,
our findings indicate that designing an oncolytic virus that is not 100% tumor-specific
can increase virus particles, which in turn, can further infect tumor cells. Moreover, our
findings indicate that when infected tissues can be regenerated, oncolytic viral infection of
normal cells could improve cancer treatment.
65
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4.1 Introduction
Oncolytic virotherapy is an emerging anti-cancer treatment modality that uses Oncolytic
Viruses (OVs). One of the most attractive features of the OVs is that they are either
naturally occurring or genetically engineered to selectively infect, replicate in and damage
tumor cells while leaving normal cells intact [96, 100]. This therapeutic approach faces a
major challenge consisting of the immune system’s response to the virus, which hinders
oncolytic virotherapy. To date, complex dynamics of oncolytic viral tumor infection and
the consequences of OV-induced immune response are poorly understood [241–243]. The
immune system has often being perceived as a major impediment to successful oncolytic
virus therapy by facilitating viral clearance [145, 227]. Additionally, clinical evidence [138,
244, 245] indicates that some oncolytic viruses have the ability to infect and replicate within
normal cells as well, especially in the brain, where neurons are unable to replicate, and the
oncolytic-induced neuronal damage could lead to undesired outcomes [102]. Evidence from
both pre-clinical and clinical experiments indicates that some oncolytic viruses (OVs) can
infect and replicate in normal cells surrounding the tumor [145, 246].
While this could be seen as another challenge to virotherapy, it could also be used to in-
crease viral potency as long as the replication within normal cells is well understood and
controlled. Much remains unknown about how to use normal cells to augment the oncolytic
virus population[247, 248]. It is important to note that when systemically administering
oncolytic virus that is not 100% tumor specific (i.e., viruses that can infect and replicate
within normal cells), infection of some normal cells can occur [138, 245]. When administer-
ing oncolytic viruses intravenously, the amount of virions that effectively reach the tumor
site is often reduced [249]. Note that viruses are small passive particles that reach their
target cells via either radial cell-to-cell spread or diffusion across concentration gradients
in soluble matters, such as blood, and propagate infection. Thus, infecting some normal
cells, by oncolytic virus, surrounding the tumor may aid to increase virus population. The
higher the number of infectious virions at the tumor territory, the higher the probability
of infecting and destroying every single tumor cell [249, 250]. It is important to investigate
how infection of the host normal cells by the OVs can enhance the oncolytic virotherapy.
To normal cells, such as liver, that can be quickly self-regenerated after a trauma or dis-
ease, infection of normal cells could be tolerable if such infection is not endemic (i.e., the
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infection does not persist forever) and could potentially aid to control tumor growth [251].
It is important to note that if the OV is not 100% tumor-specific and is administered
intravenously, then it can infect, not only the target tumor cells, but also some healthy
normal cells in the tumor site. Even though intratumoral viral injections offer direct tumor
infection, they are of limited use in regions (such as the brain) where the tumor cannot
be reached directly [111]. Thus, intravenous virus administration would be the only viable
option in those scenarios. Numerous pre-clinical attempts have been made to enhance the
oncolytic potency of some oncolytic viruses, such as recombinant VSV vectors, with limited
success.
Various mathematical models have been developed to investigate the dynamics of the
oncolytic viruses on tumor cells [144, 153, 239, 252]. None of the existing mathematical
models, however, explicitly considers the effects of the potential adaptive immune responses
against infected normal cells or against the virus itself after successful oncolytic virus
propagation. For example, the mathematical models in [144, 252], describe the interactions
of the immune cells with oncolytic viruses and tumor cells in virotherapy. While these two
models incorporated the effects of adaptive immunity as the effector and memory immune
responses, they did not consider tumor-immune interactions following successful onocolytic
viral propagation. Additionally, these two models considered intratumoral injection of the
oncolytic virus, while in our modeling attempt, we consider intravenous virus injection into
the susceptible cell population.
Up to date, there is no mathematical model that delineates how oncolytic viruses that are
not 100% tumor-specific can be used to augment oncolytic virotherapy with attenuated
effects on normal cells. A recent study by Okamoto et al. [143] illustrates how infections
of the normal cells by the oncolytic virus could enhance a cancer virotherapy prior to the
accumulation of the adaptive immune response. They modeled how apparent competition
between normal and tumor cell populations, both cell populations virally infected with a
given oncolytic virus, can drive tumor cell population to extinction prior to accumulation
of an adaptive immune response. While this model elucidated how infection of normal cells
by oncolytic viruses can aid to increase the virus population size at the tumor site and
reduce tumor burden, it did not take into account the fact that the oncolytic viral infection
on the normal cells can induce unexpected and inevitable immune responses against the
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infected normal cell population.
Our proposed model also aims to elucidate the tumor-normal-immune-viral dynamics 1−4
days in the presence of immune response triggered by the escalated viral infection of normal
cells. This is very important because the induction of activated CD8+ T cells into the
tumor site may limit subsequent oncolytic virus spread and intratumoral infection. Even
though we do not model the innate immune responses, it is important to note that the
innate immune response against the virally-infected cells is often active in about 2−7 days
post-infection [253].
4.2 Mathematical model formulation
The mathematical model is based on the diagram shown in Figure 4.1. The model’s vari-
ables and parameters are listed in Tables 4.1 and 4.2, respectively. The model describes
the interactions between normal and tumor cells in the presence of the adaptive immune
responses following an initial successful viral propagation phase on both normal and tumor
cell populations. It consists of a system of delay differential equations (DDEs) with one
discrete delay representing the time necessary to induce tumor-specific immune response.
The main objectives of the proposed model are to predict: (1) the oncolytic viral tumor-
specificity that maximises tumor reduction while minimizing the undesirable toxicity on
normal tissue surrounding the tumor; (2) the effects of the potential antitumoral and an-
tiviral immune responses in oncolytic virotherapy; and (3) tumor’s response to oncolytic
viral infections, particularly, the model’s performance to single-viral and multi-viral injec-
tions strategies. For our modeling framework, we use the basic reproductive number R0
(see Section 4.3.1) to indicate the combined therapeutic index of the oncolytic virus that
is not 100% tumor-specific as a measure of oncolytic potency of the normal and tumor cell
populations. Understanding the therapeutic index for oncolytic viruses is essential for the
assessment of safety and selectivity of oncolytic viruses [254].
Our proposed model uniquely characterizes the impact of the oncolytic virus that is not
100% tumor-specific on the normal and tumor cell populations and further assesses the
effects of corresponding antiviral and antitumoral adaptive immune responses following a
successful virus propagation in oncolytic virotherapy. Here, the oncolytic virus that is not
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TABLE. 4.1. Model Variables
Variable Description
NS(t) the total number of susceptible (uninfected) normal cell population
TS(t) the total number of susceptible (uninfected) tumor cell population
NI(t) the total number of infected normal cell population
TI(t) the total number infected tumor cell population
V (t) the total number of oncolytic virions
YT (t) the total number of tumor-specific immune cells
(primed tumor antigen-specific CD8+ T cells)
YV (t) the total number of virus-specific immune cells
(primed antiviral CD8+ T cells)
100% tumor-specific is assumed to be a vesicular stomatitis virus (VSV), and the adaptive
antitumor/antiviral immune cells are CD8+ T cells. We have chosen to use VSV in our
model because it is capable of infecting a wide range of cell lines, has a genome that is
easy to manipulate, and is capable of producing high viral titers [244, 258, 259]. More
appropriate to our model, it has potential to infect both populations of normal and tumor
cells. In order to allow the VSV to infect both normal and tumor cell populations, we
assume that the viral injections into the system are administered intravenously and close
to the tumor. One important assumption underlying our model is that the interaction
kinetics between cell population and the VSV follow mass action kinetics, and all cell
populations are homogeneously mixed as assumed in [1, 260, 261]. Homogeneous mixing
implies that there are no different cell types within one cell population. Mass action
kinetics are the appropriate interaction kinetics when one assumes that the density of
the cell populations and viral particles is proportional to the total number of cells and
viral particles [262]. Alternative to the mass action infection kinetics are the kinetics
that account for the possibility of virus infection saturation at higher virus concentrations
(e.g., see models in [263, 264]) or the virus infections that are frequency-dependent (e.g.,
see models in [239, 262]). Although such virus infection kinetics may be more realistic
than mass action kinetics, they may, however, not be well known and may lead to more
parameters.
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FIG. 4.1. A schematic representation of the interactions among normal cells, tumor cells,
immune cells, and oncolytic viral particles. Susceptible (Uninfected) normal and tumor
cells become infected by an oncolytic virus (vesicular stomatitis virus (VSV)). After suc-
cessful viral propagation within the infected cells, infected cells undergo lysis (cell rupture)
producing a progeny of new infectious viruses which spread and infect other susceptible
cells. Debris from infected cells activates the virus-specific immune cells which then in-
duces killing of infected cells and clearance of free virus. The tumor-specfic immune cells
recognise (due to expression of tumor-associated antigens (TAAs)) and kill both uninfected
and infected tumor cells.
4.2.1 Model assumptions
The biological assumptions incorporated in the model based on the discussion above and
the scientific literature are as follows:
1. The susceptible (uninfected) normal and tumor cells grow logistically at the rates,
rN and rT , up to their carrying capacities, KN and KT , respectively. The choice of
the logistic growth for uninfected tumor cells is based on the fact that tumors grow
logistically in the absence of immune response [1]. Similarly, in the absence of cancer
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cells, normal cells are assumed to grow logistically [265].
2. For infected cell populations, we assume that their lifespan is much shorter than
uninfected cell populations; hence, we do not need logistic growth.
3. Given that the oncolytic virus can successfully infect normal cells, we assume that
normal cells, in the neighbourhood of tumor host tissue, can quickly self-renew during
and after the oncolytic therapy [251].
4. To induce immune responses, oncolytic viruses are often designed to express im-
munostimulating cytokines, such as a granulocyte macrophage-colony stimulating
factor [GM-CSF] [266] and interleukin [IL]-2 [267]. We, therefore, assume that on-
colytic virus infection on both normal and tumor cell populations can induce virus-
specific immune responses mediated by antiviral CD8+ T cells [268].
5. We assume that tumor-specific immune cells (antitumor CD8+ T cells) can recognise
and kill both uninfected and infected tumor cells because tumors often express tumor-
associated antigens (TAAs) [94, 269].
6. We assume that there is no virus-specific immunity prior to oncolytic virotherapy, and
hence all infected cell populations, and virus-specific immune cells start at size 0. On
the other hand, we assume that the initial size of the susceptible (uninfected) normal
and tumor cell populations is equivalent to the size determined by the experiments at
time 0 of tumor detection. Thus, we assume that tumor-specific immunity, measured
by the number of antitumor CD8+ T cells at the tumor site, exists at the start of
oncolytic virotherapy.
7. We also assume that upon lysis of an infected cell, a progeny of new infectious
oncolytic viruses bursts out of the lysed cell, and infect neighbouring uninfected
cells.
Stellenbosch University  https://scholar.sun.ac.za
Chapter 4. Modeling potency and reduced virus tumor-specificity 72
4.2.2 Model equations
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killing by immune cells
− γV YV TI︸ ︷︷ ︸




= bTλTTI︸ ︷︷ ︸
lysis









hT + TS + TI︸ ︷︷ ︸
recruitment





= pV (TI(t− τ) +NI(t− τ))︸ ︷︷ ︸
recruitment
− δV YV︸ ︷︷ ︸
death
(4.7)
The initial conditions of the model are as follows at t = 0: NS = 10
11 cells; TS = 10
6
cells; NI = 0 cells; TI = 0 cells; YT = YV = 0 cells; V (t) = 10
9 plaque-forming units
(PFU). (PFU is a globally accepted measurement for infectious titers (virus particles);
non-infectious (defective) virions that are incapable of forming plaques cannot infect their
target cells, and thus are excluded when counting the plaque-forming units.) For τ ≤ t ≤ 0,
we have constant history functions of cell concentrations on that time interval. Thus, we
implicitly assume that the system was at equilibrium prior to time 0 and apply to above
conditions at t = 0.





, represents a logistic growth of the
normal cells with an intrinsic growth rate rN and the carrying capacity KN . Note, the
normal cell population consists of uninfected (NS) and infected cells (NI). Since the unin-
fected normal cells can become infected with the oncolytic virus at the rate βN , the second
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term, −βNNSV , denotes the reduction of normal cell population due infection with the
oncolytic virus.
In equation 4.2, the logistic tumor cell growth of the uninfected tumor cells is denoted





with the intrinsic growth rate rT and the carrying capac-
ity KT . Similarly, during oncolytic virotherapy, the tumor cell population is sub-divided
into two sub-populations, the uninfected cells represented by TS and infected tumor cells
denoted by TI . The uninfected tumor cells become infected by the oncolytic virus at the
rate βT . Hence, the second term, −βTTSV , represents the reduction of the tumor cell pop-
ulation as a result of a successful viral oncolysis (i.e., viral replication and burst). Since
some oncolytic viruses, such as the vesicular stomatitis virus (VSV), are capable of induc-
ing the antitumor immune response against the infected tumor cells [90, 258], the third
term, −γT YThY +YT TS, represents the reduction of the tumor cell population by the antitumor
adaptive immune response. The interaction between tumor and the tumor-specific immune
cells follows the Michaelis-Menten kinetics because immune cell infiltration into the tumor
is often restricted by tumor architecture [179]. Thus, γT denotes the rate at which tumor
cells are lysed by the tumor-specific immune cells and hY represents the half-saturation
constant of immune cells that supports half the maximum killing rate.
In equation 4.3, the first term, βNNSV , represents the number of normal cells that be-
come infected with the oncolytic virus. The second term, −λNNI , denotes the death of
the infected normal cells at the rate λN . Experimental evidence indicates that death of
infected normal cells may be attributed to apoptosis of the infected cells in attempt to in-
hibit virus propagation [91]. Therefore, we assume that the infection by the oncolytic virus
also induces the adaptive antiviral immune response to infected cells [93]. The third term,
−γV YVNI , represents the number of infected normal cells lysed by the antiviral immunity
with lysis rate γV .
In equation 4.4, the first term, βTTSV , represents the number of tumor cells that be-
come infected with the virus. The second term, −λTTI , denotes the death of the infected
tumor cells at the OV-induced death rate λT . Again, since tumor architecture may hinder
the adaptive antitumor immune cell infiltration [179], we consider the Michaelis-Menten
kinetics for the interaction between infected tumor cells and the adaptive antitumor im-
mune response. Hence, we model this scenario with the term γT
YT
hY +YT
TI . The last term,
−γV YV TI , represents the number of infected tumor cells that become lysed by the virus-
specific immune cells.
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In equation 4.5, upon successful viral infection and replication, the infected tumor cells
die and new oncolytic virus particles that are released from the infected tumor cell. Thus,
bT is the burst size for viruses from an infected tumor cell. The first term, bTλTTI , rep-
resents the production of new oncolytic virus particles released from infected tumor cells
after a successful viral propagation. Similarly, the second term, bNλNNI , denotes the pro-
duction of new viral particles released from the successful oncolysis of the infected normal
cells. Here, bN is the burst size for viruses from an infected normal cell. Finally, the last
term, ωV , denotes the viral clearance of the free virus from the host body by virus-specific
immune cells, at the clearance a rate ω.
In equation 4.6, the adaptive antitumor immune response depends of the cross-priming
of the T-cells by mature antigen presenting cells (e.g. macrophages) with the antigens
expressed on both infected and uninfected tumor cells [270, 271]. For simplicity, we as-
sume that such a priming process has been successful and we do not model the kinetics of




, represents the antitumoral immune response against the tumor
cells, with the immune cell recruitment rate pT . Since activation of antitumoral immune
response, mediated by CD8+ T cells, is dependent on the amount of tumor antigens, we
use Michaelis-Menten term to indicate the saturation effects of the tumor-specfic immune
response [126, 128]. For simplicity, we use the same half-saturation constant of tumor
antigens that induce half proliferation of immune cells, hY , as the half-saturation constant
of adaptive immune cells that supports half the maximum killing rate (to both viral- and
tumor-specific CD8+ T cells), hT . Finally, the last term, −δTYT , denotes that the adaptive
tumor-specific immune population declines as a result of natural cell death, at the intrinsic
death rate δT .
In equation 4.7, a delayed immune response to virus infection to both normal and tumor
cells is modeled by the term pV (TI(t− τ) +NI(t− τ)), where a parameter pV is a virus-
specific proliferate rate of the antiviral immune cells due to the presence of virus particles
(virus antigens) on the surface of the infected cells. Immune response to viral antigens
require time necessary for cell activation and proliferation. That means, antigenic stimu-
lation generating the antiviral immune response, mediated by T cells, require a period of
time τ , which may depend on prior antigenic stimulation period t− τ . Note that the delay
of antiviral immune response is also crucial for enabling first round of oncolytic virus repli-
cation and subsequent release of the viral progeny [93]. The last term, −δV YV , represents
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the natural death, with the death rate −δV , of the adaptive virus-specific immune cells.
4.2.3 Parameter estimation
To analyse and simulate our model, we determine the baseline parameter values from the
literature that most correspond to available experimental data and biological facts. Since
most of the available parameter values from the literature are reported in daily rates, we
rescaled such parameter values by dividing each of them with d∗24 hours, where d denotes
the number of days, to convert daily rates to hourly rates.
Susceptible normal cells. Uninfected normal cell proliferation rate, and the normal cell
carrying capacity, rN = 0.00275 hr
−1 and KN = 10
11 cells, has been respectively taken from
[143]. Since wild-type vesicular stomatitis virus can infect normal cells, the rate at which
it infects normal cells, βN , is not known precisely. However, for our modeling purpose, the
hourly infection rate βN = (1.7 × 10−8)/24 virion−1 hr−1 of normal cells is rescaled from
Friedman et al. [255].
Susceptible tumor cells. Similarly, we have taken the proliferation rate, rT = 0.003
hr−1, and the tumor cell carrying capacity, KT = 1.47×1011 cells, from [143]. The baseline
value of the rate at which VSV infects tumor cells, βT = 0.038/24 virion
−1 hr−1, has been
rescaled from the daily rate in Eftimie et al. [144]. This parameter value is within the
range (5×10−12.5, 5×1014) virion−1 hr−1 defined in [143], where the authors found out that
the range allows for tumor persistence after the delay of 7 days prior to accumulation of
the adaptive immune response. The lysis rate of susceptible tumor cells by tumor-specific
immune cells, γT = 1/24 hr
−1, has also been rescaled from daily rate in Eftimie et al.
[144]. The half-saturation constant of the tumor-specific immune cells that maintains half
the maximum killing rate, hT = 40 cells, has been taken from [144].
Infected normal cells. The death rate of infected normal cells, λN = 1/24 cells hr
−1,
is an ad hoc value and has been chosen to conform with plausible biological outcomes.
The rationale for this parameter value was based on the fact that the average time for
an infected cell to undergo lysis is one day [239, 255, 272]. Similarly, the lysis rate of the
infected normal cells by virus-specific immune cells, γV = 1/24 cells hr
−1 is also an ad hoc
value. This value is chosen based on the reasoning that the virus-specific immune cells do
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not distinguish between normal or tumor cells because they are recruited in response to
viral antigens expressed by infected cells [99, 273].
Infected tumor cells. Similar to normal cells, the death rate of infected tumor cells due
to VSV lysis, λT = 1/24 cells hr
−1, has been rescaled from daily rate in Eftimie et al. [144].
Oncolytic virus. The burst size of VSV from lysed infected tumor cells, bT = 1350, is
taken from [143]. For normal cells, we estimate that the oncolytic vesicular stomatitis virus
(VSV) yields the burst size of bN = 1000. This value was chosen based on the fact that
VSV infection in normal cells is usually hampered by the presence of the interferon (IFN-β
or −α) [274]. Hence we chose bN ≤ bT since tumor cells are known to acquire deficiencies
in antiviral inhibitory mechanisms [275, 276]. The clearance of the free virus particle by
tumor-specific immune cells, ω = 2.5× 10−2 hr−1 was taken from [159, 255].
Tumor-specific immune cells. The hourly proliferation rate of tumor-specific immune
cells in response to tumor antigens, pT = 0.0375/24 hr
−1, was taken and rescaled from the
daily rate in de Pillis et al. [126]. Assuming that the tumor-specific immune cells (i.e.,
tumor-specific CD8+ T cells) have a half-life of 77 days as shown in [257], we estimate the
hourly death rate of the tumor-specific immune cells, δT , to be δT =
ln(2)
(77×24) ≈ 3.75× 10
−4
hr−1.
Virus-specific immune cells. We chose the ad hoc value of the proliferation rate of
virus-specific immune cells in response to VSV antigens, pV = 0.025 hr
−1, since it is the
lower bound of the daily interval rate of the virus-specific immune cell proliferation rate
shown by Eftimie et al. [144]. We tentatively chose this lower bound value because, during
viral propagation within the infected cells, we assume that the immune response against
the infected cells would be mainly driven by debris of infected cells since VSV has fast
replication cycle [277]. Finally, the hourly death rate of the virus-specific immune cells,
δV = 0.133/24 ≈ 5.54× 10−3 hr−1 was rescaled from daily rate in Eftimie et al. [144].
4.3 Model analysis
To better understand the dynamics of the proposed model, we begin by examining the
model’s behavior about the steady states in the absence of the virus. This analysis is
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crucial for identifying the parameters of the model that help to achieve a tumour-free
state without oncolytic virotherapy. Additionally, this analysis would be important for
comprehending the effect of the adaptive immune response following oncolytic virotherapy.
We first present the model’s virus free equilibrium points. Then we derive the model’s
basic reproductive number, R0, in Section 4.3.1. The corresponding stability analysis of
the model’s virus free equilibrium points, in terms of R0, is presented in Section 4.3.2. The
non-trivial steady states of the model without virus (i.e., NI = TI = YV = V = 0) are
found by equating equations (4.1 - 4.7) to zero, which results in the following virus free
steady states:
EN : = (KN , 0, 0, 0, 0, 0, 0) Tumor-free (TF) steady state, (4.8)
ET : = (0, 0, TS0, 0, 0, 0, YT0) Tumor-only (TO) steady state (4.9)
(i.e., tumor without the surrounding normal cells),
ENT : = (KN , 0, TS0, 0, 0, 0, YT0) Co-existence steady state (4.10)







, and YT0 =
pTTS0
δT (TS0 + hT )
with
a := rT ξ, ξ = hY δT + pT
b := (γT − rT )KT ξ + (hT rT −KTγT )hY δT
c := −KT δThThY rT .
The detailed mathematical proofs of the stability analyses associated with these steady
states are provided in Section 4.3.2. Before we discuss the stability analysis of the model,
we first derive the model’s basic reproductive number in the next section.
4.3.1 Model basic reproductive number
A basic reproductive number is defined as the average number of new infections generated
by one infected cell, via cell lysis, during virotherapy in a completely susceptible cell
population [278]. In general, if R0 > 1, then, on average, the number of new infections
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resulting from one infected cell is greater than one. Thus, viral infections will persist in
both normal and tumor cell populations. If R0 < 1, then, on average, the number of new
infections generated by one infected cell in virotherapy is less than one. This implies that
the viral infections will eventually disappear from the cell populations. Here, we provide a
detailed description of the calculation of the basic reproductive number of the model. We
use the next generation matrix approach [278, 279].
Proposition 1 The basic reproductive number of model is given by





, represents the basic reproductive number of the virus when introduced
into a population of normal cells only
ii. R0T :=
(YT+hT )bT βTλTTS
((YT+hT )λT+YT γT )ω
, represents the basic reproductive number of the virus when
introduced into a population of cancer cells only.
Proof. By formally applying the next generation method, we determine the threshold
parameter R0 at a virus free equilibrium point ENT := (NS, 0, TS, 0, 0, 0, YT ) . The vectors










γvYvTI + λTTI +
γTYTTI
hY +YT
−bNλNNI − bTλTTI + ω V










γV YV + λN 0 0
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The spectral radius of the matrix MN−1 is given by






(YT + hT ) bTβTλTTS
((YT + hT )λT + YTγT )ω
.
Brief guidelines for R0 analysis. We aim to find a threshold in which the oncolytic
viruses that can exploit both normal and tumor cells, such as vesicular stomatitis virus
(VSV), can infect normal cells without much toxicity on normal cell population. The major
goal of every oncolytic virus is to infect and lyse as many tumor cells as possible without
much toxicity on the host normal tissue. The focus of our model analysis is centred around
the basic reproductive number of the model. Numerical simulations, in conjunction with
the analysis of the basic reproductive numbers, aim to shed light on design and use of
oncolytic viruses that are not 100% tumor-specific. In particular, we seek for R0N such
that
R0N +R0T ' 1 (but) < 1.
Note that if, based on the value of R0N ,
R0N ' 0 the virus cannot infect normal cells
or  1 (the virus is too toxic on normal cells, hence not admirable.)
More importantly, R0N should satisfy the following conditions:
R0N = α̃R0T , α̃ 1, where α is a small proportionality constant,
R0N = α(1−R0T ), where α is a constant fraction.




, and R0T < 1.
With these guidelines on R0, we investigate how the evolution of the oncolytic virus influ-
ences the treatment dynamics in Section 4.4. Now, we present the stability analysis of our
model associated with the free virus steady states derived above.
Stellenbosch University  https://scholar.sun.ac.za
Chapter 4. Modeling potency and reduced virus tumor-specificity 80
4.3.2 Stability analysis of the virus free steady states
Proposition 2 The virus free equilibrium points EN and ET are always unstable, while
ENT is locally asymptotically stable if and only if R0 < 1.
Proof. Using Maple, the characteristic equation of the linearized system around the
equilibrium point ENT := (NS, 0, TS, 0, 0, 0, YT ) is independent of the delays and is given
by:
(δv + z) (zKN −KNrN + 2NSrN)
(
P2z









Q3 = YT + hT
Q2 = (YT + hT )λN + (YT + hT )ω + (YT + hT )λT + YTγT
Q1 = [(YT + hT )ω + (YT + hT )λT + YTγT − (YT + hT ) bNβNNS]λN
+ ((YT + hT )λT + YTγT )ω − (YT + hT ) bTβTλTTS
Q0 =
[
((YT + hT )λT + YTγT )ω
































S + P01TS + P00
with 
P13 = 2ξ
2rT = 2ξa, ξ = hY δT + pT
P12 = ξ [(−rT + δT + γT )KT ξ + (4hT rT −KTγT )hY δT ]
= ξ [B + δT (KT ξ + 3hT rThY )]
P11 = δThThY [(2δT + γT − 2rT )KT ξ + (2hT rT −KTγT )hY δT ]
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and 
P03 = 2δT rT ξ
2
P02 = δT ξ [(γT − rT ) ξKT + (4hT rT −KTγT )hY δT ]
P01 = 2δT
2hThY [(γT − rT ) ξKT + (hT rT −KTγT )hY δT ]
P00 = −KT δT 3hT 2hY 2rT
Stability of ET :
At the virus free and tumor endemic equilibrium point, ET , we have NS = 0 reducing the
term (zKN −KNrN + 2NSrN) in the characteristic equation (4.11) to (z − rN)KN which
has rN > 0 as a root. Hence ET is unstable, implying that the tumor would persists
growing uncontrollably.
Stability of EN :
At the virus-and-tumor free equilibrium, EN , we have TS = 0 and NS = KN reducing the
term (P2z






Y (z + δT ) (z − rT )
which has a positive root rT . Therefore, EN is unstable. This condition means that normal
cells are able to grow at an appreciable level in the absence of the tumor and virus. This
result tend to highlight the significance of the ability of normal cells in continuing to
maintain normal cell homeostasis in the absence of cancerous cells [280]. Note also that
due to the choice of mass action infection kinetics in our model, viral replication does not
affect the stability of this tumor free equilibrium.
Stability of ENT :
At the virus free equilibrium with both tumor and normal cells, ENT , we can see that P2
is always positive. Let us show that P1 and P0 are positive.
P1 = 2ξa0T
3
S + ξ [b0 + δT (KT ξ + 3hT rThY )]T
2
S




2 + δThThY c0.
Stellenbosch University  https://scholar.sun.ac.za
Chapter 4. Modeling potency and reduced virus tumor-specificity 82
Using a0T
2
S + b0TS = −c0 = KT δThThY rT , we obtain
P1 = ξa0T
3
S + ξKT δThThY rTTS +
(
KT δT ξ
2 + 3hThY δTa0
)
T 2S










2 + hThY δTa0
)
T 2S + 2hThY δTa0T
2
S




2 − δThThY c0.
Furthermore, since 2hThY δTa0T
2






2 + hThY δTa0
)
T 2S − 3δThThY c0











2 + hThY δTa0
)
T 2S − 3δThThY c0










2 + 2hThY δTa0
)
T 2S − 2δThThY c0
− δThThY c0 − hThY δTa0T 2S











2 + 2hThY δTa0
)
T 2S − 2δThThY c0
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We show next that P0 > 0,
P0 = 2δT ξa0T
3
S + δT ξ [(γT − rT ) ξKT + (4hT rT −KTγT )hY δT ]T 2S
+ 2δT
2hThY [(γT − rT ) ξKT + (hT rT −KTγT )hY δT ]TS
−KT δT 3hT 2hY 2rT .
Since (γT − rT )KT ξ + (hT rT −KTγT )hY δT = b0, then
ξ [(γT − rT ) ξKT + (4hT rT −KTγT )hY δT ]
= ξb0 + 3ξhT rThY δT
= ξb0 + 3hThY δTa0,
implying that
P0 = δT ξa0T
3












2hThY b0TS −KT δT 3hT 2hY 2rT .
Therefore,












S + b0TS + c0
)
= 0.
Thus P := P2z
2 + P1z + P0 > 0.
Concerning the polynomials Q0, Q1 and Q2, we have Q2 is always positive. Moreover, Q1
and Q2 can be written as
Q1 : = ((YT + hT )ω (1−R0N) + (YT + hT )λT + YTγT )λN
+ ((YT + hT )λT + YTγT )ω (1−R0T )
Q0 : = (((YT + hT )λT + YTγT )ω (1− (R0N +R0T )))λN .
Therefore,
Stellenbosch University  https://scholar.sun.ac.za
Chapter 4. Modeling potency and reduced virus tumor-specificity 84
i. If R0 := R0N + R0T > 1, then Q0 < 0 which by Routh Hurwitz criterion [281, 282] and
the fact that Q3 > 0 imply that Q has at least one root with positive real parts.
ii. If R0 < 1, then Q0 > 0. Moreover, we have R0N < 1 and R0T < 1 which implies that
Q1 is also positive. Furthermore, we have Q2 > 0 and Q3 > 0, and
Q1Q2 =
[
(ω (YT + hT ) (1−R0N) + (YT + hT )λT + YTγT )λN
+ω [(YT + hT )λT + YTγT ] (1−R0T )
]
× [(YT + hT )λN + (YT + hT )ω + (YT + hT )λT + YTγT ]
> [ω [(YT + hT )λT + YTγT ] (1−R0T )] [(YT + hT )λN ]
> ω [(YT + hT )λT + YTγT ] (1− (R0N +R0T )) [(YT + hT )λN ]
= Q0Q3.
Thus by Routh Hurwitz, the cubic polynomial Q := Q3z
3 +Q2z
2 +Q1z+Q0 does not
have any roots with positive real parts. Hence, ENT is locally asymptotically stable
if and only if R0 < 1, implying that the transient infections on normal and tumor
cell populations would naturally be eliminated.
4.4 Results
4.4.1 Numerical simulations
The numerical solutions of our model equations (4.1 - 4.7) along with the initial condi-
tions were carried out using MATLAB dde23. We first investigate the system’s long-term
behavior. Note, at time t < 7, we assume that there are no virus-specific immune cells at
the tumor site in order to allow the virus to infect, replicate and kill some infected cells.
For all the simulations, we assumed that the susceptible tumor begins at the size measured
at time t = 0 hours in an immunocompetent host. In experiments, tumor size is often
measured in volume (mm3), then in our model we convert tumor volume to cell population
by assuming that 1 mm3 ≈ 1× 106 tumor cells, as has been done in [239, 260].
Comparing with previous studies. To facilitate comparison of our model findings
with other mathematical models, in particular with the model by Okamoto et al. [143],
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we present numerical simulations where the therapeutic dose is V = 109 pfu of the initial
free virus load. As a first step in evaluating the performance and accuracy of a model
in predicting tumor growth, we fit our model to the available experimental tumor data
used in the model by Bajzer et al. [283], who obtained it from the in vivo experiments
of human myeloma tumor xenografts implanted in immunodeficient mice [284]. The data
in [283, 284] reports both the untreated and treated (when virotherapy was introduced on
day 15 after the implantation of multiple myeloma xenografts in mice) tumor growth. We
used the untreated tumor growth data to estimate the daily tumor growth rate (rT ) by
fitting a sub-form of our model and evaluated the accuracy of the numerical simulations.
The fitting of the sub-form of our model was done by minimizing the sum of square errors
(SSE) between the experimental data points and the model output using the MATLAB
function lsqnonlin. Our model fit, with a 95% confidence interval, is shown in Figure 4.2.
FIG. 4.2. Model fitting to experimental tumor growth data using Equation 4.2, the un-
infected (susceptible) tumor cell population, TS, and other model variables set to zero.
The susceptible tumor cell population is fitted to the data with two-sided 95% con-
fidence intervals (dashed lines) computed from exponential distribution statistics. A
black dashed line is just a straight line between data points. Parameter values are
rT = 0.00258, KT = 3.12× 108, βT = γT = 0.
Since one of the goals of our study is to predict tumor’s response to oncolytic viral infection,
we observe from Figure 4.2 that the model fits (with the susceptible cell population taken
as the baseline variable) the tumor growth data fairly well. This observation provides some
assurance that uncertain model parameters fall within 95% confidence of the true tumor
growth. We further assessed our model parameter sensitivity through a global sensitivity
analysis in the subsequent section in order to gain a better understanding of the model’s
behavior to small variations in the parameters.
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Global sensitivity analysis (GSA). For our model, we performed the GSA because
a large number of parameters. Most important, we perform sensitivity analysis in order
to identify key parameters that can be varied to achieve plausible oncolytic potency and
reduced tumor-specificity of the oncolytic virus that is not 100% tumor-specific in oncolytic
Virotherapy. Following the numerical method described in [226], we per- formed Latin
hypercube sampling. We generated 1000 samples to compute the PRCC and the associated
p-values with respect to virus infection at 24-hour intervals up to 96 hours. The sensitivity
indices of the PRCC, ranging from −1 to +1, indicate the strength of the monotonic
relation between the susceptible cell population and parameter of interest. A PRCC index
of −1 indicates a strong negative monotonic relationship between a given parameter and
the model variable(s) (i.e., susceptible normal and tumor cells in this case), while the
index of +1 shows a strong positive monotonic relationship between the given parameter
and model variable.
The GSA results: model implications for oncolytic virotherapy. We investigated
the parameter sensitivity analysis with τ = 0 in the equations 4.1−4.7. Sensitivity analysis
of our model without delay (i.e., when the parameter τ = 0), Equations 4.1 − 4.7. We
present only two time snapshots in Figure 4.3.
(a) 24 hours (b) 96 hours
FIG. 4.3. Sensitivity indices of the model parameters with oncolytic virus taken as a
baseline PRCC analysis variable. Analysis was computed based on the baseline parameter
values presented in Table 4.2, with a viral dose of V = 109 plaque-forming units (pfu).
The sensitivity analysis is computed at 24 and 96 hours.
Figure 4.3 reveals high sensitivity of the model to small parameter changes at 24 and 96
hours. Most important, this global sensitivity analysis indicates which parameters account
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for the most variation in the early or late stages of oncolytic virotherapy. From a treatment
perspective, this is essential for identifying which parameters of the model could be the
“key drivers” of the success of the virotherapy at any time point. In Figure 4.3, note
that the PRCC algorithm usually assigns a PRCC value to the control variable named
“dummy”. This dummy parameter is not part of the model parameters, and hence, it does
not affect the model results in any way. According to the PRCC algorithm, the model
parameters with sensitivity index less than or equal to that of the dummy parameter are
usually taken to be not significantly different from zero (with p-value > 0.01) [226].
The PRCC subplots, Figures 4.3(a)− 4.3(b), correspond to the times of giving the single-
viral dose of V = 109 virions at the 24 and 96 hours with the initial dose given at 24-hours
after the start of the tumor treatment. At time t = 24 hours, Figure 4.3(a) indicates
that a number of parameters are statistically different from zero (with p-value < 0.01) The
significant parameters include: the rate of VSV infection to tumor cells, βT , half saturation
constant of tumor infected cells, hT , the death rate of infected normal cells, λN , death rate
of the virus-specific immune cells, δV , the proliferation rate of tumor-specific immune cells
pT , and the lysis rate of the infected normal cells by virus-specific immune cells (γV ).
From the treatment perspective, the result of the sensitivity analysis shows that infection
of normal cells can induce an antiviral immune response that could quickly eliminate the
infected cells. This suggests that oncolytic viral infection of normal cells can be useful
only when the virus replicates rapidly within infected normal cells. At t = 96 hours,
the intrinsic growth rates, rN and rT , of normal and tumor cells also become consistently
influential on normal and tumor cell populations, respectively. Similarly, death rate of the
tumor-specific immune cells, δT , proliferation rate of tumor-specific immune cells, pT , and
the half-saturation constant of the adaptive immune cells, hT , also become statistically
significant at later time point (i.e., time t = 96 hours).
Based on this global sensitivity analysis, we deduce at following treatment implications: (i)
For a period of less than 4 days, apart from direct oncolysis, an oncolytic therapy should
target recruiting more tumor-specific cells to augment the therapy. This could be achieved
by engineering the VSV to express a tumor antigen directly [285]. Viral infections usually
trigger an immune response that is essential for elimination of tumor cells [91, 227]. This
sensitivity analysis indicates why it is currently not easy to treat tumors within 4 days
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with oncolytic viruses, from on the onset of tumorigenesis. The precise time of oncogenesis
in clinic is very difficult to determine. (ii) When designing the oncolytic viruses, such as
vesicular stomatitis virus (VSV) [145] or Newcastle disease virus (NDV) [274], that are not
100% tumor-specific, it is important that such viruses replicate rapidly within normal cells
since normal cells can quickly become more sensitive and inhibitory to virus replication
over time. Global sensitivity analysis illustrates that the model is less sensitive to early
viral infection (see Figure 4.3(a)) on the normal cell population, and becomes increasingly
sensitive at later time point (Figure 4.3(b)). (iii) Tumor aggressiveness as well as the
strength of the patient tumor-specific immunity may predict patient response to oncolytic
virotherapy.
4.4.2 Treatment strategies
Having determined which parameters are most influential in our model, we now investigate
two main dosing treatment strategies in oncolytic virotherapy: (1) single-viral dose (i.e.,
one viral dose administered at three different time points once), and (2) periodic dosing
(i.e., one viral dose given at three successive time points). Currently, a full understanding
of the best plausible protocols to administer oncolytic viruses to cancer patients is still
very limited. This is partly because there are no precise clinical results for comparing two
different oncolytic virotherapeutics administered through identical routes in the same types
of tumor. It is important to note that a comprehensive comparison of clinical virotherapy
trial regimens is time-consuming and complicated [286]. There is still no common consensus
regarding:
(i) the oncolytic virus dosages (i.e., low versus high dosage. The optimum oncolytic
virus dosage in the clinic is still unknown [287]; although virus inoculum is often
manipulated in clinical trials in orders of magnitude (103 − 1010) pfu [288]),
(ii) the appropriate dosing intervals (i.e., oncolytic virus repetitive times: hourly, weekly
or monthly. A detailed review of clinical dosing intervals of various oncolytic viruses
is reported in [286]),
(iii) the best virus delivery route (e.g., systemic delivery versus intratumoral delivery.
Recent clinical application of oncolytic viruses in these routes is reviewed in [286,
289]),
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(iv) the virus administration scheme (i.e., single- versus multiple-dose [290]. The appro-
priate dosing schedule of oncolytic viruses in the clinic is still not precisely defined
[287]).
Although some of the above issues have explored in several studies (e.g., see reviews in
[132, 291]), in the present study we address some of these challenges, in particular (ii)
and (iv), from the quantitative point of view that involves the basic reproductive number,
R0, of the model. In the subsequent section, we provide brief guidelines underlining the
use of R0 analysis that conforms with plausible biological outcomes of our model. Most
importantly, R0 analysis, along with model simulations, would help to understand the
qualitative behavior of the virus dynamics in our model, identify essential parameters
necessary for tumor extinction or at least a controlled tumor state, and suggest possible
future directions for further oncolytic virotherapy research.
Oncolytic viral infection dynamics. When designing an oncolytic virus, some impor-
tant considerations include administration of variety of dosing schemes and testing different
viral doses to ensure clinical safety [292]. Here, we present the results of the model with
respect to the free-virus steady state as described in Section 4.3 as our initial steady state.
In this steady state, it is interesting to investigate the effects of the virotherapy because:
(a) When the basic reproductive number of the model is less than one (R0 < 1), then the
oncolytic virus uses both normal and tumor cell populations for its replication. Note
that, in general, if R0 > 1, the viral infections will continue to spread in at least one
cell population, as implied by the case (i.) in Section 4.3.2. It is essential to note
that if R0 < 1, viral infections will eventually disappear from both tumor and normal
cell populations over time, as implied by the case (ii.) in Section 4.3.2. Of particular
interest, we note and define the following conditions on R0N :
(i) If R0N < 1, then the infection on normal cell population will ultimately vanish
over time.
(ii) When designing an oncolytic virus that is not 100% tumor-specific, it is important
to ensure that the basic reproductive number of normal cells, R0N , is less than
that of tumor cells, R0T . In this case, the virus would infect more tumor cells
Stellenbosch University  https://scholar.sun.ac.za
Chapter 4. Modeling potency and reduced virus tumor-specificity 90
than normal cells as evidenced by a large progeny virions from dead tumor cells
[66].
(iii) R0N < R
?
0N , where R
?
0N is the maximum value of the basic reproductive number
for the normal cell population.
(iv) Evidence suggests that the number of new virions produced from infected normal
cells is somehow proportional to that produced from tumor cells [274]. Thus, we
take R0N = α(1 − R0T ), where α is a constant fraction, as explained in Brief
guidelines for R0 analysis in Section 4.3.1.
(b) In the case where R0 < 1, the viral infection on normal cells would invoke the immune
response (T-cells or NK-cells) which may eliminate the virus-infected cells [293]. Thus,
the infection of normal cells has two therapeutic outcomes:
(i) If the virus replicates and lyses infected cells quickly, then oncolytic therapy may
be enhanced by production of new virions, which can then spread to uninfected
tumor cells. Evidence indicates that fast replicating viruses (i.e., those that can
lyse infected cells quickly), can avoid being engulfed by innate and adaptive
immune cells, and have a greater opportunity to further infect uninfected cells
[294].
(ii) Early removal of infected cells might inhibit success of the oncolytic therapy
[153], but late immune response involvement might be necessary for clearing
both infected normal and tumor (both uninfected and infected) cells [295].
(c) When the basic reproductive number of the model is greater than one (R0 > 1), then
the oncolytic virus endemically uses either normal or tumor cell population for its
replication. From the treatment point of view, having R0 > 1 is an undesirable treat-
ment result in virotherapy because R0 > 1, implies that viral infections will continue
to spread in at least on cell population. Note that the basic reproductive number of
the model, R0 (see Section 4.3.1), is composed of two basic reproductive numbers, R0N
and R0T , of normal and tumor cells, respectively. When at least one of the basic repro-
ductive numbers is greater than unity, then the cell population corresponding to the
one with the basic reproductive number greater than one would be the one in which
viral infection will persists forever. Further investigation of this condition (i.e., when
Stellenbosch University  https://scholar.sun.ac.za
Chapter 4. Modeling potency and reduced virus tumor-specificity 91
R0 > 1) constitutes one of the possible model extensions which will be incorporated in
the future work.
Experimental dosing scenarios. Here we examine the hypothetical clinical dosing
schedule of the oncolytic virus to test whether this would yield better treatment response
of our hypothetical patient under single-viral dose (Scenario 1) and periodic dosing (Sce-
nario 2). The rationale behind comparison of these treatment strategies in our model is
motivated by (ii) and (iv) in Treatment strategies. We are interested in investigating
virus dynamics for hourly dosing intervals under the two virus administration scenarios
(i.e., single- versus multiple-dose). We kept the same viral dosage regimen of V = 109 pfu
for all treatment scenarios. Maintaining the same virus injection dosage is often done in
experimental research (e.g., see [113, 146]). Note that for all the simulations, the value of τ
is fixed at 7 hours, and τ was shown not to affect the stability of the virus-free equilibrium
points. Hence, we have omitted the effects of time-varying delays in the present discus-
sions. The results of the model simulations when R0 < 1 are given in Figure 4.4(a)−4.4(b)
for periodic dosing scenario, and Figure 4.5(a)− 4.5(b) for single-viral dose scenario.
(a) (b)
FIG. 4.4. Plots of the susceptible normal and tumor cell populations when a virus is ad-
ministered at three successive times, with a viral dose of V = 109 pfu. Figure 4.5(a) shows
how the oncolytic virus reduces the susceptible normal cell population during multiple-viral
dose scheme. Figure 4.4(b) shows how successive viral doses can lead to tumor eradication
or at least keep the tumor in transient dormancy, which is followed by tumor relapse.
Given that the infected normal tissues in the neighbourhood of the tumor has capacity to
self-regenerate [251], we note from Figure 4.5(a) that the susceptible normal cells re-grow
to the carrying capacity when the amount of viral particles reduces. From Figure 4.4, it
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(a) (b)
FIG. 4.5. Plots of individual susceptible normal and tumor cell populations when the
single dose of V = 109 pfu is administered at three different time points. Figure 4.5(a)
shows a reduction and rapid self-renewing of the susceptible normal cell population during
an oncolytic virotherapy. Figure 4.5(b) shows the single-viral dose scheme leads to tumor
reduction, but tumor still grows after the initial reduction.
can be observed that administering the viral doses at successive time points leads to rapid
reduction of both susceptible normal and tumor cell populations.
4.4.3 Tolerable normal cell depletion
In conjunction with the Brief guidelines for R0 analysis in Section 4.3.1, we investigate
how much should normal cells be infected by the oncolytic virus in order to maximize
tumor reduction. One plausible approach in which normal cells can augment oncolytic
virotherapy is to allow the virus to infect some normal cells in the tumor site, given that
the basic reproductive number of the virus is less than unity (i.e., R0 < 1).
In cancer treatment, white blood cell (WBC) count (which incorporates all circulating
lymphocytes) is an important factor which is used to determine health status of a patient
prior to treatment. Most importantly, in clinics, WBC count is a first diagnostic measure
used to screen for potential virus infection [296]. In humans, the normal WBC count is
in the range of approximately 5 × 109 − 1010 cells/µl [296]. In our model, it is crucial
to track a population of normal (healthy) cells because it is important not to deplete
normal cells beyond tolerable losses. Thus, we need to determine a threshold, denoted by
ÑS cells, at which normal cells should not be depleted. However, since it often difficult
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to delineate what population of normal (non-cancerous) cells constitute in clinics, in our
model simulations, we link the population of normal cells with white blood cells. White
blood cells are always present whenever there is infection. Since oncolytic viruses that are
not 100% tumor specific can also infect non-cancerous cells (even white blood cells such
as neutrophils and monocytes), we use WBC count as a measure of normal cell depletion
resulting from oncolytic virus infection in the vicinity of tumor cells. More importantly, we
track the normal cell population in order to determine a stage at which our hypothetical
patient would no longer attain full remission from therapy. We assume the following
relationship between normal cell population and WBC count:
ÑS = α1B and that (4.13)
B̃ = fB0, (4.14)
where ÑS denotes the total minimum number of normal (healthy) cells that should not be
depleted in virotherapy, α1 denotes a constant fraction, B̃ denotes the cutoff level of white
blood cell count for humans, below which treatment should cease, f denotes a constant
fraction, and B0 denotes the initial normal WBC count prior to treatment. Here, we chose
B̃ = 108 cells/µl and B0 = 4.2 × 1010 cells/µl are taken in [297]. Thus, we estimate
f = B̃/B0 = 10
8/4.2× 1010 = 2.4× 10−3. We estimate ÑS = fN0S = KN × (2.4× 10−3) =
2.4× 109 cells, where N0S = KN denotes the carrying capacity of normal cells at the start
of oncolytic virotherapy. Here, ÑS serves as the level at which our hypothetical patient
would no longer attain full remission if the oncolytic therapy continues.
We present results α = 3
4
, shown in Figure 4.6 and Figure 4.7. When α = 1
2
, we obtain
Figures 4.4 with corresponding cell depletion profile shown in Tables 4.3. Note that when
α = 0, then the oncolytic virus is 100% tumor-specific since R0 = R0N +R0T .
As we would expect, under periodic dosing scheme, whenever R0N = 3(1 − R0T )/4, it is
possible to drive tumor population to extinction, shown in Figure 4.8(b) and Table 4.4,
while minimizing much loss of normal cell depletion, shown in Figures 4.8(a) and Table 4.4.
For all tested values of R0 < 1, we note that as long as R0N =
3(1−R0T )
4
, the tumor was
eliminated. Also, we note that increasing values of R0N slightly, the tumor can still be
controlled. Most importantly, we observe that multi-viral (periodic dosing) dosing schemes
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(a) (b)
FIG. 4.6. Relative comparison of cell depletion when the oncolytic virus is administered at








The corresponding cell depletion profile is provided in Tables 4.4
(a) (b)
FIG. 4.7. Relative comparison of cell depletion when the oncolytic virus is administered








offers better results in terms of tumor cell depletion, shown in Figures 4.8(a) and 4.8(b).
Thus, we compared minimum cell depletion for each cell population for varying values of
α under scenario 1. Results are provided in Tables 4.3 and 4.4.
Notably, from Table 4.4, when R0N is close to R0T , tumor cell population is diametrically
reduced and become eliminated between time t = 168 and t = 192 hours. We note that
at time t = 192 hours, there are 0.057081 cells because our model is based on delay
differential equations (DDEs). Numerical solutions from the DDEs can only provide some
information on the average behavior of the variables of the model; thus, complete tumor
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(a) (b)
FIG. 4.8. Simulation of cell depletion when R0N =
3(1−R0T )
4
. Figure 4.7(a) indicates a
decline in normal cell population. Figure 4.7(b) shows the tumor shrinks down to zero
over time.
elimination cannot be guaranteed in our model. In principle, however, when the average
number of cells is less than one, then we can assume that such cells are ideally eradicated.
Hence the tumor cells are eradicated in this scenario. On the other hand, interestingly,
we note that the population of normal cells has not reached the threshold value, ÑS =
KN × (2.4× 10−3) = 2.4× 109 cells, beyond which we expect our hypothetical patient not
to attain complete tumor remission. Most importantly, our results indicate no toxicity to
normal cells, since the minimum depletion of 6.331 × 109 normal cells, at time t = 192
hours, is above the threshold value, ÑS cells. What these results suggest is that designing
an oncolytic virus that is capable of exploiting a significant number of normal cells in the
neighbourhood of the tumor, can plausibly drive tumor cells to extinction. Our results are
more applicable the treatment scenario where tumors that cannot be reached directly.
4.5 Discussion
In this work, we set out to answer the main question of “How can oncolytic virus in-
fection of some normal cells in the vicinity of tumor cells enhance oncolytic
virotherapy?”To this end, we developed a delay differential equation model that de-
scribes the dynamics of the oncolytic virus that is not 100% tumor-specific on normal and
tumor cell populations. A major focus of our model analysis was to explore and delineate
the effects of oncolytic potency and specificity of viruses that not 100% tumor-specific in
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virotherapy. We now outline all the notable features of our model analyses and simulations
that provide a comprehensive picture of the model evolution and behavior on how oncolytic
viruses differentially exploit the populations of normal and tumor cells during oncolytic
virotherapy.
The oncolytic viral tumor-specificity. From a mathematical point of view, we
sought for the solutions of the model that provide a succinct framework on the oncolytic
viral tumor-specificity that maximises tumor reduction while minimizing the undesirable
toxicity on normal cell population surrounding the tumor. Most importantly, the model
predicts the evolution of three non-trivial virus free steady states; the tumor-free steady
state in which only normal cells are ultimately present, the tumor-only steady state in
which only tumor cells are present, and the co-existence steady state in which both normal
and tumor cells are present. The model equilibria analysis and simulations show that
the coexistence steady state plays a crucial role in controlling viral infections on normal
cell population at the onset of virotherapy. In particular, they show that whenever the
basic reproductive number R0 < 1, infection of normal cells by the oncolytic virus may
be tolerable only if such infections can aid to eliminate tumor cells (see Figure 4.8(b) and
Table 4.4) that would otherwise be difficult.
We then examined differing trajectories of oncolytic virus infection on tumor cells and
a limited number of normal cells. From the model simulations, Figure 4.5(a) and Fig-
ure 4.4(a), we note that normal cells quickly self-regenerate after initial reduction. The
attenuated damage on normal cells has distinct treatment explanations: (a) Direct viral
oncolysis is limited by early induction of antiviral immune response, (b) Virus propaga-
tion is inhibited by beta interferon (IFN-β) that is often secreted by normal cells. On the
other hand, we assume that infecting a limited portion of normal cell in the tumor bed
with oncolytic virus could augment oncolytic virotherapy. Given that the virus can infect
and replicate in normal cells, a progeny of infectious virions produced from lysed cells can
further spread and infect other uninfected tumor cells. Whenever the basic reproductive
number of normal cells is less than one, RON < 1, viral infections on normal cells would
eventually stop, coupled by the fact that normal cells often rapidly inhibit virus propaga-
tion [91]. Our findings suggest that oncolytic viral infection of normal cells can be useful
only when the virus replicates rapidly within infected normal cells.
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Most interestingly, our results, from Table 4.4, indicates that oncolytic viruses that are
capable of exploiting some normal cells, as their replication factories, can drive tumor
cells to extinction within biologically reasonable time frame. We emphasize here that
such oncolytic viruses should have a higher replication preferential profile, as illustrated
by respective basic reproductive numbers in our model, to tumor cells than normal cells.
It can be seen from Table 4.4 and Table 4.3, that when the oncolytic virus exploits more
normal cells within a given threshold, then tumor cell population is driven to extinction
rapidly, as shown explicitly in Table 4.4. From clinical point of view, our theoretical results
suggest that in normal cell population that can quickly self-renew (e.g., white blood cells or
the liver), oncolytic virus infection on limited portion of normal cells may aid to eradicate
tumor cells that would otherwise be difficult to eliminate. This is achievable and tolerable
only if such viral infections are not endemic (i.e., the basic reproductive number of the
virus is less than unity, R0 < 1).
The effects of the potential antitumoral and antiviral immune responses in
oncolytic virotherapy. Global sensitivity analysis elucidates that the model is very
sensitive to a number of parameters at the initial dose (i.e., at time t = 24 hours). For
tumor cell population, proliferation rate of uninfected tumor cells, rT , is the most positively
correlated parameter with the viral particles. At this early stage of tumor development,
as the proliferation rate of susceptible tumor cells, rT , increases, tumor density will also
increase. This observation is conformable with other findings that tumor cell proliferation
is a major essential factor for benign tumors, particularly the malignant tumors [298].
Note that the susceptible tumor cell population would only decrease if virus replication
outpaced the intrinsic tumor growth rate. This observation is in agreement with the
simulation results in Figure 4.4(b) and Figure 4.5(b) which indicates rapid reduction of the
susceptible tumor cell population when the VSV doses are administered periodically (i.e.,
at time t = 24). Note that for all time points of viral dose (see Figures 4.3(a)−4.3(b)), lysis
rate of susceptible tumor cells by tumor-specific immune cells (γT ) is the major determinant
parameter in the model. Interestingly, this result confirms the idea that a success of an
oncolytic virotherapy does not only depend on direct oncolysis but also on the influence of
immune response against tumor cells [90].
For normal cells, we similarly interpret the positive and negative correlations between the
parameters of normal cells and the oncolytic viral particles. The sensitivity analysis reveals
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that the model is highly sensitive to the lysis rate of the infected normal cells by virus-
specific immune cells (γV ) in first viral dose time point (i.e., at time t = 24 hours). This
observation suggests that initial viral infection of normal cells, can quickly induce antiviral
immune response against the infected cells.
Assessing the effectiveness of treatment strategies on tumor and normal cells
after injection with oncolytic virus. We investigated the effects of two treatment
strategies in oncolytic virotherapy: one single-viral dose illustrated in Figure 4.5, where
viral dose is administered at three independent times, and multiple-viral doses (i.e., periodic
dosing schedule) shown in Figure 4.4, where the virus is given at three successive times.
The value of R0 provides useful insights on the dynamics of oncolytic viral infection on
normal and tumor cell populations because: (a) Whenever the basic reproductive number
of the model is less than one (R0 < 1), the oncolytic viral replication occurs in both normal
and tumor cell populations; (b) When R0 < 1, viral infections on normal cells might trigger
antiviral immune response against the infected cells [293]. From Figure 4.5, we note that
single-viral dosing strategy reduces susceptible normal cells by same amount, irrespective
of the time of dosing, and the cells are rapidly self-renewing. Similarly, this strategy yields
similar results with respect to tumor cells. The cell count of the susceptible cell population
is quickly reduce, and followed by a rapid tumor relapse. In Figure 4.4, we note that
multiple-viral dosing (i.e., periodic dosing) has a significant effect on the susceptible tumor
cell population than on normal cell population. This strategy suggests that continued
periodic dosing may eradicate the tumor or at least delay tumor growth. Comparing these
two therapeutic strategies, we note that multiple-viral dose regime, shown Figure 4.4, offers
more favorable treatment outcomes than the single-viral dose regime, shown Figure 4.5,
with respect to reduction of susceptible tumor cell population.
Our model results are comparable with other mathematical models. Our model predicts
that the oncolytic virus (such as VSV) that lyses infected cells fast, may drive tumor cell
population to extinction rapidly. This finding is consistent with the model by Wein et
al. [299] who modeled tumor-virus dynamics using a system of partial differential equa-
tions. Indeed, evidence indicates that if the oncolytic virus kills infected cells fast, then
the progeny of new virions has a chance to spread and infect other uninfected tumor
cells, prior to accumulation of adaptive immunity [294]. Otherwise, the induced adaptive
immune response would then eradicate both infected and the remnant uninfected tumor
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cells. Furthermore, our computational results also conform with results from Okamoto et
al. [143] in that oncolytic virus infection of some normal cells can facilitate tumor con-
trol. Even better, our computational results, illustrated in Table 4.4 and Figure 4.8(b),
indicate that tumor cell population can quickly be eradicated whenever the oncolytic virus
exploits a significant amount of normal cells above a given acceptable threshold value. It
is also shown that tumor burden can at least be reduced, as indicated in Table 4.3, but
not completely eradicated within the given biological time frame.
Our results suggest that when designing an oncolytic virus that is not 100% tumor-specific,
it is important to consider viral dosing scheduling (with respect to time and frequency of
dosing) because oncolytic viral infections on normal cells might yield desirable or undesir-
able outcomes in virotherapy. This could be seen from Figure 4.5(a) − 4.5(b), for single
dosing schedule, and Figure 4.4(a)−4.4(b), for multiple dosing schedule, that different dos-
ing strategies provide different outcomes. From the sensitivity analysis, our results suggest
that when developing the oncolytic virus that is not 100% tumor-specific, it is important to
note that viral infections on normal cells could lead to early induction of antiviral immune
response that might inhibit further viral propagation.
4.6 Conclusion
In conclusion, our mathematical model shows that viral infections on normal cells can
indeed augment oncolytic virotherapy if the virus replicates fast within the infected cells.
Our results may be useful in the discovery of new oncolytic viruses or attenuation of
known wild viral strains, such wild-type oncolytic VSV [259] or VSV variants. Results of
our global sensitivity analysis have provided invaluable insights about the parameters that
influence growth kinetics and tumors’ response to oncolytic virus, and the adaptive immune
response. Our findings support the design of oncolytic viruses that is not 100% tumor-
specific, but have higher oncolytic potency towards tumor cells than normal cells, and have
high capacity to recruitment adaptive antiviral and antitumoral immune responses. We
believe our work opens new possibilities for designing new attenuated oncolytic viruses
that can be examined in a clinical setting under complex scenarios in which tumors cannot
be reached directly.
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Finally, an important model extension would be to account for spatial intratumoral (within
tumor) heterogeneity. It is known that that tumor heterogeneity can affect virus diffusivity
within tumor cells. Another interesting possible of the model extension would be to ac-
count for variations of the immune responses towards infected and uninfected tumor cells.
Currently, our model does not account for varying tumor immune responses when imple-
menting experimental oncolytic viral dosages. Pre-existing antiviral immune responses,
when treating patients who were exposed to oncolytic virotherapy before, may result in
differing treatment response rates in the clinic.
.
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TABLE. 4.3. Minimum cell reduction achievable when R0N = (1−R0T )/2
Time (hrs) Normal cells Tumor cells
Without therapy, t = 0 1× 1011 2.647× 1010
t = 24 7.2764× 1010 9.0057× 109
t = 48 5.889× 1010 2.2719× 109
t = 72 5.1158× 1010 5.8419× 108
t = 96 4.6375× 1010 1.5049× 108
t = 120 4.3228× 1010 3.8686× 107
t = 144 4.1055× 1010 9.9173× 106
t = 168 3.9494× 1010 2.5356× 106
t = 192 3.8358× 1010 6.4674× 105
TABLE. 4.4. Minimum cell reduction achievable when R0N = 3(1−R0T )/4
Time (hrs) Normal cells Tumor cells
Without therapy, t = 0 1× 1011 2.647× 1010
t = 24 5.22× 1010 1.2889× 109
t = 48 3.2569× 1010 4.3147× 107
t = 72 2.2536× 1010 1.4405× 106
t = 96 1.6541× 1010 4.7884× 104
t = 120 1.2607× 1010 1.5857× 103
t = 144 9.8565× 109 5.2378× 101
t = 168 7.8477× 109 1.7291
t = 192 6.331× 109 0.057081
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Mathematical Model of Oncolytic
Virus Delivery by Cell Carriers
This chapter aims at answering the third question in this thesis: How can the use of cell
carriers for the delivery of oncolytic virus particles to tumor sites affect the
outcomes of oncolytic virotherapy in the presence of active immune response?
To this end, we construct a new ordinary differential-equation based mathematical model
to describe the local interactions of tumor cells with natural killer (NK) cells, cytotoxic
T lymphocytes (CTLs), chimeric antigen receptor–engineered T cells (oAd-CAR T cells)
and mesenchymal stem cells (oAd-MSCs) loaded with oncolytic adenovirus, and the free
oncolytic adenovirus viruses within tumor microenvironment. The aim of this study is
to simulate and compare the therapeutic efficacies of the mesenchymal stem cells and
engineered chimeric antigen receptor–engineered T cells in delivering oncolytic viruses to
tumor site in the presence of active local antitumor and antiviral immune cells. In addition
to determining the efficacy of two carrier cell-based treatments, we also investigate the
long-term impact of the immune response within tumor microenvironment.
Our numerical simulations suggest that, at low lysis rates, the greatest efficacy (as indicated
by the virus-mediated cell deaths) is achievable with the oAd-CAR T cell based therapy
than with the oAd-MSC based therapy. A combination of oAd-CAR T cell and oAd-
MSC based therapies is possible extension of the current model to further investigate the
synergistic effects of these therapies
103
Stellenbosch University  https://scholar.sun.ac.za
Chapter 5. Model of cell carriers 104
Before we discuss the modeling framework herein this chapter, we first present some bio-
logical background motivating the development of our novel mathematical model.
5.1 Introduction
For most advanced or metastatic tumors, only a limited number of therapeutic options
are available for cancer patients. Oncolytic virotherapy is currently considered to be one
of the most promising treatment modalities against most advanced tumor cells. Tumor
cells are destroyed by oncolytic viruses (OVs) that are naturally occurring or genetically
engineered to preferentially infect and replicate within tumor cells, while having a limited
or no toxicity to normal cells. A major obstacle with oncolytic virotherapy, however, is
that when viruses cannot be injected directly into a target tumor, only a limited fraction
of oncolytic viruses administered intravenously manage to migrate and reach the target
tumor site. This is often due to antiviral immunity in the blood which rapidly clears the
viruses [66, 112, 300–305]. Clinical evidence indicates that even for high doses of oncolytic
viruses [302, 306], for the intravenous route, an efficient systemic delivery of oncolytic virus
particles is still limited [109, 305, 307].
In attempt to surmount this systemic delivery obstacle, several strategies have been ex-
plored, including use of cells, that have potential to migrate towards tumor microenviron-
ment, as delivery vehicles for oncolytic viruses. Recent evidence indicates that using carrier
cells for delivering oncolytic virus particles that targets tumor cells or tumor microenviron-
ment, is a promising treatment approach to systemic delivery [112, 247, 308–314]. Some
carrier cells are used as “Trojan horses” which can internalize the OVs and allow virus repli-
cation, but have no role after successful OV delivery in tumor sites [300, 301, 315, 316].
A variety of pre-clinical and clinical studies have elucidated that different types of host
immune cells are capable of recognising, migrating to and accumulating within tumors or
tumor microenvirnment [301, 316–318]. In addition, various studies have demonstrated
that certain types of cells, such as cytokine-induced killer (CIK) cells loaded with the
vaccinia virus (VV) [308, 313], T-cells loaded with vesicular stomatitis virus (VSV) [319],
dendritic cells loaded with oncolytic reovirus [301], macrophages loaded with adenovirus
[317], chimeric antigen receptor (CAR)–engineered T cells loaded with vesicular stomatitis
Stellenbosch University  https://scholar.sun.ac.za
Chapter 5. Model of cell carriers 105
virus (VSV) with mutations in the M protein (VSV∆M51) and “double-deleted” vaccina
virus (vvDD), and mesenchymal stem cells loaded with oncolytic measles viruses [320],
have potential to delivery the OVs to tumors.
Mesenchymal stem cells (MSCs) have also proven to exhibit inherent tumor-trafficking
properties, and can efficiently be used to delivery the oncolytic viruses to tumor sites. Most
importantly, the MSC cell-based therapies can potentiate both tumor oncolysis and anti-
tumor immune responses necessary for a complete tumor elimination [92, 309]. Another
important attribute of MSCs which often make them appropriate candidates for oncolytic
virus delivery is that they support viral replication while loaded with the virus [280, 321,
322]. Furthermore, MSCs are capable of protecting the loaded virus from immune-mediated
neutralization [320, 321, 323–328].
On one hand, the engineered CAR T cells have shown that they are also capable of deliver-
ing oncolytic viruses to tumor sites [114]. Apart from protecting the virus from neutralizing
antibodies, CAR-T cells are known to retain their antitumor functions while loaded with
the virus [247, 319]. This feature makes them an attractive treatment because they can
destroy tumor cells prior to their lysis by the pre-loaded virus. In this study, we also in-
vestigate the efficacy of CAR-T cell based therapy in delivering oncolytic viruses to tumor
site.
Despite promising pre-clinical and clinical evidence that sheds light on how carrier cells
can be used as delivery vehicles for oncolytic viruses, multiple challenges remain to be
fully addressed before such approaches can be applied in a clinical setting. The MSCs
derived from different tissues in a patient can produce widely varying outcomes in relation
to secretion of cytokines and chemokines, and immunomodulatory potential [287, 329, 330].
Hence, it becomes difficult to predict how different patients will respond to the MSC-based
cell carrier therapies [329]. Moreover, MSCs can be highly heterogeneous [331, 332]; as
such, it is also difficult to predict their behavior in vivo [112]. Thus, there is a clear need
for new research to understand dynamical behavior of MSCs as carriers of oncolytic viral
vectors.
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5.1.1 Relevant Mathematical Models
There are several mathematical models that describe the complexity of tumor-immune
cells interactions [125–130, 152]. A detailed review of some of these tumor-immune models
can be found in [123, 131–134]. More recently, in [291] a succinct review of mathemati-
cal models of immunotherapy is provided. There are few mathematical models that show
how cells, such as macrophages [148, 149], can be used as delivery vehicles of therapeutic
agents to tumor sites. In [148], a mathematical model that describes an accumulation of
engineered macrophages to hypoxic tumor sites was developed. Through model simula-
tions, it was shown that a combination of the macrophage-based therapies and conventional
chemotherapy is necessary for achieving a complete tumor eradication.
In another study, two modes of action by therapeutic drugs delivered by macrophages:
either the macrophages delivered an enzyme that activates an externally applied pro-drug
(the bystander model) or they directly delivered the cytotoxic factors into a hypoxic tumor
site (the local model) were investigated [149]. Using the local model, it was indicated that
macrophage are capable of migrating and accumulating in hypoxic sites and induce tumor
cell lysis. Although the models in [148, 149] considered the use of cell-based therapies for
delivery of chemotherapeutic drugs to tumor sites, none of them considered the effects of
immune responses within tumor microenvironment. Here, we develop non-spatial math-
ematical model to investigate the comparative efficacy of delivering oncolytic viruses by
either T cells or mesenchymal stem cells (MSC) to tumor site in the presence of active
immune response.
5.2 Materials and methods
5.2.1 Experiments: Oncolytic virus delivery by mesenchymal
stem cells
Before we turn our attention to a mathematical modeling perspective, we briefly provide
information on the datasets we used for parameter estimation of the model parameters. The
data was obtained via collaboration with experimental oncologists at Prof. Chae-Ok Yun’s
Laboratory at Hanyang University. The experiment for assessment of the mesenchymal
Stellenbosch University  https://scholar.sun.ac.za
Chapter 5. Model of cell carriers 107
stem cells (MSCs) as cell carriers of an oncolytic Adenovirus (Ad) was done for both in
vitro and in vivo settings.
(a) Determining the infection of MSCs with oncolytic Adenoviral (Ad) vectors.
Fixed quantity of MSCs were seeded onto a well plate then infected with various pre-
determined unit of MOI (multiplicity of infection). For example, 10 MOI means that
10 infectious virus particles have been infected into one cell.
(b) Determining the cell viability of MSCs. The cell viability of MSCs was deter-
mined by measuring the conversion of 3-(4, 5-dimethylthiazol-2-yl)-2, 5- diphenyltetra-
zolium bromide (MTT) to formazan by live cells. Briefly, 1− 2× 104 cells were seeded
into a 96 well plate at overnight and infected with oncolytic adenovirus (oAd) (at MOI
of 0.5 to 50). After 2 to 7 days of incubation at 37 ◦C, 50 µl of MTT in phosphate
buffered saline (PBS) (2 mg/ml) was added to each well. After 4 hours incubation at
37 ◦C, the supernatant was discarded and the precipitate was dissolved with 200 µl of
dimethylsulfoxide (DMSO). Plates were then read on a microplate reader at 540 nm.
All assays were performed in triplicate. Number of living cells was calculated from
non-infected cells cultured and treated with MTT in the same condition, as were the
experimental groups.
(c) Assessing the replication of oncolytic Ad in MSCs. To assess the viral
production of oncolytic Ads, MSCs were seeded in 24-well plates at approximately
60% confluency and then infected with oncolytic Ad at an MOI of 0.5 to 100. After 2
or 5 days of incubation at 37 ◦C, supernatants and cell pellets were collected and freeze-
thawed three times to harvest both extracellular and intracellular viral particles. Real-
time quantitative PCR was used to assess the total number of viral genomes in each
sample by quantifying Ad protein IX detected on capsid of mature virion. Samples were
analyzed in triplicate, and data were processed using the SDS 19.1 software package.
(d) Performing the in vivo tumor growth analysis. To compare the antitumor
effect of MSC, oAd, and oAd-MSC, the orthotopic hepatocellular carcinoma cancer
model was established by injecting 1 × 106 firefly luciferase-expressing Hep3B cells
into the left lobe of the liver in athymic nude mice. At 7 days post implantation,
blood was harvested by retro-orbital bleeding, and the level of AFP was analyzed by
enzyme-linked immunosorbent assay (ELISA) according to manufacturer’s instruction.
The mice were randomly divided into three groups by serum AFP level and treated
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with an intravenous injection of PBS, 1 × 106 MSCs, 5 × 108 virus particles (VP)
of oAd, and oAd-MSC (1 × 106 MSCs infected with 5 × 108 VP of oAd) on day 9
and 13 post tumor cell implantation (n = 6 per group). Optical imaging, with an
IVIS SPECTRUM instrument, was conducted every week and luciferase activity was
quantitatively analyzed with IGOR-PRO Living Image software.
In the next section, we present a mathematical model to assess the feasibility of delivering
the oncolytic adenoviruses with the MSC to tumor site in the presence of active immune
response (an aspect which was not assessed in the experiments). We additionally explore
the use of an alternative carrier cell, chimeric antigen receptor–engineered T (CAR T)
cells, that is known to maintain delivery and cytotoxicity activities when delivering the
oncolytic viruses [114].
5.2.2 Mathematical model
In this section, we present the formulation of the mathematical model that describes the use
of the mesenchymal stem cell-based and T cell-based therapies for the delivery of oncolytic
viruses to tumor site. We use the model to simulate and compare the efficacy of each
therapy with respect to tumor reduction. This comparison is essential for understanding
the possible treatment benefits of each therapy. For our modeling perspective, we assume
that the oncolytic adenovirus is successfully pre-loaded on both chimeric antigen receptor–
engineered T (CAR T) cells and mesenchymal stem cells (MSCs). These carrier cells
migrate to tumor sites where they deliver the oncolytic viruses via cell lysis. The carrier cell
migration or trafficking occurs across complex multiple cellular networks from the injection
site. In this study, however, we consider the carrier cell migration or trafficking to tumor
site, but rather we focus on the interaction kinetics between the carrier cells, oncolytic virus,
antitumor and antiviral immune cells, and tumor cells within tumor microenvironment.
The MSC are only used as “Trojan horses” and have no other role when they are at the
tumor microenvironment prior to their lysis by the oncolytic viruses. The oAd-CAR T
cells, on the other hand, interact with tumor cells and may induce the death of tumor cells
until they become exhausted or lysed by the pre-loaded virus. In this study, the oncolytic
viruses reach the tumor site only through the delivery by either oAd-CAR T cells or oAd-
MSCs. Our model consists of a system of ordinary differential equations (ODEs) describing
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the interactions between the tumor cells, natural killer (NK) cells, cytotoxic T lymphocytes
(CTLs), oncolytic adenovirus loaded chimeric antigen receptor–engineered T (oAd-CAR
T) cells, and oncolytic adenovirus loaded mesenchymal stem cells (oAd-MSC) within tumor
microenvironment.
On the other hand, we assume that there are other local immune lymphocytes within
the tumor microenvironment: Natural killer (NK) cells and the activated cytotoxic T
lymphocytes (CTLs). For simplicity, we assume that the oncolytic viruses can only interact
with tumor cells at the tumor site, even though it is possible that viruses can also interact
with immune cells as well [239]. Using this new mathematical framework, our major goals
are twofolds:
(a) To assess and analyze the efficacy of either the oAd-MSCs or oAd-CAR T cells when
used as delivery vehicles of oncolytic viruses, from a quantitative perspective;
(b) To investigate the possible effects of antitumoral and antiviral immune responses within
tumor microenvironment before and after the delivery of oncolytic viruses at tumor site.
Model assumptions: Our model builds upon the following biological assumptions:
(i) In the absence of immune response and oncolytic virotherapy, tumor growth is char-
acterized by logistic growth dynamics. A logistic growth function has robustly fitted
tumor growth data in several previous models [152, 216, 333–336].
(ii) As part of the innate immunity, NK cells are always present in the tumor microen-
vironment, even in the absence of tumor cells, while CTLs are present only when a
tumor is present, as done in [1, 152, 212].
(iii) We also assume that both NK cells and CTLs can actively penetrate the tumor
microenvironment and kill tumor cells [17, 19, 236, 337, 338]. After a finite number
of encounters with tumor cells, we assume that each NK cell and CTL will eventually
cease to be effective against tumor cells, as done in [1, 131, 339].
(iv) After lysis of the carrier cells, the oncolytic viruses infect tumor cells. Since not all
viruses can successfully infect tumor cells, we assume that free viruses are cleared by
the antiviral immune cells within the tumor microenvironment.
(v) Finally, we assume that the tumor microenvironment is homogeneous. This assump-
tion simplifies the model in that the geometry of the tumor microenvironment is
negligible; hence, our mathematical model becomes non-spatial.
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5.3 Model formulation
We present a full system of ODEs with a detailed description of how each equation of the
state variable is derived in this study. A description of model variables and parameters
is presented in Table 5.1 and Table 5.2, respectively. Using the mathematical framework
discussed above, the model consists of the following cell populations, and the oncolytic
virions.
TABLE. 5.1. Model Variables
Variable Description
Tu(t) the total number of uninfected tumor cells
Ti(t) the total number of infected tumor cells
Mi(t) the total number of MSC carriers in the tumor microenvironment
V (t) the total number of virions released within tumor microenvironment
EK(t) the total the number of NK cells within tumor microenvironment
EC(t) the total the number of activated CTLs within tumor microenvironment
Z(t) the total the number of oAd-CAR T cells within tumor microenvironment
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1 if y = oAd-CAR T cell0 otherwise (5.10)
f(Z, Tu) = gZTu (5.11)
The Heaviside step function, ρ(y), in equation (5.1) engenders death of the tumor cell if the
carrier cell is the oAd-CAR T cell, and the functional response function, f(Z, Tu), governs
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the interactions between the tumor cells and oAd-CAR T cells. The initial conditions of the






1×106 = 270 plaque forming units (pfu), EK0 = 0 cells, EC0 = 0 cells.
PFU is a generally accepted measurement for infectious titers (virus particles). Note that
V ? is the number of virions recovered at day 5 post-infection of the oAd-MSCs, at 20 MOI
in vitro, and thus may represent the tentative number of virions to be released into the
tumor microenvironment for the in vivo setting.
The term, D in equation 5.9, represents a ratio-dependent tumor cell kill by activated
CTLs, derived in [1] from the experimental data in [195]. The parameters, d and l, denote
the maximum fractional tumor cell lysis by CTLs and a CTL strength scaling exponent,
respectively. The parameter hEC in D represents the activated CTL toxicity constant that
supports half maximum CTL killing rate.





, indicates that in the absence of on-
colytic virus infection and immune response, the uninfected tumor cells grow logistically
with an intrinsic growth rate, aT , and with carrying capacity, KT . The second term,
−βT (t, ti,MOI)TuV , denotes the infection of tumor cells by oncolytic virions (V ) released
within tumor microenvironment, at the infection rate, βT (t, ti,MOI). Note that the infec-
tion rate, βT (t, ti,MOI), depends on the time of treatment (i.e., here, the time at which the
luciferase-expressing Hep3B cells were implanted into the 6 week old male nu/nu mice.),
t, the time of oncolytic infection, ti, and the multiplicity of infection, MOI. Note that
βT (t, ti,MOI) = 0 whenever 0 ≤ t < ti, and βT (t, ti,MOI) > 0 for ti ≤ t∗i , where t∗i is the
terminal time of the experiment (i.e., for in vivo setting, t∗i denotes the time at which mice
were killed in the experiment). The third term, −λTEKTu, represents a direct NK-induced
tumor cell death, with the rate of tumor cell death λT . The fourth term, −DTu, represents
tumor cell lysis by activated tumor-specific CTLs. The term D defined in equation 5.9,
represents a ratio-dependent CTL-induced tumor cell death. This function form of cell
lysis is a novel term derived by de Pillis et al. [1]. More information and justification of
this ratio cell lysis can be found in [1] and [126]. This term has successfully been employed
in number of models [216, 333–335, 340]. The last term, ρf(Z, Tu) represents the tumor-
induced cell death by cytotoxic oAd-CAR T cells. For simplicity, the functional response
function, f(Z, Tu) = gZTu, is assumed to follow the mass-action kinetics, with a constant
tumor killing rate g by the oAd-CAR T cells. This simplification is based on the notion
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that these oAd-CAR T cells, loaded with oncolytic virus, are injected into the body, not
recruited from the lymph node like normal CD8+ T cells. Cytotoxic T cells are recruited
to tumor microenvironments due to the presence of chemicals released by tumor cells [133].
In equation 5.2, an instantaneous transfer of a population of uninfected tumor cells to
infected cell population is represented by the first term, βT (t, ti,MOI)TuV . The oncolytic
lysis of infected tumor cells is denoted by the second term, −lv(t, ti,MOI)Ti, with lysis
rate lv(t, ti,MOI). Similar to infection rate, βT , the lysis rate, lv(t, ti,MOI), also depends
on the time of treatment, t, the time of oncolytic infection, ti, and the multiplicity of in-
fection, MOI. We assume that the death of the infected cells occurs very rapidly following
the viral infection; hence, the intrinsic growth of infected cells is neglected. The oncolytic
viral infections often foster infected tumor cells to express tumor antigens which are recog-
nised by NK cells [96, 341, 342]. The rate at which NK cells lyse infected tumor cells is
represented by the third term, −λTEKTi, where λT is the rate of NK-induced tumor death.
The last term, DTi, denotes the tumor cell death induced by CTLs (assumed to be similar
the cell lysis of uninfected tumor cells by activated CTLs).
In equation 5.3, the first term, SM(t), represents a constant supply of MSC carrier cells
into the tumor microenvironment. SM correspond to value from the oAd-MSC data, and
it reflects the total number MSCs which were infected with the oncolytic adenovirus for
both in vitro and in vitro settings. The last term, −lv(t, ti,MOI)Mi, represents lysis of
MSC carrier cells within tumor microenvironment by the pre-loaded replication-competent
oncolytic adenovirus. Here we assume that when t < ti, there are no oAd-MSCs within
the tumor microenvironment.
In equation 5.4, the first term, lv(t, ti,MOI)bMMi, represents the production of new
virions from the lysed oAd-MSCs, where lv(t, ti,MOI) is the lysing rate of a MSC carrier.
During the oncolytic virus propagation (or upon lysis) within the infected cell, a progeny
of new infectious virions are released from each infected cell. Thus, bM is the burst size
for viruses from the MSC carriers. After successful virus replication within infected tumor
cells, Ti, new virus particles are released and further infect the neighbouring uninfected
tumor cells. Hence, the second term, lv(t, ti,MOI)bTTi, represents the production of new
virions from the lysed infected tumor cells, with the lysis rate lv(t, ti,MOI). The third
term, lv(t, ti,MOI)bZZ, represents the production of new virions from oAd-CAR T cells,
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with the lysis rate lv(t, ti,MOI) and burst size bZ . An immune induced virus inactivation
and elimination is represented by the last term, ωV , where ω is the virus clearance rate
within tumor microenvironment. Note that in the tumor microenvironment, free viruses
are susceptible to neutralization by circulating antibodies and/or other antiviral immune
cells.
In equation 5.5, as part of the innate immunity, NK cells are always present at the tumor
site [2, 7, 8], and have been shown to play a vital role in immunosurveillance of tumors
[4, 5, 31, 137, 196, 213]. Thus, the first term, SEK (t), represents a constant supply of NK
cells into the tumor microevironment, as done in previous models [1, 152]. The second term,
−rKλTEK(Tu + Ti), represents an inactivation of NK cells as a result of their interaction
with tumor cells. The proportion of NK cells that gets inactivated during tumor-NK cell
interactions is represented by rK , and λT is the rate of NK-induced tumor death. Note
that this inactivation occurs when an NK cell encounters a tumor cell several times and
consequently cease to be cytotoxic and undergo apoptosis [63, 343]. This mass-action
term has successfully been employed in previous models of tumor-immune interactions
[1, 144, 152, 216, 333–335]. The natural death of NK cells is represented by the last term,
−µKEK , where µK is the rate of NK cell death.





, represents the proliferation of activated
CTLs within tumor microenvironment [344, 345], where qC is the proliferation rate of CTLs
within tumor site. The CTLs, serving as a key component of the adaptive immunity, are
recruited from the lymph node to the tumor microenvironment. The CTL recruitment
occurs due to the presence of tumor antigens or oncolytic cell death that often exposes
a plethora of tumor associated antigens. This antigenic recruitment is denoted by the
term, −γEC , where γ is the recruitment rate of CTLs. Note that this term is negative
because CTLs are present at the tumor site only when tumor cells are present, as done in
[1, 152, 346]. The third term, −rCEC(Tu + Ti), represents the CTL inactivation, at the
rate rC , as a result of their interaction with tumor cells. The last term, −µCEC , represents
the natural death of CTLs, with the constant death rate µC .
In equation 5.8, a constant supply oAd-CAR T cells into the tumor microenvironment
is denoted by the first term, SZ(t). The second term, lv(t, ti,MOI)Z, represents the oAd-
CAR T cell death by oncolytic virus, with the lysis rate lv(t, ti,MOI). Note that even
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though the equations (5.3) and (5.8) look similar, Z and Mi differs in their genetic make-
up. In addition to the loaded oncolytic virus, the chimeric antigen receptor (CAR)-T cells
also have specific genes inserted into their genomes to induce a robust recognition and
binding to tumor-associated antigens (TAAs) expressed on the surface of tumor cells [347].
5.4 Parameter estimation
We estimated the values of unknown parameters from the available datasets and/or by
considering the plausible biological observations. The values of available parameters and
their sources are presented in Table 5.2. In our model, the data-derived parameter esti-
mates were determined by changing values of the unknown parameters until the minimum
difference between model output (simulation) and the experimental data is attained as
define by the sum of squares error (SSE).
The uninfected tumor. To estimate the tumor growth, aT = 0.41, we used the Least-
squares minimization (leastsquares) algorithm in scipy.optimize package to fit the logistic
growth equation (5.1) to uninfected tumor growth data (orthotopic tumor xenografts from
6 week old male nude/nude mice), shown in Figure 5.1. Tumor carrying capacity, KT =
2.145× 104, is an ad hoc value and was chosen to give possible biological outcomes. Note
that the proliferation of uninfected tumor cells follows an exponential growth law in the
early stage of tumor growth, and also that the data was collected for a short experimental
duration of 60 days. This simplistic observation is consisted with other models that capture
the early tumor growth dynamics [148, 239, 263, 348]. Additionally, the oAd-CAR T cell
killing rate, g = 1 per day, is also ad hoc value chosen to ensure tumor cell death induced
by the oAd-CAR T cells.
The MSC carriers. We used the in vitro MSC cell viability data to estimate the cell
death dynamics of the oncolytic adenovirus. In particular, having the fixed number of
MSC cells, SM = 1× 106, we used equation (5.3) to fit lv to MSC cell viability data at day
5. Figure 5.2 indicates cell viability of 5E4 MSC cells at varied incubation time points.
The MSC cells were treated with various doses of oncolytic adenovirus (i.e., at different
multiplicity of infection (MOI). Note 1 MOI is 1 virus per cell). By minimizing the sum of
square errors (SSE) between the MSC-loaded oncolytic adenovirus (oAd-MSC) data points
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FIG. 5.1. Fit of equation (5.1) simulation to experimental uninfected tumor growth data
to find the parameter aT , with fixed KT = 2.145× 104 mm3 and βT = λT = 0. We convert
tumor size to volume using a conversion factor of 106 cells to 1 mm3, and plot the simulated
tumor size from equation (5.1) in terms of volume.
FIG. 5.2. In vitro cytotoxicity of naked oncolytic adenovirus in MSC. The cell viability
determined at day 2, 5 and 7.
and the model simulation using the MATLAB function lsqnonlin, we determined various
cell death for given MOIs, as shown Table 5.3.
Two fits of equation (5.3) for MOI 5 and 50 are shown in Figure 5.3.
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(a) 5 MOI (b) 50 MOI
FIG. 5.3. Fits of equation (5.3) simulations to MSC cell viability data to find the parameter
lv, with SM = 1× 106 MSC cells/mice fixed.
The total number of infected MSC carriers, SM = 1 × 106 cells, is the initial number of
MSCs injected at the beginning of treatment. This value is often manipulated in treat-
ment/clinical settings, and may change from injection time point to another. In this study,
SM = 1× 106 cells, is kept constant throughout the injection time points.
The oncolytic virus. The virus burst sizes, bM(ti,MOI), is determined by dividing the
infectious progeny viruses produced from each infected cell by the initial number of cells





1×106 = 270 plaque forming units (pfu), where V
? is
the average virus yields recovered from each infected cell at day 5 post-infection of the
oAd-MSCs. The infectious viruses for day 2 and 5 are given in Table 5.4.
The activated CTLs. Although the proliferation of CTLs often occur the lymph node
[351], the proliferation rate of CTLs within tumor microenvironment, qC = 0.25 cells day
−1,
is an ad hoc value and was chosen to give possible biological outcomes. This value is as-
sumed to be similar to the proliferation rate of immune cells in [352].
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5.5 Results
In this section, we present and discuss numerical solutions of our model.
5.5.1 Numerical simulations of alternative carrier cell-based ther-
apeutics
We now present numerical simulations of our model that illustrate main features of our
model. Most importantly, we investigate some possible carrier cell-based treatment strate-
gies that could offer effective tumor reduction. We also assess the influence of potential
immune response against the oAd-MSC therapeutics as antiviral immune response and an-
titumor immune response mediated by oncolytic viruses. This is very important because
immune responses have proven to be critical components that regulate the antitumor effi-
cacy of the virus in clinical trials.
5.5.2 Varying lysis rate
To further investigate possible conditions that might offer enhanced oAd-MSC therapeutic
efficacy, we simulated the effect of varying the lysis rate (lv) of the oncolytic virus. Fig-
ure 5.4 indicates the results of varying lysis rate between 0.1 and 1. The results displayed
in Figure 5.4 indicates that loading oncolytic viruses that high lysis rates leads to rapid
destruction of the oAd-MSCs. This might pose a challenge of premature lysis of the carrier
cell before reaching the target tumor cells [112]. The observation shown in Figure 5.4 imply
that it could be better to load a low replicating oncolytic viruses on oAd-MSC in order to
allow the oAd-MSCs to reach their target sites, as shown experimental study in [353].
5.5.3 Efficacy of oAd-MSC mediated infection against tumor growth
To investigate conditions that might enhance the oAd-MSC therapeutic efficacy, we simu-
lated cell death profiles upon arrival of the oAd-MSCs within tumor site. The simulated
dynamics are shown in Figure 5.5. The time zero (day 0) in Figure 5.5 refers to the infec-
tion time (i.e., the time the oAd-MSCs arrive within tumor microenvironment), ti. Here,
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FIG. 5.4. Simulated effects of varying lysis rate on MSC-loaded oncolytic adenovirus.
FIG. 5.5. Simulated efficacy of oAd-MSC therapy with respect to tumor growth. This
indicates that oAd-MSC therapy leads to transient tumor reduction.
tumor cells are possibly infected on day 0 as the oAd-MSCs become lysed by the virus. The
observation displayed in Figure 5.5 indicates that the oAd-MSC therapy leads to transient
reduction of tumor burden and a quick tumor relapse. In this simulation, we set a low
lysis rate, lv = 0.35 day
−1, to allow the oAd-MSC to interact with tumor cells prior to
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their lysis by the oncolytic virus. Other parameter values are as given in Table 5.2. The
oAd-MSCs are, however, not cytotoxic against tumor cells as they are used as “Trojan
horses” in this study. In this figure, we notice that tumor growth relapse does not reach
the plateau quickly as observed when there is no therapy (dashed blue line).
5.5.4 Efficacy of oAd-CAR T cell mediated infection against tu-
mor growth
To further investigate possible therapeutic conditions that might give rise to improved
treatment outcomes, we also simulated the dynamics of the interactions of oAd-CAR T
cells within tumor microenvironment. Similar to oAd-MSC based therapy, we set a low
lysis rate, lv = 0.35 day
−1, to allow the oAd-CAR T cells to interact with tumor cells
prior to their lysis by the oncolytic virus. Figure 5.6 shows tumor growth versus time
when the oAd-CAR T cells are within tumor site, with the first interactions or virus lysis
occurring on day 0. This simulation indicates that oAd-CAR T cell therapy can possibly
FIG. 5.6. Simulated efficacy of oAd-CAR T cell therapy with respect to tumor growth.
The changed parameter value from Table 5.2 was lv = 0.35 day
−1. Other parameter values
were kept same as in the Table 5.2.
lead to tumor elimination or rapid decline in tumour burden. This is partly because the
oAd-CAR T cells not only deliver oncolytic viruses, but also kill tumor cells during their
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interactions. This observation is consistent with experimental outcomes reported in [114].
Similar to the observations in Figure 5.5, we see that while tumor infection increases, the
oAd-CAR T cell population continually declines over time, indicating a possibility of cell
death by oncolytic viruses.
5.5.5 The effect of stronger immune response
Since the immune response can have the confounding effects in oncolytic virotherapy, we
considered where the presence of cytotoxic immune cells within tumor microenvironment
can have any impact during the carrier cell-based therapies. To investigate the possible
effects of stronger immune response, we increased the NK cell constant supply from the
baseline value of SEK = 1.30 × 104 cells in Table 5.2 by 10-fold, which gives an improved
value of SEK = 1.30 × 105 cells. We considered increasing the value of NK supply be-
cause the influx of NK supply within tumor microenvironment has been shown to enhance
treatment outcomes [87, 152, 173, 232, 238, 354]. The result of our simulations with the
modified NK influx is shown in Figure 5.7. In this simulation, we set a very low virus
FIG. 5.7. Simulation of improved immune response within tumor microenvironment during
oAd-CAR T cell therapy. The NK cell supply was set at SEK = 1.30× 105 cells, and a low
lysis rate of lv = 0.035 per day. Other parameter values are as listed in Table 5.2.
lysis rate to minimize the confounding effects of oncolytic viruses. This is essential for
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minimizing early antiviral activities of NK cells which might lead to clearance of the free
viruses within tumor microenvironment or infection of tumor cells during the oAd-CAR T
cell therapy. Figure 5.7 indicates that increasing NK cell supply can aid to reduce tumor
burden.
5.6 Discussion and conclusions
By using a quantitative approach, we investigated how the use of cell carriers in delivering
oncolytic viruses to tumor microenvironment can affect tumor growth and progression. We
developed a novel mathematical model that describes the local interactions of tumor cells
with natural killer cells, cytotoxic T lymphocytes, chimeric antigen receptor–engineered
T cells, mesenchymal stem cells, and oncolytic viruses. The aim of this study is to simu-
late and compare the therapeutic efficacies of the mesenchymal stem cells and engineered
chimeric antigen receptor–engineered T cells in delivering oncolytic viruses to tumor site
where there are active local antitumor and antiviral immune cells. Although the thera-
peutic benefits of the MSC-based [355] and CAR-T cell-based [114] therapies in delivering
oncolytic viruses to tumor cells in vitro in immunodeficient mice have been previously
assessed, our model results may further give useful insights into the possible in vivo cell
dynamics in immunocompetent hosts. Our proposed simple and non-spatial mathematical
model devised and analysed in this study shed light on the dynamical behaviors of tumor
cells upon their interactions with either the MSCs or CAR-T cells loaded with oncolytic
viruses, and the oncolytic viruses at the tumor site. The effect of local immune response,
at tumor site, was also investigated to asses its influence during oncolytic virotherapy.
It is important to note that the local immune response can have therapeutic benefits by
clearing free viruses after all tumor cells are destroyed by oncolytic viruses. On the other
hand, it can have negative treatment effects if the viruses are removed immediately after
being released from the carrier cells into the tumor microenvironment. Obviously, this
early antiviral may subsequently diminish the efficacy of the carrier cell-based therapies.
Although the data we used to estimate the unknown parameters in our model reports the
MSC cell viability for day 2, 5 and 7 post infection of MSCs with oncolytic adenovirus at
0 to 50 multiplicity of infection (MOI) (0, 0.5, 1, 2, 5, 10, 20, and 50), we only considered
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the lysis rates associated with day 5 for illustrative purposes. The results of our param-
eter estimation and two snapshots of our sub-model fits are indicated in Table 5.3 and
Figure 5.3, respectively. These results suggest that the MOI is an important factor that
governs the cell viability of the MSC as higher MOI results in rapid destruction of the
carrier cell (see Figure Figure 5.3). This finding is of relevant importance because infecting
the MSCs at lower MOIs may result in insufficient viral titers released from the infected
MSCs at the tumor microenvironment, while infecting the MSC at higher MOIs might
destroy the carrier cells rapidly, possibly before their arrival at the tumor site during an
in vivo treatment.
Since the efficacy of certain carrier cell types may depend on the multiplicity of infection
(MOI) [114] and/or the rate at which the viruses lyse the carrier cell, we considered the
effects of altering the lysis rate in Figure 5.4. From Figure 5.4, we found that high lysis
rates might lead to rapid oAd-MSC destruction, which might limit the efficacy of the oAd-
MSCs in delivering the oncolytic viruses to tumor sites. On the other hand, in Figure 5.6
it is shown that low lysis rates may lead to improved therapeutic outcomes when using
oAd-CAR T cells in delivering the oncolytic viruses to tumor sites. Intuitively, for oAd-
CAR T cell based therapy, low lysis rates may allow the oAd-CAR T cell to perform their
cytotoxic activities and deliver the oncolytic viruses deep into the tumor. Similarly, our
model results in Figure 5.7 indicate that high number of the natural killer cells within tumor
microenvironment may augment the oncolytic virotherapy, given that the slow replicating
viruses are pre-loaded on the MSCs. We do note, however, that slow replicating viruses
may take a long time to reduce a large tumor [263, 264]. Our findings support the fact that
use of immune carrier cells to deliver oncolytic viruses can result in improved antitumor
outcomes [312].
In conclusion, our numerical simulations suggest that, at low lysis rates, the greatest ef-
ficacy (as indicated by the virus-mediated cell deaths) is achievable with the oAd-CAR
T cell based therapy than with the oAd-MSC based therapy. Simulations of the combi-
nation of oAd-CAR T cell and oAd-MSC based therapies is a future work on this model
to further investigate the synergistic effects of these therapies. Additionally, parameter
sensitivity analysis shall be performed to assess the significance of each parameter in our
model. Pre-clinical studies, however, will be necessary to quantify the tolerable toxicities
associated with this combination strategy and its impact in debugging the tumor burden.
Stellenbosch University  https://scholar.sun.ac.za
Chapter 5. Model of cell carriers 124
We are currently in collaboration with the experimentalists, from Prof. Chae-Ok Yun’s
Laboratory at Hanyang University, who will provide us with the relevant data we will be
using in our future model validation.
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TABLE. 5.3. Estimates of oncolytic virus lysis rates (lv) for various MOIs at day 5.









TABLE. 5.4. The virus replication profiles at various MOIs on day 2 and 5.
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Chapter 6
Conclusions
In this chapter, we present a summary of our work and discuss major scientific contributions
in this thesis. We also outline possible future directions for immunotherapy and oncolytic
virotherapy.
6.1 Summary
In this section, we summarise the accomplishment of the three major aims of this thesis
specified in Chapter 1, which we restate below:
1. To formulate a novel differential-equation based mathematical model for the immune
surveillance of tumors. The model describes how tumor cells evolve and survive the
brief encounter with the immune system mediated by natural killer (NK) cells and
the activated CD8+ cytotoxic T lymphocytes (CTLs).
2. To develop an original delay differential equation mathematical model describing the
interactions between the oncolytic virus, the tumor cells, the normal cells, and the
antitumoral and antiviral immune responses. We derive the model’s basic reproduc-
tive number within tumor and normal cell populations and use their ratio as a metric
for virus tumor-specificity.
3. To construct a new differential-equation based mathematical model that describes
the use of the mesenchymal stem cell-based and T cell-based therapies for the delivery
of oncolytic viruses to tumor site. We use the model to simulate and compare the
127
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efficacy of delivering oncolytic viruses by either type of therapy. This comparison is
essential for understanding the possible treatment benefits of each therapy.
Accomplishment of aim 1:
To describe how various tumor cells evolve and survive their transient encounters with
the natural killer (NK) cells and the activated CD8+ cytotoxic T lymphocytes (CTLs),
we constructed a novel ODE based mathematical framework presented in Chapter 3. The
developed model focused specifically on unravelling complex tumor escape mechanism using
a Fas/FasL system that enable tumor cells to evade their encounters with immune cells.
Using our modeling approach, we were able to predict key interaction features that enable
tumor escape from immune surveillance. A novel feature unravelled by our model is that
survival of tumor cells from their brief encounter with a certain immune cell enable the
tumor cells to acquire an immune-resistant phenotype. This immune-resistant phenotype
protects the tumor cells, that survived their encounters with immune cells, from subsequent
attacks by the same immune cell or immune cells of the same type. This is consistent with
experimental works in [2, 26, 47]. Our simulation results indicated that increasing an
external supply of NK cells might enhance NK-cell immune surveillance that is necessary
for controlling tumor growth and progression.
Accomplishment of aim 2:
To examine how to increase an oncolytic potency and reduced virus tumor-specificity in
oncolytic virotherapy, we built a novel DDE based mathematical model detailed in Chapter
4. In particular, the developed model focuses on how oncolytic virus infection of some
normal cells in the vicinity of tumor cells can enhance oncolytic virotherapy. The model
consists of a system of delay differential equations describing the interactions between
the oncolytic virus, the tumor cells, the normal cells, and the antitumoral and antiviral
immune responses. The basic reproductive number of the model within tumor and normal
cell populations was derived and used as a measure of virus tumor-specificity. Additionally,
a thorough stability analysis of the free virus steady states was performed. Interestingly,
through numerical simulations, we discovered that using a certain number of normal cell
can aid in amplification of virus particles, and hence lead to improved oncolysis. This is the
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first mathematical model which illustrates how a controlled infection of normal cells within
tumor territory can augment oncolytic virotherapy. The findings inherent in this research
have important consequences for the discovery of new oncolytic virus or attenuation of
wild type oncolytic virus vectors.
Accomplishment of aim 3:
To investigate how the use of mesenchymal stem cells (MSCs) or engineered chimeric
antigen receptor–engineered T cells (CAR T cells) in delivering oncolytic viruses to tumor
site can influence the outcomes of oncolytic virotherapy, we developed an original ODE
based mathematical model presented in Chapter 5. The mathematical model describes the
interactions of tumor cells with local immune cells (i.e., immune lymphocytes within tumor
microenvironment), free oncolytic viruses, CAR T cells and MSCs both pre-infected with
the oncolytic adenovirus. Through comparative simulations of each monotherapy, we found
that at low lysis rates, the greatest efficacy (evidenced large number of virus-mediated cell
death of tumor cells) is achievable with the oAd-CAR T cell based therapy than with
the oAd-MSC based therapy. This observation if consistent with experimental results in
[114]. From a clinical perspective, use of oAd-CAR T cells in delivering oncolytic viruses to
tumor sites may constitute a favourable treatment regime since the engineered oAd-CAR
T cells may not only deliver their therapeutic payloads into the tumor microenvironment,
but also maintain their antitumor activities. One concern about CAR T cell therapy is
a poor targeting of tumor cells. Recent reports indicates that CAR T cells also damage
healthy normal cells which rarely express tumor associated antigens [356].
6.2 Contributions of this thesis
In this section, we include the major contributions of this thesis to the field of mathematical
oncology as well as experimental and clinical oncology.
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6.2.1 Mathematical oncology
An increasing understanding in cellular interactions between tumor cells, immune cells
and oncolytic viruses has necessitated the utilization of mathematical modeling techniques
to better understand the complexity of biological systems. Herein this thesis, we devised
three novel mathematical models that deal with cellular interactions between tumor cells,
various types of immune cells, and oncolytic viruses. The mathematical model discussed in
Chapter 3 provides useful information for modeling and understanding of tumor-immune
surveillance. To this end, our work developed in Chapter 3, published in the Journal of
Theoretical Biology, has already been cited in 4 research works - one purely experimental
and three mathematical. Mathematical models developed in Chapters 4 and 5 contain
invaluable information that quantitatively indicate how increase virus particles within tu-
mor microenvironment and how efficacious certain cell-based therapies are in delivering
oncolytic viruses to tumor site, respectively. Although modeling of tumor interactions
with oncolytic viruses is challenging, the mathematical models developed in this thesis
provide a basic information in understanding some aspects of modeling oncolytic viruses.
In general, from a modelling viewpoint, our modeling frameworks developed in this thesis
are relatively straight-forward to follow, and may serve as starting points for further re-
search related to complex cellular interactions between tumor cells, normal cells, immune
cells and oncolytic viruses.
6.2.2 Clinical and experimental Oncology
Our work in Chapter 3 highlighted some important areas of clinical research that can
be exploited to enhance immune surveillance. In particular, our numerical simulations
have predicted how the natural killer (NK) cell-based immunotherapeutic approaches can
augment tumor-immune surveillance. The numerical results contained in Chapter 4 are
essential for testing our hypotheses, experimentally, related to a potential controlled use of
some normal cells to enhance oncolytic virotherapy or at least control tumor cell population
growth. As an example, clinical evidence indicates that a certain portion of liver can be
cut without sacrificing functional ability of a liver [357]. In a similar manner, the use of
some normal cells in the vicinity of tumor cells, may be invaluable for controlling tumor
growth and progression. Our results clearly indicates that such approach is indeed feasible.
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The research contained in Chapter 4 is helpful in discovery of new oncolytic viral vectors
or attenuation of the known wild-type viral vectors. To quantify the interaction dynamics
within tumor microenvironment prior to experimentation of using certain cells as carriers
of oncolytic viruses, may help to cut done the costs associated with such experiments. The
research presented in Chapter 5, illustrates how the use of certain cell types as cellular
carriers of oncolytic viruses influences the therapeutic outcomes of cell-based therapies,
particularly in immunocompetent hosts.
6.3 Future research
Our work opens new avenues of research in the field of biological and mathematical on-
cology. We now outline our future research to address the relevant alternative approaches
motivated from the research in this thesis. One such an alternative approach includes use
of tumor associated endothelial cells as oncolytic viral factories. Some oncolytic viruses
have a natural preferential tropism for tumor and/or associated endothelial cells while oth-
ers need to be genetically engineered to direct their specificity to tumor and/or associated
endothelial cells [91, 99, 141]. Infecting tumor endothelial cells with oncolytic viruses has
dual significance: (a) Viruses released from tumor endothelial cells would undoubtedly
increase virus particles within tumor microenvironment; (b) Infection of tumor associated
endothelial cells may cause tumor vascular collapse, thereby augmenting anti-angiogenesis
treatment. To this end, we extend the model developed in Chapter 5.
Model formulation. Here, we propose a novel non-spatial mathematical model that
describes the dynamics of the interactions between the respective cell populations of tumor
cells, tumor endothelial cells, immune cell carriers within the tumor, and immune cell
carriers circulating in the tumor vasculature. The model also considers the population of
oncolytic virus particles and their potential interactions with the cell populations. The
immune cell carriers extravasate from the tumor vasculature into a solid vascular tumor
through an invasion-type extravasation [358]. It is important to note that carrier cells
may extravasate from blood vessels to tumor cell in a variety of mechanisms. They may
extravasate via leaky tumor endothelium [359, 360] or in a conventional manner in which
a cell extravasates from the blood stream (i.e., through an engagement of the immune cell
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carrier and endothelial adhesion molecules) [361]. Through their interaction with tumor
cells, cell carriers actively penetrate into the tumor cells and form cell-in-cell structures
(i.e., a phenomenon in which a cell of different type is found inside the cytoplasm of another
cell) [139, 362, 363]. The formation of cell-in-cell structure appears some time after the
tumor and carrier cell became in contact. Additionally, the carrier cells within the tumor
also kill tumor cells. For example, HOZOT cells [139] and CIK cells [308, 309], are known
to retain their cytotoxic activity against tumor cells when internalized within the tumor.
For simplicity, we do not consider the effect of the volume occupied by the carrier cell
inside the tumor cell, instead we simply consider the carrier cell inside the solid tumor
as one of its cell constituents. To account for the effects of oncolytic virus infection on
tumor cells, tumor comprises of the uninfected and infected cells, as other cell constituents.
Furthermore, we omit details of the interaction dynamics regulating the immune cell carrier
infiltration into the tumor, such as cognate ligand receptor binding [337] or entosis (i.e., a
non-apoptotic cell migration which results in tumor cell invasion) [364].
Although ample evidence suggests that immune cells can effectively infiltrate tumor cells
[17, 19, 139, 236, 337, 365, 366], there is also some evidence that some tumor-specific
lymphocytes may not extravasate from the tumor vasculature [337, 338, 359, 367]. Hence,
we assume that some carrier cells may be unable to extravasate from the tumor vasculature
in the vicinity of the tumor. That means, we assume that the carrier cells that are unable to
extravasate from tumor vasculature are “trapped” in the tortuous and disorganized tumor
blood vessels, just like an observed phenomenon where the activated T cells are being held
back in the tumor vasculature or microenvironment [368–370].
The model consists of the following variable: the total number of uninfected tumor cell
population, Tu(t), the total number of infected tumor cell population, Ti(t), the total num-
ber of uninfected tumor endothelial cell population, Eu(t), the total number of infected
tumor endothelial cell population, Ei(t), the total number of carrier cell population circu-
lating in the tumor vasculature, Cb(t), the total number of carrier cell population within
the tumor, CT (t), the total number of oncolytic virions in the tumor vasculature, VE(t),
and the total number of oncolytic virions within the tumor, VT (t).
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that describes the probability that a carrier cell from the tumor vasculature will infiltrate
the tumor. The parameter Max CT denotes the maximum number of carrier cells that can
infiltrate the tumor, and µTb is the rate of exponential decay due to carrier cell exhaustion
during extravasation and/or infiltration. The means, pT is the probability that the carrier
cell will infiltrate the tumor after extravasating the tumor vasculature. Since not every
immune cell can infiltrate the tumor, we assume that there is a maximum rate at which
carrier cells can enter the tumor, as has been done with the dendritic cells (DCs) in [333].
This is in agreement with clinical observations that immune cells, such as tumor-infiltrating
lymphocytes (TILs), cannot infiltrate tumors unlimitedly since tumor often develop mech-
anisms to inhibit efficient immune cell infiltration [17, 338, 371]. Also, note that pT decays
exponentially as a function of the carrier cell concentration in the tumor vasculature. The
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function qT = 1 − pT describes the probability that a carrier cell will not extravasate the
tumor vasculature.





, indicates that in the absence of
oncolytic virus infection, the uninfected tumor cells grow logistically with an intrinsic
growth rate, aT , subject to the carrying capacity of the tumor cells, KT . In the absence of
oncolytic virus infection, vascular tumor depends on the tumor vascularization (i.e., the flow
of blood from the new vessels formed by angiogenesis) [360, 372–374]. For simplicity, we
do not consider the subcellular events leading to tumor angiogenesis, instead, we consider
the interaction of the tumor cells with the tumor endothelial cells resulting from tumor
angiogenesis. The second term, −lvβTTi TuTi+Tu , denotes the infection of tumor cells by
the oncolytic virus and is proportional to the oncolytic viral death by lysis. The ratio-
dependent viral infection kinetics of this type has also been considered in [144, 262]. The
kinetics of this type are more applicable when one assumes that the density of the infected
cell population does not change with the number of the uninfected cells or virions [262]. We
considered the ratio-dependent viral infection kinetics because the infection of uninfected
tumor cells does not depend directly on the number of virions, but rather of the number of
immune carrier cells within the tumor. The saturable immune-mediated killing mechanism
of the carrier cells is defined by the term, −δe(−µCT Tu) CT
hT+CT
Tu, where the tumor cells
are killed by the immune carrier cells at the rate δ. Apart from the plausible cytotoxic
killing mechanism exerted by carrier cells inside the tumor [139, 308, 309], to infiltrate
into tumors, carrier cells may invade the tumor [139, 364]. Such immune carrier cell
invasiveness is governed by the parameter, δ. The formation of cell-in-cell structure depends
on the uninfected tumor cell concentrations at time t − ρ. The time delay, ρ, represents
the extravasation-infiltration connection time: the transient time required between tumor
vasculature and tumor before tumor invasion can begin. Note that the carrier cells may not
only extravasate from the tumor vasculature when tumor cells and tumor endothelial cells
are adjacent, but also plausibly at any point in the tumor vasculature. Thus, the time lapse
from carrier cell extravasation and actual tumor invasion is endowed in the delay ρ. Hence,
the encounter between the carrier cells and tumor cells, which results in the formation of
cell-in-cell structures, occurs at the time of t − ρ. Note that we assume that the carrier
cell extravasation occurs in the vicinity of tumor cells, and there are no cellular material,
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such as stroma or extracellular matrix (ECM), that may impede the carrier cell trafficking
and infiltration into the tumor. On the other hand, the survival probability of the carrier
cells during the tumor invasion is considered by the term e−µCT Tu , where µCT is the natural
death of the immune carrier cell within the tumor. Note that the probability of carrier cell
survival during tumor invasion decays exponentially as a function of the concentration of
uninfected tumor cells. Similar cell survival functions of this type has also been considered
in [375, 376]. The parameter, hT , denotes the half-saturation constant that supports half
maximum killing of the tumor cells.
In equation 6.2, the instantaneous transfer of a subpopulation of the uninfected tumor
cells to the infected cell subpopulation following the oncolytic virus infection is represented
by the first term, lvβTTi
Tu
Ti+Tu
. The death of the infected tumor cells, at the lysis rate lv,
via bursting of the replication-competent viral particles, is denoted by the last term, −lvTi.
Here, we assume that the death of the infected cell occurs very rapidly following the virus
infection, hence the intrinsic growth of infected cell is neglected.






, in the absence of the oncolytic treatment. The parameters, aE and
KE, define the intrinsic growth rate and the carrying capacity of the tumor endothelial
cells, respectively. In this study, we assume that tumor endothelial cells grow logistically in
the absence of treatment, as has been done in [377]. Upon infection with the oncolytic virus
particles, the instantaneous shift of the subpopulation of the uninfected tumor endothelial
cells to the infected cell subpopulation is denoted by the term, −βEEuVE. The infection
rate of the tumor endothelial cells by the oncolytic virions are defined by βE. Here, we
model the oncolytic virus infection with a mass action term, as done in [143]. Under this
scenario, the infection rate is dependent on the number of uninfected tumor endothelial
cells and the amount of oncolytic virions. We consider the mass action kinetics because
the infection of the tumor endothelial cells depends on the amount of free oncolytic virus
particles released from lysed carrier cells in the tumor vasculature, not on the carrier
cell infiltrates. Note that tumor endothelium is also known to be prohibitive to entry
of tumor-specific lymphocytes [360]. Hence we assume that the circulating carrier cells
would ultimately to be destroyed by the loaded virus. After lysis, there would be free virus
particles circulating in the tumor vasculature that could infect the tumor endothelial cells.
Stellenbosch University  https://scholar.sun.ac.za
Chapter 6. Conclusions 136
In equation 6.4, the instantaneous transfer of uninfected tumor endothelial cells to in-
fected subpopulation is represented by the first term, βEEuVE. The lysis of the infected
tumor endothelial cells is defined by the last term, −lvEi, with lysis rate lv.
In equation 6.5, the first term, S, represents the constant source of the carrier cells
into the tumor vasculature from an appropriate injection site in the vicinity of the tumor.
The last term, −rbCb(t− ρ), denotes the extravasation of the carrier cells from the tumor
vasculature at the rate rb. We assume that the extravasation rate of the carrier cell from
the tumor vasculature is the same as tumor infiltration rate into the tumor cells. In other
words, we assume an invasion-type extravasation [358].
In equation 6.6, the carrier cell infiltration into the tumor is represented by the term
rbCb(t − ρ), where rb is the rate of immune cell infiltration into the tumor. This term
accounts for newly infiltrated carrier cells that appear in the uninfected tumor cell pop-
ulation, T , ρ time units after extravasation from the tumor vasculature. In this study,
the rate of carrier cell infiltration, can also be regarded as the rate at which the carrier
cell invades the tumor. Since the infiltration of immune cells into tumors facilitates direct
cell-cell contact, some immune carrier cells may die or become deactivated during their
interactions with tumor cells. Thus, the second term, −δe−µCT Tu CT
hT+CT
Tu, denotes the car-
rier cell death resulting from tumor-immune cells battle. The last term, −lvCT , represents
the death of the carrier cells inside the tumor due to cell lysis initiated by the loaded
replication-competent oncolytic virus.
In equation 6.7, upon lysis of infected carrier cells within the tumor, some newly produced
viruses could successfully infect tumor cells. Hence, the infected tumor cells, Ti, are lysed by
virus particles. Thus, the first term, lvβTTi, represents the production of new virions from
the lysed infected tumor cells, at a rate lvβT that is proportional to their lysis. Similarly,
the second term, lvβEEi, denotes the production of new virions from the lysed infected
tumor endothelial cells, Ei, at a rate lvβE that is proportional to their lysis. An immune
induced [378] or non-immune induced [101] virus inactivation and elimination is represented
by the last term, ωVE, where ω is the clearance rate. Note that in the tumor vasculature,
free viruses are susceptible to neutralization by circulating antibodies or other anti-virus
immune cells. For simplicity, we assume that the virus clearance rate (ω) embodies the
immune-induced clearance or potential inactivation by an innate immune response.
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In equation 6.8, once the infected carrier cells within the tumor are lysed by the replication-
competent virus, a new progeny of oncolytic virus particles would then infect neighbouring
tumor cells. After successful virus replication within the infected tumor cells, Ti, new virus
particles are released and further infect the neighbouring uninfected tumor cells. Thus, the
first term, lvβTTi, represents the production of new virions from the lysed infected tumor
cells, at a rate lvβT that is proportional to their lysis. Similarly, the second term, lvβEEi,
denotes the increase in the concentration of virus particles within the tumor as a result
of the virions released from the lysed infected tumor endothelial cells, Ei, at a rate lvβE
that is proportional to their lysis. Virus clearance inactivation and elimination within the
tumor is represented by the last term, ωVT , where ω is the clearance rate. The virus par-
ticles within the tumor are susceptible to tumor-mediated inactivation mechanisms. For
example, an inhibition of protein kinase (PKR) autophosphorylation as a resulting from
activation of a ras signal transduction pathway by tumor cells leads to virus inactivation
[101]. Here, we assume that the virus clearance rate (ω) embodies tumor-mediated inacti-
vation mechanisms. Note that there are no free virus particles within tumor because the
moment a virus enters a tumor cell, it becomes retained within the cell it entered only,
hence it cannot infect other cells. Thus, it cannot constitute the free virus population, as in
the tumor vasculature. This assumption is consistent with models in [144, 149, 283, 379].
A thorough analytical and numerical investigation of the system described by equations
6.1-6.8 may highlight the feasibility of joint battle of oncolytic viruses and the immune
cell-based carrier therapies in controlling tumor growth.
6.4 Final remarks
The modeling effort in this thesis is the first attempt at relating tumor-immune surveillance
to the development of tumor cell immunoresistance, use of controlled oncolytic infections
of some normal cells in the vicinity of tumor cells to augment oncolytic virotherapy, and
the delivery of oncolytic viruses to tumor site by the mesenchymal stem cells and the
engineered antigen receptor–engineered T cells in the presence of active immune response.
Mathematical modeling, in conjunction with experimental research, may provide useful
insights into the dynamics of tumor-immune interactions which are pertinent in designing
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effective immuno- and oncolytic viro-therapies.
The research carried out in this thesis has highlighted the importance of immune surveil-
lance in controling tumor growth and progression, and has suggested plausible treatment
regimes that can be engaged to minimize tumor escape. Our work is consistent with ex-
perimental results which indicate that the immune surveillance can be greatly enhanced
through NK cell-based immunotherapeutic approaches such an infiltration of autologous
(patients’ own) NK cells [87, 238]. We further showed how some outstanding challenges
in oncolytic virotherapy, such as insufficient infectious viral titers within tumor microen-
vironment, can be addressed. For example, a controlled infection of some normal cells,
within the vicinity of tumor cells, by oncolytic viruses that are not 100% tumor-specific
can increase the infectious virus particles within tumor microenvironment.
Since our work is purely quantitative, further experimental research is warranted to test
the scientific findings and assumptions of the mathematical models developed in this thesis.
We are in close collaborations with the experimental oncologists, at Prof. Chae-Ok Yun’s
Laboratory for Bioengineering at Hanyang University, who will provide us with the relevant
data to validate the mathematical models devised in this thesis.
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